Insufficent data points (0) to generate a histogram of RSD values

( Species:Human)
ANOVA results for this metabolite where p-value <=0.05

Name Study_id Analysis_id ANOVA p-Value FDR Experimental Conditions (factors)
[13C]-ISOLEUCINEST000009AN0000239.230E-33.150E-2gender;female;male
[13C]-LEUCINEST000009AN0000231.290E-43.200E-3AFTER_MEAL_TIME;30_MIN;NO_WAIT
BOC-ASNST000009AN0000234.370E-31.260E-2SURGERY;GASTRIC_BAND;ROUX_EN_Y;LEAN_CONTROL
BOC-ASNST000009AN0000231.350E-23.750E-2POST_SURGERY_TIME;12MO;6MO;NO_SURGERY;PRE_SURGERY
BOC-ASNST000009AN0000234.560E-22.550E-1AFTER_MEAL_TIME;30_MIN;NO_WAIT
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATEST000009AN0000244.230E-28.560E-2SURGERY;GASTRIC_BAND;ROUX_EN_Y;LEAN_CONTROL
DOCOSADIENOATEST000009AN0000243.130E-54.140E-4gender;female;male
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATEST000009AN0000245.500E-63.500E-5AFTER_MEAL_TIME;30_MIN;NO_WAIT
BOC-ASNST000010AN0000252.440E-37.520E-3FCS;FCS;NO_FCS
BOC-ASNST000010AN0000254.940E-21.120E-1Hours;72;0;12;24;2
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATEST000010AN0000262.840E-62.000E-5FCS;FCS;NO_FCS
URIDINE 5`-DIPHOSPHOGLUCOSEST000010AN0000269.620E-32.220E-1TGF;NO_TGF;TGF
URIDINE 5`-DIPHOSPHOGLUCOSEST000010AN0000261.620E-25.110E-2FCS;FCS;NO_FCS
URIDINE 5`-DIPHOSPHOGLUCOSEST000010AN0000263.390E-28.170E-2Hours;72;0;12;24;2
URIDINE 5`-DIPHOSPHOGLUCURONIC ACIDST000010AN0000262.450E-22.870E-1TGF;NO_TGF;TGF
BOC-ASNST000011AN0000274.770E-21.770E-1COLLECTION_COUNTRY;ETHIOPIA;TANZANIA
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATEST000011AN0000283.150E-22.020E-1ETHNICITY_ASSIGNED;AMHARA;ARGOBBA;MURSI;SABUE;WEYTO;HADZABE;...
N-ACETYL-D-HEXOSAMINEST000011AN0000285.990E-33.510E-2COLLECTION_COUNTRY;ETHIOPIA;TANZANIA
N-ACETYL-D-HEXOSAMINEST000011AN0000282.410E-21.050E-1gender;male;female
[13C]-ARGININEST000016AN0000331.460E-63.740E-6Material;Cells;Media
[13C]-ARGININEST000016AN0000331.720E-35.170E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-ARGININEST000016AN0000334.050E-31.610E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
[13C]-ASPARTIC ACIDST000016AN0000331.080E-56.010E-5Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-ASPARTIC ACIDST000016AN0000331.940E-51.430E-4Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
[13C]-ASPARTIC ACIDST000016AN0000335.930E-39.570E-3Material;Cells;Media
[13C]-GLUTAMATEST000016AN0000331.100E-198.850E-19Material;Cells;Media
[13C]-GLUTAMATEST000016AN0000339.460E-32.390E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-HISTIDINEST000016AN0000333.800E-72.920E-6Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-HISTIDINEST000016AN0000335.170E-49.710E-4Material;Cells;Media
[13C]-LEUCINEST000016AN0000332.880E-151.680E-14Material;Cells;Media
[13C]-LYSINEST000016AN0000335.440E-267.770E-25Material;Cells;Media
[13C]-LYSINEST000016AN0000332.160E-36.230E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-PHENYLALANINEST000016AN0000332.070E-33.550E-3Material;Cells;Media
[13C]-PROLINEST000016AN0000331.060E-362.780E-35Material;Cells;Media
[13C]-THREONINEST000016AN0000334.970E-246.210E-23Material;Cells;Media
[13C]-TYROSINEST000016AN0000334.790E-183.470E-17Material;Cells;Media
[13C]-VALINEST000016AN0000332.750E-346.550E-33Material;Cells;Media
2-AMINO-2-DEOXYHEXOPYRANOSEST000016AN0000337.930E-31.230E-2Material;Cells;Media
AMINOHYDROXYBENZOIC ACIDST000016AN0000332.240E-23.290E-2Material;Cells;Media
AMINOHYDROXYBUTANOIC ACIDST000016AN0000332.720E-212.470E-20Material;Cells;Media
AMINOHYDROXYBUTANOIC ACIDST000016AN0000333.110E-41.260E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
AMINOHYDROXYBUTANOIC ACIDST000016AN0000333.740E-31.520E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
BOC-ALA-OHST000016AN0000331.210E-673.030E-65Material;Cells;Media
BOC-ASNST000016AN0000334.550E-61.130E-5Material;Cells;Media
BOC-ASP-OHST000016AN0000337.930E-32.020E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
BOC-HIS-OHST000016AN0000332.440E-151.450E-14Material;Cells;Media
BOC-HIS-OHST000016AN0000335.310E-32.080E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
BOC-HIS-OHST000016AN0000332.970E-26.510E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
BOC-LYS-OHST000016AN0000333.470E-46.790E-4Material;Cells;Media
BOC-PRO-OHST000016AN0000338.260E-132.430E-11Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
BOC-PRO-OHST000016AN0000331.520E-123.310E-11Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
C-GLYCOSYLTRYPTOPHANST000016AN0000339.220E-103.340E-9Material;Cells;Media
C-GLYCOSYLTRYPTOPHANST000016AN0000339.840E-43.130E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
C-GLYCOSYLTRYPTOPHANST000016AN0000333.590E-31.480E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)ST000016AN0000334.810E-51.040E-4Material;Cells;Media
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)ST000016AN0000332.630E-25.870E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
DIHEXOSEST000016AN0000332.330E-315.060E-30Material;Cells;Media
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (???)ST000016AN0000339.240E-31.430E-2Material;Cells;Media
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (???)ST000016AN0000334.220E-21.170E-1Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000016AN0000331.020E-52.430E-5Material;Cells;Media
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000016AN0000338.090E-42.710E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000016AN0000332.300E-31.040E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
DIMETHYLXANTHINEST000016AN0000335.180E-53.460E-4Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
DIMETHYLXANTHINEST000016AN0000331.790E-43.600E-4Material;Cells;Media
DIMETHYLXANTHINEST000016AN0000333.890E-41.480E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
DIOLEOYLPHOSPHATIDYLCHOLINEST000016AN0000334.600E-71.260E-6Material;Cells;Media
DIOLEOYLPHOSPHATIDYLCHOLINEST000016AN0000331.540E-25.270E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
DOCOSAHEXAENOYLGLYCEROPHOSPHOETHANOLAMINEST000016AN0000334.350E-48.360E-4Material;Cells;Media
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINEST000016AN0000332.920E-141.550E-13Material;Cells;Media
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINEST000016AN0000335.890E-31.560E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
ETHYL 3-INDOLE ACETATEST000016AN0000333.900E-36.500E-3Material;Cells;Media
GLUCARIC/GULARIC/SACCHARIC ACIDST000016AN0000335.850E-71.580E-6Material;Cells;Media
GLYCERALDEHYDE 3-PHOSPHATE DIETHYL ACETALST000016AN0000333.830E-25.380E-2Material;Cells;Media
GLYCOLITHOCHOLIC ACID ETHYL ESTERST000016AN0000331.870E-24.420E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
MEVALOLACTONEST000016AN0000333.840E-63.050E-5Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
MEVALOLACTONEST000016AN0000332.130E-49.020E-4Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
MEVALOLACTONEST000016AN0000335.280E-38.620E-3Material;Cells;Media
N-ACETYL-D-HEXOSAMINEST000016AN0000331.020E-144.270E-13Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
N-ACETYL-D-HEXOSAMINEST000016AN0000332.810E-147.390E-13Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
N-ACETYL-D-HEXOSAMINEST000016AN0000338.760E-51.820E-4Material;Cells;Media
N-BOC-D-GLUCOSAMINEST000016AN0000331.540E-85.010E-8Material;Cells;Media
N-BOC-D-GLUCOSAMINEST000016AN0000332.640E-25.870E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
O-PHOSPHONOHEXOPYRANOSEST000016AN0000332.890E-56.440E-5Material;Cells;Media
O-PHOSPHONOHEXOPYRANOSEST000016AN0000331.440E-24.970E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINEST000016AN0000333.970E-81.220E-7Material;Cells;Media
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINEST000016AN0000334.250E-31.160E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINEST000016AN0000334.630E-21.260E-1Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
PYRIDINE CARBOXYLIC ACIDST000016AN0000337.130E-162.720E-14Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
PYRIDINE CARBOXYLIC ACIDST000016AN0000333.870E-25.420E-2Material;Cells;Media
SELENOCYSTAMINEST000016AN0000336.950E-31.100E-2Material;Cells;Media
AMINOHYDROXYBUTANOIC ACIDST000041AN0000633.160E-27.450E-1Visit;1;2;3;4;5;6;7
BOC-ALA-OHST000041AN0000636.680E-31.280E-1Group;Control;NAFLD
BOC-ASP-OHST000041AN0000631.730E-21.960E-1Group;Control;NAFLD
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (POSSIBLY)ST000041AN0000633.420E-23.160E-1Group;Control;NAFLD
GLUCARIC/GULARIC/SACCHARIC ACIDST000041AN0000639.810E-31.500E-1Group;Control;NAFLD
[13C]-HISTIDINEST000042AN0000641.660E-24.910E-1Condition;Acute lung injury;Healthy
[13C]-ARGININEST000044AN0000682.660E-21.750E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-ASPARTIC ACIDST000044AN0000683.640E-21.940E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-GLUTAMATEST000044AN0000682.600E-21.740E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-HISTIDINEST000044AN0000684.280E-22.050E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-ISOLEUCINEST000044AN0000682.100E-21.570E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-LEUCINEST000044AN0000682.260E-21.640E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-LYSINEST000044AN0000681.640E-21.380E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-PHENYLALANINEST000044AN0000683.630E-21.940E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-PROLINEST000044AN0000682.360E-21.690E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-THREONINEST000044AN0000682.450E-21.720E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-TYROSINEST000044AN0000682.150E-21.590E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-VALINEST000044AN0000682.020E-21.560E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
AMINOHYDROXYBUTANOIC ACIDST000044AN0000683.960E-21.980E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-ASNST000044AN0000683.800E-21.940E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
DIACYL-PHOSPHATIDYLCHOLINEST000044AN0000688.300E-42.810E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
PYRIDINE CARBOXYLIC ACIDST000044AN0000683.110E-21.900E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
AMINOHYDROXYBUTANOIC ACIDST000044AN0000692.110E-28.660E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
AMINOPENTANOIC ACIDST000044AN0000692.560E-32.080E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-ALA-OHST000044AN0000697.820E-34.400E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-ASNST000044AN0000693.200E-32.440E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-PHE-OHST000044AN0000694.540E-32.860E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-SER-OHST000044AN0000697.750E-41.090E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
GUANOSINE 5`-DIPHOSPHO-D-MANNOSEST000044AN0000693.600E-32.500E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
HEPTADECENOATE (*)ST000044AN0000691.050E-52.480E-3Pancreas tissue type;Normal area of the pancreas with tumor;...
HYDROXYISOVALERATE (*)ST000044AN0000691.340E-26.190E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
O-PHOSPHONOHEXOPYRANOSEST000044AN0000693.050E-21.150E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)ST000044AN0000691.670E-31.610E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
PYRIDINE CARBOXYLIC ACIDST000044AN0000691.420E-26.450E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
THYMIDINE-5`-DIPHOSPHO-ALPHA-D-GLUCOSEST000044AN0000693.580E-21.290E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
URIDINE 5`-DIPHOSPHOGLUCOSEST000044AN0000695.650E-33.340E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-ARGININEST000043AN0000701.130E-23.880E-2Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
[13C]-GLUTAMATEST000043AN0000704.580E-21.150E-1Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-ALA (+NA)ST000043AN0000702.620E-27.870E-2Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-ALA-OHST000043AN0000703.090E-28.790E-2Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-ASP-OHST000043AN0000703.020E-31.310E-2Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-LYS-OHST000043AN0000705.680E-53.630E-4Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-PHE-OHST000043AN0000706.690E-43.550E-3Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
25-hydroxyvitaminD225-(beta-glucuronide)/25hydroxyergocalciferol25-(beta-glucuronide)ST000045AN0000724.260E-22.380E-1Treatment;Insulin Withdrawal;Saline Infusion
O-DesmethyloxotolrestatsulfateST000045AN0000721.840E-21.440E-1Treatment;Insulin Withdrawal;Saline Infusion
7-HydroxyprochlorperazineglucuronideST000045AN0000732.450E-21.120E-1Treatment;Insulin Withdrawal;Saline Infusion
2-OxovalericacidST000045AN0000752.790E-34.820E-2Treatment;Insulin Withdrawal;Saline Infusion
VD2716ST000045AN0000752.890E-21.530E-1Treatment;Insulin Withdrawal;Saline Infusion
2-docosanamidoethanesulfonicacidST000046AN0000765.610E-34.820E-2Cognitive Status;AD;CN;MCI
4-Hydroxybenzylcyanide+6.609466ST000046AN0000763.280E-21.340E-1Cognitive Status;AD;CN;MCI
4-Hydroxypyridine+1.305617ST000046AN0000763.990E-21.530E-1Cognitive Status;AD;CN;MCI
8-Amino-7-oxononanoateST000046AN0000763.660E-33.960E-2Cognitive Status;AD;CN;MCI
cyclohexylammonium+2.7358363ST000046AN0000763.610E-21.430E-1Cognitive Status;AD;CN;MCI
cyclohexylammonium+5.197659ST000046AN0000762.730E-21.210E-1Cognitive Status;AD;CN;MCI
deschlorobenzoylIndomethacinST000046AN0000761.330E-27.650E-2Cognitive Status;AD;CN;MCI
DIHYDROFISSINOLIDEST000046AN0000766.010E-61.680E-4Cognitive Status;AD;CN;MCI
isoamylnitriteST000046AN0000764.320E-34.370E-2Cognitive Status;AD;CN;MCI
LorazepamglucuronideST000046AN0000762.070E-21.070E-1Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000046AN0000763.020E-21.310E-1Cognitive Status;AD;CN;MCI
N-HISTIDYL-2-AMINONAPHTHALENE(betaNA)ST000046AN0000766.580E-82.850E-6Cognitive Status;AD;CN;MCI
OLEANANOICACIDACETATEST000046AN0000762.520E-81.430E-6Cognitive Status;AD;CN;MCI
TROMETHAMINE+5.1856112ST000046AN0000766.090E-41.160E-2Cognitive Status;AD;CN;MCI
TROMETHAMINE+5.4366517ST000046AN0000766.150E-51.540E-3Cognitive Status;AD;CN;MCI
TROMETHAMINE+5.9955096ST000046AN0000762.480E-21.200E-1Cognitive Status;AD;CN;MCI
URSINICACIDST000046AN0000763.870E-21.510E-1Cognitive Status;AD;CN;MCI
1-octadecanoyl-rac-glycerolST000046AN0000772.210E-21.560E-1Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanol+5.1998544ST000046AN0000771.370E-21.280E-1Cognitive Status;AD;CN;MCI
2-docosanamidoethanesulfonicacidST000046AN0000772.300E-21.560E-1Cognitive Status;AD;CN;MCI
4-HydroxybenzylcyanideST000046AN0000774.890E-22.170E-1Cognitive Status;AD;CN;MCI
4-HydroxypyridineST000046AN0000776.890E-39.840E-2Cognitive Status;AD;CN;MCI
4-Hydroxypyridine+1.305617ST000046AN0000774.540E-22.100E-1Cognitive Status;AD;CN;MCI
8-HydroxypromazineST000046AN0000772.480E-21.620E-1Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amine+5.481559ST000046AN0000774.150E-22.020E-1Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amine+5.6003766ST000046AN0000776.660E-43.000E-2Cognitive Status;AD;CN;MCI
ChloramphenicolalcoholST000046AN0000773.050E-21.690E-1Cognitive Status;AD;CN;MCI
cyclohexylammoniumST000046AN0000771.260E-21.250E-1Cognitive Status;AD;CN;MCI
EthosuximideM7ST000046AN0000771.370E-35.240E-2Cognitive Status;AD;CN;MCI
isoamylnitriteST000046AN0000771.770E-21.380E-1Cognitive Status;AD;CN;MCI
L-gamma-Cyano-gamma-aminobutyricacid+1.2438003ST000046AN0000773.220E-21.700E-1Cognitive Status;AD;CN;MCI
o-ToluenesulfamideST000046AN0000771.780E-21.380E-1Cognitive Status;AD;CN;MCI
PropionylglycinemethylesterST000046AN0000774.200E-42.090E-2Cognitive Status;AD;CN;MCI
Propionylglycinemethylester+6.2598743ST000046AN0000776.910E-39.840E-2Cognitive Status;AD;CN;MCI
PyrazinoicacidST000046AN0000771.610E-21.370E-1Cognitive Status;AD;CN;MCI
TROMETHAMINE+5.7465215ST000046AN0000773.070E-21.690E-1Cognitive Status;AD;CN;MCI
URSINICACIDST000046AN0000774.750E-22.140E-1Cognitive Status;AD;CN;MCI
19-hydroxy-17-oxoandrost-5-en-3-beta-ylsulfateST000046AN0000781.290E-26.950E-2Cognitive Status;AD;CN;MCI
1-NaphthoicacidglucuronideST000046AN0000781.070E-25.990E-2Cognitive Status;AD;CN;MCI
6-(2-CHLORO-5-(TRIFLUOROMETHYL)PHENYL)-1-PHENYL-2-THIOBIUREA-0.88713235ST000046AN0000783.260E-33.160E-2Cognitive Status;AD;CN;MCI
ANHYDROBRAZILICACIDST000046AN0000784.840E-21.600E-1Cognitive Status;AD;CN;MCI
D1-2-HydroxymethylethisteroneST000046AN0000782.380E-32.700E-2Cognitive Status;AD;CN;MCI
D1-2-Hydroxymethylethisterone-11.471997ST000046AN0000781.030E-31.520E-2Cognitive Status;AD;CN;MCI
DiglycolicacidST000046AN0000783.180E-21.220E-1Cognitive Status;AD;CN;MCI
DIHYDROMUNDULETONEST000046AN0000782.240E-32.630E-2Cognitive Status;AD;CN;MCI
DiphenylmethylphosphineoxideST000046AN0000782.700E-47.070E-3Cognitive Status;AD;CN;MCI
D-PhenyllacticacidST000046AN0000781.510E-27.650E-2Cognitive Status;AD;CN;MCI
GemfibrozilM2ST000046AN0000783.700E-21.320E-1Cognitive Status;AD;CN;MCI
isoamylnitriteST000046AN0000784.440E-33.600E-2Cognitive Status;AD;CN;MCI
IsoquinolineN-oxideST000046AN0000786.960E-34.550E-2Cognitive Status;AD;CN;MCI
METHYL7-DESHYDROXYPYROGALLIN-4-CARBOXYLATEST000046AN0000785.140E-65.100E-4Cognitive Status;AD;CN;MCI
methyl8-[2-(2-formyl-vinyl)-3-hydroxy-5-oxo-cyclopentyl]-octanoateST000046AN0000783.710E-48.410E-3Cognitive Status;AD;CN;MCI
RitodrineglucuronideST000046AN0000786.490E-41.100E-2Cognitive Status;AD;CN;MCI
SodiumtetradecylsulfateST000046AN0000782.560E-32.730E-2Cognitive Status;AD;CN;MCI
TRIDESACETOXYKHIVORINST000046AN0000783.260E-21.230E-1Cognitive Status;AD;CN;MCI
17a-Ethynylestradiol2-glucuronideST000046AN0000791.670E-32.380E-2Cognitive Status;AD;CN;MCI
19-hydroxy-17-oxoandrost-5-en-3-beta-ylsulfateST000046AN0000799.910E-36.760E-2Cognitive Status;AD;CN;MCI
7-hydroxyTetranorIloprostST000046AN0000791.780E-29.010E-2Cognitive Status;AD;CN;MCI
ApionicacidST000046AN0000792.520E-21.110E-1Cognitive Status;AD;CN;MCI
Bifemelane(M4)ST000046AN0000791.480E-28.110E-2Cognitive Status;AD;CN;MCI
B-ureidoisobutyricacid-6.84278ST000046AN0000794.420E-33.930E-2Cognitive Status;AD;CN;MCI
D1-2-Hydroxymethylethisterone-2.831552ST000046AN0000796.700E-35.350E-2Cognitive Status;AD;CN;MCI
EPIAFZELECHINTRIMETHYLETHERST000046AN0000794.100E-21.440E-1Cognitive Status;AD;CN;MCI
IsoquinolineN-oxideST000046AN0000793.820E-33.530E-2Cognitive Status;AD;CN;MCI
Mono-N-depropylprobenecidST000046AN0000791.600E-28.450E-2Cognitive Status;AD;CN;MCI
N-Acetyl-5-aminosalicylicacid-3.4608338ST000046AN0000793.460E-21.280E-1Cognitive Status;AD;CN;MCI
N-Acetyl-5-hydroxysulfapyridineST000046AN0000794.690E-33.950E-2Cognitive Status;AD;CN;MCI
p-HydroxyphenylbutazoneglucuronideST000046AN0000791.880E-29.110E-2Cognitive Status;AD;CN;MCI
PropionylglycinemethylesterST000046AN0000793.800E-21.350E-1Cognitive Status;AD;CN;MCI
SAPPANONEA7-METHYLETHERST000046AN0000793.370E-21.280E-1Cognitive Status;AD;CN;MCI
SulfateST000046AN0000791.770E-29.010E-2Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanolST000047AN0000802.970E-22.150E-1Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanol+3.3926477ST000047AN0000809.720E-43.870E-2Cognitive Status;AD;CN;MCI
7-DEACETOXY-7-OXOKHIVORINST000047AN0000803.540E-22.350E-1Cognitive Status;AD;CN;MCI
8-Amino-7-oxononanoateST000047AN0000806.930E-31.370E-1Cognitive Status;AD;CN;MCI
8-Amino-7-oxononanoate+4.7958198ST000047AN0000803.040E-22.150E-1Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amineST000047AN0000801.650E-41.570E-2Cognitive Status;AD;CN;MCI
DIHYDROSPATHELIACHROMENEST000047AN0000802.210E-21.880E-1Cognitive Status;AD;CN;MCI
HECOGENINACETATEST000047AN0000804.150E-22.500E-1Cognitive Status;AD;CN;MCI
MeradimateST000047AN0000805.080E-31.260E-1Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000047AN0000802.490E-21.950E-1Cognitive Status;AD;CN;MCI
PentazocinetransacidST000047AN0000803.910E-22.470E-1Cognitive Status;AD;CN;MCI
PEUCENINST000047AN0000804.500E-22.500E-1Cognitive Status;AD;CN;MCI
PEUCENIN+7.86186ST000047AN0000804.280E-22.500E-1Cognitive Status;AD;CN;MCI
Pinacidil-N-OxideST000047AN0000801.680E-21.800E-1Cognitive Status;AD;CN;MCI
VALERYLSALYCILATEST000047AN0000801.530E-35.600E-2Cognitive Status;AD;CN;MCI
1-octadecanoyl-rac-glycerol+2.8676724ST000047AN0000811.030E-21.040E-1Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanolST000047AN0000813.460E-21.970E-1Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanol+5.204487ST000047AN0000814.200E-22.080E-1Cognitive Status;AD;CN;MCI
2-hexacosanamidoethanesulfonicacidST000047AN0000814.190E-22.080E-1Cognitive Status;AD;CN;MCI
4-Aminophenyl1-thio-beta-D-glucuronideST000047AN0000813.510E-35.470E-2Cognitive Status;AD;CN;MCI
4-Hydroxypyridine+4.290232ST000047AN0000818.250E-39.130E-2Cognitive Status;AD;CN;MCI
8-Amino-7-oxononanoateST000047AN0000819.230E-39.580E-2Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amineST000047AN0000814.630E-22.150E-1Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amine+5.4374814ST000047AN0000819.990E-59.760E-3Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amine+5.586841ST000047AN0000811.320E-21.140E-1Cognitive Status;AD;CN;MCI
cefamandolenafateST000047AN0000813.000E-21.810E-1Cognitive Status;AD;CN;MCI
ChloramphenicolalcoholST000047AN0000811.910E-21.420E-1Cognitive Status;AD;CN;MCI
DesmethylnimodipineST000047AN0000812.020E-34.190E-2Cognitive Status;AD;CN;MCI
EB1213ST000047AN0000812.270E-21.610E-1Cognitive Status;AD;CN;MCI
EPICATECHINPENTAACETATEST000047AN0000811.410E-41.000E-2Cognitive Status;AD;CN;MCI
FluoresceinmonoglucuronideST000047AN0000811.960E-34.190E-2Cognitive Status;AD;CN;MCI
fluphenazineenanthateST000047AN0000814.610E-22.150E-1Cognitive Status;AD;CN;MCI
isoamylnitriteST000047AN0000812.660E-34.560E-2Cognitive Status;AD;CN;MCI
Meradimate+2.886999ST000047AN0000814.090E-22.080E-1Cognitive Status;AD;CN;MCI
N-Acetyl-p-benzoquinonimineST000047AN0000813.000E-34.820E-2Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000047AN0000811.360E-21.150E-1Cognitive Status;AD;CN;MCI
PyrazinoicacidST000047AN0000815.710E-37.210E-2Cognitive Status;AD;CN;MCI
TROMETHAMINEST000047AN0000818.710E-39.240E-2Cognitive Status;AD;CN;MCI
VALERYLSALYCILATEST000047AN0000816.920E-42.450E-2Cognitive Status;AD;CN;MCI
4-HydroxytacrineST000047AN0000823.010E-21.600E-1Cognitive Status;AD;CN;MCI
4-Methylumbelliferylbeta-D-glucuronideST000047AN0000822.500E-33.670E-2Cognitive Status;AD;CN;MCI
8-hydroxymianseringlucuronideST000047AN0000822.420E-21.480E-1Cognitive Status;AD;CN;MCI
FenoterolsulfateST000047AN0000822.930E-21.590E-1Cognitive Status;AD;CN;MCI
L-Asparticacidb-semialdehydeST000047AN0000821.920E-33.430E-2Cognitive Status;AD;CN;MCI
N-DidesethylquinagolideST000047AN0000823.420E-74.270E-5Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000047AN0000822.130E-21.420E-1Cognitive Status;AD;CN;MCI
ORTHOTHYMOTINICACIDST000047AN0000822.320E-21.450E-1Cognitive Status;AD;CN;MCI
(R)-3-Methyl-2-oxobutanoateST000047AN0000822.820E-21.590E-1Cognitive Status;AD;CN;MCI
threo-Isocitricacid-1.0347548ST000047AN0000822.220E-21.420E-1Cognitive Status;AD;CN;MCI
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoicacidST000047AN0000832.510E-32.980E-2Cognitive Status;AD;CN;MCI
3alpha-HYDROXY-3-DEOXYANGOLENSICACIDMETHYLESTERST000047AN0000831.220E-28.350E-2Cognitive Status;AD;CN;MCI
3-(a-Naphthoxy)lacticacidST000047AN0000832.790E-21.510E-1Cognitive Status;AD;CN;MCI
3-HydroxyphenytoinST000047AN0000831.620E-32.090E-2Cognitive Status;AD;CN;MCI
7-hydroxyTetranorIloprostST000047AN0000833.810E-33.830E-2Cognitive Status;AD;CN;MCI
desmethylnortriptylineglucuronideST000047AN0000835.350E-34.490E-2Cognitive Status;AD;CN;MCI
gamma-HydroxyphenylbutazoneglucuronideST000047AN0000833.820E-33.830E-2Cognitive Status;AD;CN;MCI
IsobutyrylglycinemethylesterST000047AN0000833.350E-21.650E-1Cognitive Status;AD;CN;MCI
MethoxsalenMetaboliteST000047AN0000835.660E-84.540E-6Cognitive Status;AD;CN;MCI
Mono-N-depropylprobenecidST000047AN0000831.520E-29.740E-2Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000047AN0000832.960E-21.530E-1Cognitive Status;AD;CN;MCI
z dioctylphtalateST000054AN0000921.740E-179.070E-16treatment;Basal ;DCIS ;HER2 ;LumA ;LumB ;Reduction ;Total Po...
z dioctylphtalateST000054AN0000922.330E-111.030E-9pool aliquot;no;yes
maltotriose minorST000058AN0000962.720E-52.390E-4Treatment;Group 1;Group 2;Group 3;Group 4;Group 5;Group 6;Gr...
cytidine-5-monophosphate NISTST000061AN0000993.150E-28.210E-2Source;Group 1 - Subcutaenous Fat;Group 2 - Visceral Fat;Met...
tocopherol beta NISTST000061AN0000992.000E-26.190E-2Source;Group 1 - Subcutaenous Fat;Group 2 - Visceral Fat;Met...
N-acetylglycine NISTST000062AN0001001.190E-26.800E-2Source;Group 1 - Score 0;Group 2 - Score 50
2-ketoglucose dimethylacetal NISTST000063AN0001013.000E-31.350E-2Source;Group 1 - Score 0;Group 2 - Score 50
ATP-H2O-13C0+15N0ST000076AN0001214.080E-25.990E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
ATP-H2O-13C2+15N0ST000076AN0001211.130E-24.230E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GLCUR-13C0+15N0ST000076AN0001218.720E-63.370E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GLCUR-13C13+15N0ST000076AN0001217.780E-41.000E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C0+15N0ST000076AN0001211.070E-42.070E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C11+15N0ST000076AN0001211.270E-24.230E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C12+15N0ST000076AN0001212.840E-25.990E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C13+15N0ST000076AN0001217.600E-33.500E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C15+15N0ST000076AN0001211.700E-25.030E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C5+15N0ST000076AN0001214.290E-25.990E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C6+15N0ST000076AN0001214.360E-32.640E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C7+15N0ST000076AN0001212.410E-25.980E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
bOHbutyrate-13C0ST000076AN0001223.090E-29.100E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
bOHbutyrate-13C2ST000076AN0001224.570E-32.100E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
bOHbutyrate-13C4ST000076AN0001222.650E-42.430E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
bOHbutyrate-ALLST000076AN0001221.430E-41.710E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
OHPro-13C5ST000076AN0001227.330E-45.150E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C0ST000076AN0001222.440E-27.760E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C2ST000076AN0001224.320E-69.390E-5Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C3ST000076AN0001221.350E-24.900E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C4ST000076AN0001224.200E-43.460E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C5ST000076AN0001225.230E-44.150E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C6ST000076AN0001229.020E-51.270E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
t-aconitate-13C0ST000076AN0001228.690E-51.270E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
t-aconitate-13C2ST000076AN0001222.250E-27.270E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
t-aconitate-13C4ST000076AN0001222.050E-27.010E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
t-aconitate-ALLST000076AN0001221.850E-26.410E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
Benzyl dodecyl dimethylammonium cationST000077AN0001233.660E-94.910E-9Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
Benzyl dodecyl dimethylammonium cationST000077AN0001233.160E-89.430E-8Treatment;100uM Met ;370uM Hcy ;quality check
Benzyl tetradecyl dimethylammonium cationST000077AN0001232.750E-73.060E-7Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
Benzyl tetradecyl dimethylammonium cationST000077AN0001232.640E-54.460E-5Treatment;100uM Met ;370uM Hcy ;quality check
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enineST000077AN0001231.410E-61.530E-6Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enineST000077AN0001232.290E-64.590E-6Treatment;100uM Met ;370uM Hcy ;quality check
cytidine-5-monophosphate NISTST000087AN0001391.030E-21.450E-2Time Point;18 hours;4 hours
enolpyruvate NISTST000087AN0001399.390E-31.350E-2Time Point;18 hours;4 hours
N-acetylmannosamine minorST000087AN0001391.450E-32.830E-3Time Point;18 hours;4 hours
saccharic acidST000087AN0001391.960E-33.430E-3Time Point;18 hours;4 hours
1-Hexadecylpyridinium cationST000089AN0001415.230E-96.570E-9Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Benzyl dodecyl dimethylammonium cation (disinfectant)ST000089AN0001412.450E-277.240E-27Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Benzyl tetradecyl dimethylammonium cation (disinfectant)ST000089AN0001412.130E-351.900E-34Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Hydromorphone (anesthetic)ST000089AN0001411.660E-61.870E-6Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Lyso-PAF C-18ST000089AN0001411.340E-284.630E-28Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enineST000089AN0001417.590E-201.510E-19Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
N-Stearoyl-4-sphingenyl-1-O-phosphorylcholineST000089AN0001416.750E-98.450E-9Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
2-keto-l-gluconic acidST000092AN0001468.360E-61.220E-5Gender;N/A;Female;Male
2-keto-l-gluconic acidST000092AN0001468.660E-51.220E-4Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
2-keto-l-gluconic acidST000092AN0001464.570E-47.140E-4Solution Added;N/A;None;Urease;Water
2-keto-l-gluconic acidST000092AN0001462.000E-22.920E-2Urease Treatment;No treatment;Urease pre-treatment;Water pre...
3-methyl-3-hydroxybutyric acidST000092AN0001461.980E-93.760E-9Gender;N/A;Female;Male
3-methyl-3-hydroxybutyric acidST000092AN0001464.530E-88.470E-8Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
3-methyl-3-hydroxybutyric acidST000092AN0001463.920E-45.590E-4Volume Urine (µL);100;10;25;50;5
glucosylglycerolST000092AN0001462.800E-1393.550E-138Solution Added;N/A;None;Urease;Water
glucosylglycerolST000092AN0001461.440E-792.740E-78Volume Urine (µL);100;10;25;50;5
glucosylglycerolST000092AN0001461.500E-515.710E-50Gender;N/A;Female;Male
glucosylglycerolST000092AN0001463.050E-491.160E-47Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
glucosylglycerolST000092AN0001469.150E-126.130E-11Urease Treatment;No treatment;Urease pre-treatment;Water pre...
isohydroxybutyric acidST000092AN0001463.930E-2307.460E-229Solution Added;N/A;None;Urease;Water
isohydroxybutyric acidST000092AN0001462.000E-772.840E-76Volume Urine (µL);100;10;25;50;5
isohydroxybutyric acidST000092AN0001461.320E-321.070E-31Gender;N/A;Female;Male
isohydroxybutyric acidST000092AN0001461.360E-301.190E-29Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
isohydroxybutyric acidST000092AN0001461.990E-87.830E-8Urease Treatment;No treatment;Urease pre-treatment;Water pre...
urea (partial derivative)ST000092AN0001464.290E-59.970E-5Urease Treatment;No treatment;Urease pre-treatment;Water pre...
urea (partial derivative)ST000092AN0001468.150E-31.130E-2Solution Added;N/A;None;Urease;Water
VGAHAGEYGAEALER*ST000093AN0001494.500E-22.860E-1condition;FFA affected ;FFA unaffected ;Scalp biopsy normal
VGAHAGEYGAEALER*ST000093AN0001494.500E-22.860E-1location;frontal scalp;occipital scalp;NA
1-AG bST000096AN0001548.250E-111.070E-9Timepoint;18 hours;4 hours;NA
1-LG bST000096AN0001544.250E-71.110E-6Timepoint;18 hours;4 hours;NA
1-OG bST000096AN0001541.230E-85.310E-8Timepoint;18 hours;4 hours;NA
2-AG bST000096AN0001541.340E-31.580E-3Timepoint;18 hours;4 hours;NA
2-LG bST000096AN0001545.090E-59.460E-5Timepoint;18 hours;4 hours;NA
2-OG bST000096AN0001542.510E-55.430E-5Timepoint;18 hours;4 hours;NA
2-OG bST000096AN0001544.760E-21.770E-1Sample Type;Adipocyte ;Co-culture ;Control ;Media blank
[13C]-ARGININEST000105AN0001733.130E-25.450E-1CPAP;No CPAP;After CPAP
[13C]-LYSINEST000105AN0001731.080E-27.280E-2Sampling;After SWS onset;Morning fasting
[13C]-PROLINEST000105AN0001733.130E-23.500E-1PCOS;No PCOS;PCOS
[13C]-PROLINEST000105AN0001734.410E-22.080E-1Sampling;After SWS onset;Morning fasting
AMINOHYDROXYBUTANOIC ACIDST000105AN0001734.980E-25.620E-1CPAP;No CPAP;After CPAP
BOC-ALA (+NA)ST000105AN0001739.340E-51.670E-3Sampling;After SWS onset;Morning fasting
BOC-ALA (+NA)ST000105AN0001733.360E-25.450E-1CPAP;No CPAP;After CPAP
BOC-PHE-OHST000105AN0001731.410E-31.660E-2Sampling;After SWS onset;Morning fasting
BOC-PRO-OHST000105AN0001733.830E-24.040E-1Gender;Female;Male
C-GLYCOSYLTRYPTOPHAN (*)ST000105AN0001731.140E-22.920E-1OSA;Negative;Positive
DIHEXOSEST000105AN0001731.710E-101.760E-8Sampling;After SWS onset;Morning fasting
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000105AN0001733.480E-58.440E-4Sampling;After SWS onset;Morning fasting
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000105AN0001733.920E-37.680E-2Gender;Female;Male
DIMETHYLXANTHINEST000105AN0001731.060E-27.280E-2Sampling;After SWS onset;Morning fasting
DIMETHYLXANTHINE (*)ST000105AN0001732.400E-43.800E-3Sampling;After SWS onset;Morning fasting
DIMETHYLXANTHINE (*)ST000105AN0001734.790E-24.390E-1Gender;Female;Male
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINE (*)ST000105AN0001731.830E-21.120E-1Sampling;After SWS onset;Morning fasting
ETHYL 3-INDOLE ACETATEST000105AN0001732.080E-22.440E-1Gender;Female;Male
ETHYL 3-INDOLE ACETATEST000105AN0001732.330E-22.990E-1PCOS;No PCOS;PCOS
MEVALOLACTONEST000105AN0001731.480E-236.090E-21Sampling;After SWS onset;Morning fasting
SELENOCYSTAMINEST000105AN0001735.980E-35.240E-2Sampling;After SWS onset;Morning fasting
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)ST000105AN0001741.150E-21.690E-1Gender;Female;Male
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)ST000105AN0001741.790E-24.190E-1OSA;Negative;Positive
AMINOPENTANOIC ACIDST000105AN0001742.210E-24.190E-1OSA;Negative;Positive
ARACHIDONOYLGLYCEROPHOSPHOETHANOLAMINE (*)ST000105AN0001742.070E-89.870E-7Sampling;After SWS onset;Morning fasting
ARACHIDONOYLGLYCEROPHOSPHOINOSITOL (*)ST000105AN0001743.270E-65.680E-5Sampling;After SWS onset;Morning fasting
BOC-ALA-OHST000105AN0001746.830E-33.570E-2Sampling;After SWS onset;Morning fasting
BOC-ASP-OHST000105AN0001741.640E-26.040E-1CPAP;No CPAP;After CPAP
BOC-ASP-OHST000105AN0001743.820E-25.090E-1OSA;Negative;Positive
BOC-HIS-OHST000105AN0001741.700E-27.220E-2Sampling;After SWS onset;Morning fasting
BOC-HIS-OHST000105AN0001743.690E-25.090E-1OSA;Negative;Positive
BOC-MET-OHST000105AN0001743.100E-21.190E-1Sampling;After SWS onset;Morning fasting
BOC-MET-OHST000105AN0001743.930E-26.250E-1CPAP;No CPAP;After CPAP
BOC-MET-OHST000105AN0001744.610E-25.090E-1OSA;Negative;Positive
BOC-PHE-OHST000105AN0001742.480E-23.250E-1PCOS;No PCOS;PCOS
DIHEXOSEST000105AN0001747.890E-111.510E-8Sampling;After SWS onset;Morning fasting
DOCOSADIENOATE (*)ST000105AN0001745.610E-33.090E-2Sampling;After SWS onset;Morning fasting
DOCOSAPENTAENOATE (*)ST000105AN0001745.380E-56.630E-4Sampling;After SWS onset;Morning fasting
GLYCOCHENODEOXYCHOLATE / GLYCODEOXYCHOLATE (*)ST000105AN0001742.380E-53.130E-4Sampling;After SWS onset;Morning fasting
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)ST000105AN0001742.690E-23.320E-1PCOS;No PCOS;PCOS
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)ST000105AN0001743.010E-21.160E-1Sampling;After SWS onset;Morning fasting
HEPTADECENOATE (*)ST000105AN0001743.780E-43.520E-3Sampling;After SWS onset;Morning fasting
HYDROXYISOVALERATE (*)ST000105AN0001742.580E-31.410E-1PCOS;No PCOS;PCOS
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)ST000105AN0001741.510E-41.640E-3Sampling;After SWS onset;Morning fasting
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)ST000105AN0001744.190E-32.000E-1OSA;Negative;Positive
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)ST000105AN0001744.230E-37.690E-2Gender;Female;Male
PYRIDINE CARBOXYLIC ACIDST000105AN0001744.260E-23.540E-1Gender;Female;Male
SALICYLURIC GLUCURONIDE (*)ST000105AN0001741.260E-22.400E-1PCOS;No PCOS;PCOS
SALICYLURIC GLUCURONIDE (*)ST000105AN0001742.870E-21.130E-1Sampling;After SWS onset;Morning fasting
[13C]-ASPARTIC ACIDST000106AN0001752.650E-31.100E-1Constitution;Lean;Obese
[13C]-LEUCINEST000106AN0001751.310E-33.210E-2Sampling time;0 min;60 min
[13C]-TYROSINEST000106AN0001752.890E-35.130E-2Sampling time;0 min;60 min
[13C]-VALINEST000106AN0001753.790E-24.680E-1Constitution;Lean;Obese
2-AMINO-2-DEOXYHEXOPYRANOSEST000106AN0001751.330E-24.280E-1Visit;1;2
2-AMINO-2-DEOXYHEXOPYRANOSEST000106AN0001754.190E-23.060E-1Sampling time;0 min;60 min
AMINOHYDROXYBUTANOIC ACIDST000106AN0001753.410E-22.620E-1Sampling time;0 min;60 min
BOC-HIS-OHST000106AN0001756.650E-38.940E-2Sampling time;0 min;60 min
BOC-PRO-OHST000106AN0001753.100E-22.460E-1Sampling time;0 min;60 min
C-GLYCOSYLTRYPTOPHAN (*)ST000106AN0001752.100E-31.060E-1Constitution;Lean;Obese
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)ST000106AN0001751.070E-21.200E-1Sampling time;0 min;60 min
DIHEXOSEST000106AN0001751.620E-47.560E-3Sampling time;0 min;60 min
DIOLEOYLPHOSPHATIDYLCHOLINEST000106AN0001758.250E-54.530E-3Sampling time;0 min;60 min
N-ACETYL-D-HEXOSAMINEST000106AN0001751.970E-31.060E-1Constitution;Lean;Obese
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE (*)ST000106AN0001758.680E-31.090E-1Sampling time;0 min;60 min
PYRIDINE CARBOXYLIC ACIDST000106AN0001755.350E-34.280E-1Visit;1;2
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)ST000106AN0001763.550E-21.990E-1Sampling time;0 min;60 min
AMINOHYDROXYBUTANOIC ACIDST000106AN0001761.840E-21.410E-1Sampling time;0 min;60 min
AMINOPENTANOIC ACIDST000106AN0001763.120E-21.880E-1Sampling time;0 min;60 min
ARACHIDONOYLGLYCEROPHOSPHOETHANOLAMINE (*)ST000106AN0001769.850E-38.650E-2Sampling time;0 min;60 min
ARACHIDONOYLGLYCEROPHOSPHOINOSITOL (*)ST000106AN0001761.410E-31.840E-2Sampling time;0 min;60 min
BOC-ASNST000106AN0001764.560E-25.150E-1Visit;1;2
BOC-ASN-OHST000106AN0001764.660E-25.150E-1Visit;1;2
BOC-ASP-OHST000106AN0001761.850E-23.570E-1Visit;1;2
DIHEXOSEST000106AN0001762.710E-54.980E-4Sampling time;0 min;60 min
DOCOSAPENTAENOATE (*)ST000106AN0001764.020E-102.320E-8Sampling time;0 min;60 min
DOCOSAPENTAENOATE (*)ST000106AN0001764.330E-25.150E-1Visit;1;2
GLYCOCHENODEOXYCHOLATE / GLYCODEOXYCHOLATE (*)ST000106AN0001769.850E-51.660E-3Sampling time;0 min;60 min
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)ST000106AN0001764.300E-22.210E-1Sampling time;0 min;60 min
HEPTADECENOATE (*)ST000106AN0001761.070E-94.310E-8Sampling time;0 min;60 min
HYDROXYACETAMINOPHEN SULFATE (*)ST000106AN0001761.350E-73.030E-6Sampling time;0 min;60 min
HYDROXYISOVALERATE (*)ST000106AN0001761.680E-56.810E-3Visit;1;2
GAB-ALLST000110AN0001852.400E-26.370E-2Oxygen Condition;hypoxia;normoxia
OHPro-ALLST000110AN0001857.300E-53.400E-3Oxygen Condition;hypoxia;normoxia
GAB-ALLST000113AN0001912.400E-24.370E-1Oxygen Condition;hypoxia;normoxia
Pro258-ALLST000113AN0001911.940E-22.590E-1Treatment;None;Tetracycline
bOHbutyrate-13C0ST000114AN0001941.440E-66.660E-5Treatment;None;Tetracycline
bOHbutyrate-13C1ST000114AN0001941.880E-31.340E-2Treatment;None;Tetracycline
bOHbutyrate-ALLST000114AN0001943.010E-61.050E-4Treatment;None;Tetracycline
[calc GSH-13C]ST000114AN0001945.980E-46.620E-3Treatment;None;Tetracycline
GAB-13C0ST000114AN0001941.430E-949.960E-93Oxygen Condition;hypoxia;normoxia
GAB-ALLST000114AN0001941.430E-949.960E-93Oxygen Condition;hypoxia;normoxia
OHPro-13C0ST000114AN0001945.280E-46.620E-3Treatment;None;Tetracycline
OHPro-ALLST000114AN0001947.080E-46.620E-3Treatment;None;Tetracycline
Pro258-13C0ST000114AN0001946.630E-33.690E-2Treatment;None;Tetracycline
Pro258-13C1ST000114AN0001947.140E-46.620E-3Treatment;None;Tetracycline
Pro258-13C2ST000114AN0001941.470E-27.290E-2Treatment;None;Tetracycline
Pro258-13C5ST000114AN0001943.210E-22.630E-1Oxygen Condition;hypoxia;normoxia
Pro258-ALLST000114AN0001943.070E-46.100E-3Treatment;None;Tetracycline
t-aconitate-ALLST000114AN0001942.400E-28.780E-2Treatment;None;Tetracycline
Hydroxybutyrate3ST000137AN0002191.380E-31.140E-2Sample Group;Control;Patient
16a-Hydroxyestrone-13C0[+QDA adduct+Na]+ST000142AN0002255.980E-326.130E-31Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C0[+Na]+ST000142AN0002254.740E-326.130E-31Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C0[+QDA adduct+Na]+ST000142AN0002256.330E-326.130E-31Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C1[+QDA adduct+Na]+ST000142AN0002258.660E-326.130E-31Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C3[+QDA adduct+Na]+ST000142AN0002254.760E-326.130E-31Treatment;13C-Glc;unlabeled
(2-Butylbenzofuran-3-yl)(4-hydroxyphenyl)ketone-13C0[+Na]+ST000142AN0002257.120E-44.200E-3Treatment;13C-Glc;unlabeled
2-Dehydro-xylonate-13C0[+H]+ST000142AN0002258.530E-326.130E-31Treatment;13C-Glc;unlabeled
2-Demethylmenaquinone-13C0[+Na]+ST000142AN0002258.830E-326.150E-31Treatment;13C-Glc;unlabeled
2-Heptyl-3-hydroxy-quinolone-13C0[+H]+ST000142AN0002258.630E-326.130E-31Treatment;13C-Glc;unlabeled
2-Heptyl-3-hydroxy-quinolone-13C1[+H]+ST000142AN0002251.910E-311.130E-30Treatment;13C-Glc;unlabeled
2-Oxo-8-methylthiooctanoate-13C0[+Na]+ST000142AN0002257.960E-336.130E-31Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C0[+QDA adduct+Na]+ST000142AN0002252.340E-326.130E-31Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C1[+QDA adduct+Na]+ST000142AN0002257.740E-326.130E-31Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C2[+QDA adduct+Na]+ST000142AN0002256.480E-326.130E-31Treatment;13C-Glc;unlabeled
3-Deoxy-glycero-galacto-2-nonulosonic acid-13C0[+QDA adduct+Na]+ST000142AN0002255.830E-326.130E-31Treatment;13C-Glc;unlabeled
3-Hydroxyethylbacteriochlorophyllide a-13C0[+Na]+ST000142AN0002252.980E-326.130E-31Treatment;13C-Glc;unlabeled
3-Iodo-4-hydroxyphenylpyruvate-13C0[+QDA adduct+Na]+ST000142AN0002256.910E-326.130E-31Treatment;13C-Glc;unlabeled
4-Ketoanhydrochlortetracycline-13C0[+H]+ST000142AN0002252.100E-326.130E-31Treatment;13C-Glc;unlabeled
4-Keto-ATC-13C0[+13CD3 QDA]+ST000142AN0002254.080E-326.130E-31Treatment;13C-Glc;unlabeled
4-Sulfobenzaldehyde-13C0[+Na]+ST000142AN0002257.600E-326.130E-31Treatment;13C-Glc;unlabeled
5-Chloro-2-hydroxymuconic semialdehyde-13C0[+Na]+ST000142AN0002251.090E-316.860E-31Treatment;13C-Glc;unlabeled
5-Methyl-2-furaldehyde-13C0[+QDA adduct]+ST000142AN0002251.840E-326.130E-31Treatment;13C-Glc;unlabeled
6-Azaequilenin-13C0[+H]+ST000142AN0002257.200E-326.130E-31Treatment;13C-Glc;unlabeled
6-Hydroxykynurenate-13C0[+Na]+ST000142AN0002252.680E-326.130E-31Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C0[+Na]+ST000142AN0002254.060E-326.130E-31Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C2[+Na]+ST000142AN0002253.280E-326.130E-31Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C4[+Na]+ST000142AN0002257.430E-326.130E-31Treatment;13C-Glc;unlabeled
Abscisic acid GLC ester-13C0[+QDA adduct]+ST000142AN0002255.900E-326.130E-31Treatment;13C-Glc;unlabeled
Alisol A-13C0[+13CD3 QDA]+ST000142AN0002259.600E-326.300E-31Treatment;13C-Glc;unlabeled
Aloinoside A-13C0[+13CD3 QDA]+ST000142AN0002256.210E-326.130E-31Treatment;13C-Glc;unlabeled
AminoDHS-13C0[+H]+ST000142AN0002259.200E-326.150E-31Treatment;13C-Glc;unlabeled
Aminomuconic acid semialdehyde-13C0[+Na]+ST000142AN0002251.060E-316.700E-31Treatment;13C-Glc;unlabeled
Aquayamycin-13C0[+13CD3 QDA]+ST000142AN0002252.660E-326.130E-31Treatment;13C-Glc;unlabeled
Atheroline-13C1[+H]+ST000142AN0002253.130E-326.130E-31Treatment;13C-Glc;unlabeled
Atheroline-13C6[+H]+ST000142AN0002258.280E-326.130E-31Treatment;13C-Glc;unlabeled
Bacteriochlorophyllide a-13C0[+QDA adduct]+ST000142AN0002254.230E-326.130E-31Treatment;13C-Glc;unlabeled
Benzoquinoneacetate-13C1[+QDA adduct+Na]+ST000142AN0002252.960E-21.630E-1Treatment;13C-Glc;unlabeled
B-Norcholest-4-en-3-one-13C0[+Na]+ST000142AN0002255.690E-326.130E-31Treatment;13C-Glc;unlabeled
C-132-Carboxypyropheophorbide a-13C0[+QDA adduct+Na]+ST000142AN0002257.880E-336.130E-31Treatment;13C-Glc;unlabeled
CAI-1-13C0[+13CD3 QDA]+ST000142AN0002253.540E-21.920E-1Treatment;13C-Glc;unlabeled
Candletoxin A-13C0[+13CD3 QDA]+ST000142AN0002256.320E-326.130E-31Treatment;13C-Glc;unlabeled
Chalcomycin-13C0[+QDA adduct]+ST000142AN0002251.950E-326.130E-31Treatment;13C-Glc;unlabeled
Chalcomycin-13C1[+QDA adduct]+ST000142AN0002256.120E-326.130E-31Treatment;13C-Glc;unlabeled
Chloroacetoacetanilide-13C0[+QDA adduct]+ST000142AN0002251.900E-326.130E-31Treatment;13C-Glc;unlabeled
Cinncassiol C1-13C0[+QDA adduct+Na]+ST000142AN0002254.100E-326.130E-31Treatment;13C-Glc;unlabeled
Cinncassiol C2-13C0[+13CD3 QDA]+ST000142AN0002251.210E-317.410E-31Treatment;13C-Glc;unlabeled
Cyanidin-3-rhamnoglucoside chloride-13C0[+Na]+ST000142AN0002252.710E-21.500E-1Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C0[+Na]+ST000142AN0002252.290E-326.130E-31Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C0[+QDA adduct]+ST000142AN0002255.160E-326.130E-31Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C19[+QDA adduct]+ST000142AN0002259.490E-326.250E-31Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C1[+QDA adduct]+ST000142AN0002253.800E-326.130E-31Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C20[+QDA adduct]+ST000142AN0002252.810E-326.130E-31Treatment;13C-Glc;unlabeled
Deamino-alpha-keto-demethylphosphinothricin-13C0[+QDA adduct]+ST000142AN0002251.550E-28.770E-2Treatment;13C-Glc;unlabeled
Decanoyl acetaldehyde-13C0[+13CD3 QDA]+ST000142AN0002251.970E-326.130E-31Treatment;13C-Glc;unlabeled
Decanoyl acetaldehyde-13C0[+Na]+ST000142AN0002252.850E-326.130E-31Treatment;13C-Glc;unlabeled
Dehydro-fructose-13C0[+H]+ST000142AN0002259.470E-326.250E-31Treatment;13C-Glc;unlabeled
Dehydro-fructose-13C1[+H]+ST000142AN0002256.630E-326.130E-31Treatment;13C-Glc;unlabeled
Dehydropantoate-13C0[+Na]+ST000142AN0002252.530E-326.130E-31Treatment;13C-Glc;unlabeled
Delphinidin 3-O-glucoside-13C0[+QDA adduct+Na]+ST000142AN0002254.350E-22.340E-1Treatment;13C-Glc;unlabeled
Delphinidin 3-O-glucoside-13C1[+QDA adduct+Na]+ST000142AN0002255.610E-326.130E-31Treatment;13C-Glc;unlabeled
Deoxycarminomycin-13C0[+QDA adduct]+ST000142AN0002257.550E-326.130E-31Treatment;13C-Glc;unlabeled
Dihydrocarminomycin-13C0[+13CD3 QDA]+ST000142AN0002256.170E-326.130E-31Treatment;13C-Glc;unlabeled
Dihydrogossypetin-13C0[+13CD3 QDA]+ST000142AN0002256.730E-326.130E-31Treatment;13C-Glc;unlabeled
dihydro-keto-PGF2a-13C0[+Na]+ST000142AN0002256.970E-326.130E-31Treatment;13C-Glc;unlabeled
Dihydroxanthommatin-13C0[+13CD3 QDA]+ST000142AN0002253.550E-326.130E-31Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C0[+H]+ST000142AN0002258.780E-326.130E-31Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C1[+H]+ST000142AN0002258.300E-326.130E-31Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C3[+H]+ST000142AN0002251.050E-316.700E-31Treatment;13C-Glc;unlabeled
Divinylprotochlorophyllide-13C0[+QDA adduct]+ST000142AN0002256.730E-326.130E-31Treatment;13C-Glc;unlabeled
Epothilone C-13C0[+H]+ST000142AN0002256.420E-326.130E-31Treatment;13C-Glc;unlabeled
Flavonol 3-O-beta-glucosyl-(1->2)-beta-glucoside-13C0[+QDA adduct]+ST000142AN0002258.050E-326.130E-31Treatment;13C-Glc;unlabeled
Flavonol 3-O-xylosylglycoside-13C0[+13CD3 QDA]+ST000142AN0002259.430E-336.130E-31Treatment;13C-Glc;unlabeled
GD1b (36:2)-13C0[+13CD3 QDA]+ST000142AN0002251.030E-316.620E-31Treatment;13C-Glc;unlabeled
Geranylchrysin-13C0[+13CD3 QDA]+ST000142AN0002251.150E-317.100E-31Treatment;13C-Glc;unlabeled
Glutamate semialdehyde-13C0[+13CD3 QDA]+ST000142AN0002254.230E-22.280E-1Treatment;13C-Glc;unlabeled
GQ1c (34:1)-13C0[+13CD3 QDA]+ST000142AN0002253.610E-326.130E-31Treatment;13C-Glc;unlabeled
Hinokitiol glucoside-13C0[+H]+ST000142AN0002258.870E-326.150E-31Treatment;13C-Glc;unlabeled
Hydrocortisone sodium succinate-13C0[+13CD3 QDA]+ST000142AN0002253.900E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C1[+H]+ST000142AN0002254.640E-22.470E-1Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C4[+H]+ST000142AN0002252.140E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C8[+H]+ST000142AN0002252.480E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxyamoorstatin-13C0[+QDA adduct]+ST000142AN0002255.380E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxyanthraquinone-13C0[+QDA adduct+Na]+ST000142AN0002251.590E-319.480E-31Treatment;13C-Glc;unlabeled
Hydroxy-carboxybenzalpyruvate-13C0[+H]+ST000142AN0002259.320E-326.180E-31Treatment;13C-Glc;unlabeled
Hydroxycinnamyl aldehyde-13C0[+Na]+ST000142AN0002255.910E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxyhexanone-13C0[+QDA adduct]+ST000142AN0002254.300E-32.500E-2Treatment;13C-Glc;unlabeled
Hydroxykynurenamine-13C0[+QDA adduct]+ST000142AN0002253.570E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxykynurenamine-13C0[+QDA adduct+Na]+ST000142AN0002254.120E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxymuconic semialdehyde-13C0[+QDA adduct+Na]+ST000142AN0002251.170E-317.200E-31Treatment;13C-Glc;unlabeled
Hydroxy-naphthoquinone-13C0[+H]+ST000142AN0002252.770E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxyretinal-13C0[+H]+ST000142AN0002252.100E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxystreptomycin-13C0[+H]+ST000142AN0002257.880E-326.130E-31Treatment;13C-Glc;unlabeled
Hygromycin A-13C0[+QDA adduct]+ST000142AN0002251.300E-317.850E-31Treatment;13C-Glc;unlabeled
Isophenoxazine-13C0[+H]+ST000142AN0002255.900E-326.130E-31Treatment;13C-Glc;unlabeled
Isophenoxazine-13C10[+QDA adduct+Na]+ST000142AN0002255.620E-326.130E-31Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C6[+QDA adduct]+ST000142AN0002256.800E-326.130E-31Treatment;13C-Glc;unlabeled
Ketoetiocholanolone-13C0[+Na]+ST000142AN0002255.390E-326.130E-31Treatment;13C-Glc;unlabeled
Ketohexanoate-13C5[+QDA adduct]+ST000142AN0002254.640E-22.470E-1Treatment;13C-Glc;unlabeled
Khellol glucoside-13C0[+13CD3 QDA]+ST000142AN0002252.100E-21.180E-1Treatment;13C-Glc;unlabeled
Kolanone-13C0[+H]+ST000142AN0002256.620E-326.130E-31Treatment;13C-Glc;unlabeled
Lankamycin-13C0[+QDA adduct]+ST000142AN0002254.800E-326.130E-31Treatment;13C-Glc;unlabeled
Maleylpyruvate-13C0[+QDA adduct+Na]+ST000142AN0002252.510E-21.400E-1Treatment;13C-Glc;unlabeled
Melengestrol acetate-13C0[+Na]+ST000142AN0002258.110E-326.130E-31Treatment;13C-Glc;unlabeled
Methyl-isopropylhexadienal-13C0[+13CD3 QDA]+ST000142AN0002254.260E-22.290E-1Treatment;13C-Glc;unlabeled
Methyl-isopropylhexadienal-13C0[+Na]+ST000142AN0002252.650E-326.130E-31Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C0[+QDA adduct]+ST000142AN0002256.680E-326.130E-31Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C1[+QDA adduct]+ST000142AN0002252.700E-326.130E-31Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C6[+QDA adduct]+ST000142AN0002256.950E-326.130E-31Treatment;13C-Glc;unlabeled
N2-Succinyl-glutamic acid 5-semialdehyde-13C0[+H]+ST000142AN0002258.310E-326.130E-31Treatment;13C-Glc;unlabeled
N2-Succinyl-glutamic acid 5-semialdehyde-13C1[+H]+ST000142AN0002256.150E-326.130E-31Treatment;13C-Glc;unlabeled
Nanchangmycin-13C0[+Na]+ST000142AN0002254.090E-326.130E-31Treatment;13C-Glc;unlabeled
Nanchangmycin-13C0[+QDA adduct+Na]+ST000142AN0002258.090E-326.130E-31Treatment;13C-Glc;unlabeled
Nanchangmycin-13C1[+QDA adduct+Na]+ST000142AN0002256.600E-326.130E-31Treatment;13C-Glc;unlabeled
Naphthoquinone-13C0[+H]+ST000142AN0002258.730E-326.130E-31Treatment;13C-Glc;unlabeled
Nigakilactone K-13C0[+13CD3 QDA]+ST000142AN0002252.760E-326.130E-31Treatment;13C-Glc;unlabeled
Nigakilactone M-13C0[+QDA adduct+Na]+ST000142AN0002255.520E-326.130E-31Treatment;13C-Glc;unlabeled
Nitrophenyl-ketovalidamine-13C0[+H]+ST000142AN0002255.450E-326.130E-31Treatment;13C-Glc;unlabeled
N-Methyl-2-oxoglutaramate-13C0[+Na]+ST000142AN0002252.340E-326.130E-31Treatment;13C-Glc;unlabeled
N-tert-Butyloxycarbonyl-deacetyl-leupeptin-13C0[+13CD3 QDA]+ST000142AN0002255.550E-326.130E-31Treatment;13C-Glc;unlabeled
Oleoylglycerone phosphate-13C0[+QDA adduct+Na]+ST000142AN0002256.230E-326.130E-31Treatment;13C-Glc;unlabeled
Oxalomalate-13C0[+H]+ST000142AN0002257.760E-326.130E-31Treatment;13C-Glc;unlabeled
Oxalomalate-13C1[+H]+ST000142AN0002252.920E-326.130E-31Treatment;13C-Glc;unlabeled
Oxo-4-phosphonobutanoate-13C0[+QDA adduct]+ST000142AN0002256.860E-326.130E-31Treatment;13C-Glc;unlabeled
Oxononanoate-13C8[+QDA adduct]+ST000142AN0002252.010E-326.130E-31Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C0[+H]+ST000142AN0002251.110E-316.910E-31Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C0[+QDA adduct+Na]+ST000142AN0002251.690E-326.130E-31Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C1[+QDA adduct+Na]+ST000142AN0002255.980E-326.130E-31Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C4[+QDA adduct+Na]+ST000142AN0002252.580E-326.130E-31Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C5[+QDA adduct+Na]+ST000142AN0002254.840E-326.130E-31Treatment;13C-Glc;unlabeled
Oxostearate-13C0[+H]+ST000142AN0002258.300E-326.130E-31Treatment;13C-Glc;unlabeled
Oxostearate-13C2[+QDA adduct]+ST000142AN0002251.450E-28.270E-2Treatment;13C-Glc;unlabeled
PD116740-13C0[+QDA adduct]+ST000142AN0002257.770E-326.130E-31Treatment;13C-Glc;unlabeled
PD116740-13C1[+QDA adduct]+ST000142AN0002257.280E-326.130E-31Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C0[+QDA adduct]+ST000142AN0002258.640E-326.130E-31Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C12[+QDA adduct]+ST000142AN0002253.270E-326.130E-31Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C1[+QDA adduct]+ST000142AN0002254.080E-326.130E-31Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C9[+QDA adduct]+ST000142AN0002259.560E-326.280E-31Treatment;13C-Glc;unlabeled
Phenylpyruviate-13C6[+QDA adduct]+ST000142AN0002257.140E-326.130E-31Treatment;13C-Glc;unlabeled
Phosphohydroxypyruvate-13C0[+H]+ST000142AN0002251.100E-316.910E-31Treatment;13C-Glc;unlabeled
Picrasin F-13C0[+13CD3 QDA]+ST000142AN0002256.350E-326.130E-31Treatment;13C-Glc;unlabeled
Picrasin F-13C1[+13CD3 QDA]+ST000142AN0002259.220E-326.150E-31Treatment;13C-Glc;unlabeled
Picrasin F-13C19[+13CD3 QDA]+ST000142AN0002257.080E-326.130E-31Treatment;13C-Glc;unlabeled
Picrasin F-13C20[+13CD3 QDA]+ST000142AN0002253.170E-326.130E-31Treatment;13C-Glc;unlabeled
Prednisolone 21-all-cis-farnesylate-13C0[+QDA adduct]+ST000142AN0002257.370E-326.130E-31Treatment;13C-Glc;unlabeled
Prephenate-13C0[+H]+ST000142AN0002256.440E-326.130E-31Treatment;13C-Glc;unlabeled
Prohydrojasmon-13C0[+13CD3 QDA]+ST000142AN0002252.850E-21.570E-1Treatment;13C-Glc;unlabeled
Prohydrojasmon-13C0[+H]+ST000142AN0002252.740E-326.130E-31Treatment;13C-Glc;unlabeled
Propiomazine hydrochloride-13C0[+13CD3 QDA]+ST000142AN0002255.850E-326.130E-31Treatment;13C-Glc;unlabeled
Quinoclamin-13C0[+H]+ST000142AN0002256.030E-326.130E-31Treatment;13C-Glc;unlabeled
Quinoclamin-13C0[+Na]+ST000142AN0002258.930E-326.150E-31Treatment;13C-Glc;unlabeled
Rehmaionoside C-13C0[+Na]+ST000142AN0002257.870E-326.130E-31Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C0[+13CD3 QDA]+ST000142AN0002257.020E-326.130E-31Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C1[+13CD3 QDA]+ST000142AN0002256.260E-326.130E-31Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C2[+13CD3 QDA]+ST000142AN0002258.350E-326.130E-31Treatment;13C-Glc;unlabeled
Rifamycin S-13C0[+QDA adduct]+ST000142AN0002252.520E-326.130E-31Treatment;13C-Glc;unlabeled
SC-1271-13C0[+QDA adduct+Na]+ST000142AN0002258.850E-326.150E-31Treatment;13C-Glc;unlabeled
Sedoheptulose phosphate-13C0[+Na]+ST000142AN0002252.130E-326.130E-31Treatment;13C-Glc;unlabeled
Sethoxydim-13C0[+H]+ST000142AN0002258.690E-326.130E-31Treatment;13C-Glc;unlabeled
Sialyllactosamine-13C0[+QDA adduct+Na]+ST000142AN0002255.350E-326.130E-31Treatment;13C-Glc;unlabeled
Sodium equilin sulfate-13C0[+13CD3 QDA]+ST000142AN0002255.060E-326.130E-31Treatment;13C-Glc;unlabeled
Spectinomycin dihydrochloride-13C0[+QDA adduct+Na]+ST000142AN0002259.010E-326.150E-31Treatment;13C-Glc;unlabeled
Stanolone benzoate-13C0[+Na]+ST000142AN0002254.070E-326.130E-31Treatment;13C-Glc;unlabeled
Tepraloxydim-13C0[+13CD3 QDA]+ST000142AN0002254.220E-326.130E-31Treatment;13C-Glc;unlabeled
Testosterone decanoate-13C0[+13CD3 QDA]+ST000142AN0002259.330E-326.180E-31Treatment;13C-Glc;unlabeled
Testosterone isocaproate-13C9[+Na]+ST000142AN0002256.080E-326.130E-31Treatment;13C-Glc;unlabeled
Thujaplicin-13C0[+13CD3 QDA]+ST000142AN0002251.090E-26.280E-2Treatment;13C-Glc;unlabeled
Triamcinolone diacetate-13C0[+QDA adduct+Na]+ST000142AN0002258.050E-326.130E-31Treatment;13C-Glc;unlabeled
Trinexapac-ethyl-13C0[+Na]+ST000142AN0002258.640E-326.130E-31Treatment;13C-Glc;unlabeled
Uracil 5-carbaldehyde-13C1[+QDA adduct]+ST000142AN0002256.390E-326.130E-31Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C0[+Na]+ST000142AN0002253.150E-326.130E-31Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C1[+Na]+ST000142AN0002252.720E-326.130E-31Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C9[+Na]+ST000142AN0002253.510E-326.130E-31Treatment;13C-Glc;unlabeled
Xanthumin-13C0[+Na]+ST000142AN0002254.910E-22.600E-1Treatment;13C-Glc;unlabeled
YC-17-13C0[+Na]+ST000142AN0002256.070E-326.130E-31Treatment;13C-Glc;unlabeled
11-O-Demethylpradimicinone II-13C0[+13CD3 QDA]+ST000148AN0002357.990E-34.100E-2Treatment;13C-Glc;unlabeled
12-(2-Cyclopenten-1-yl)-2-dodecanone-13C10[+QDA adduct]+ST000148AN0002351.930E-27.980E-2Treatment;13C-Glc;unlabeled
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C0[+Na]+ST000148AN0002351.390E-26.240E-2Treatment;13C-Glc;unlabeled
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C1[+13CD3 QDA]+ST000148AN0002351.730E-27.400E-2Treatment;13C-Glc;unlabeled
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C1[+QDA adduct]+ST000148AN0002354.770E-21.620E-1Treatment;13C-Glc;unlabeled
17beta-Hydroxy-5alpha-androst-2-ene-2-carboxaldehyde-13C1[+QDA adduct]+ST000148AN0002353.130E-21.160E-1Treatment;13C-Glc;unlabeled
2-Dehydro-3-deoxy-arabinonate-13C0[+Na]+ST000148AN0002357.440E-33.890E-2Treatment;13C-Glc;unlabeled
3-Oxotetradecanoate-13C0[+13CD3 QDA]+ST000148AN0002356.750E-33.650E-2Treatment;13C-Glc;unlabeled
3-Oxotetradecanoate-13C0[+QDA adduct]+ST000148AN0002352.540E-29.830E-2Treatment;13C-Glc;unlabeled
4-Nitroestrone-13C0[+QDA adduct]+ST000148AN0002351.460E-67.450E-4Treatment;13C-Glc;unlabeled
4-Oxocyclohexanecarboxylate-13C0[+QDA adduct]+ST000148AN0002353.020E-21.130E-1Treatment;13C-Glc;unlabeled
[6]-Shogaol-13C0[+H]+ST000148AN0002351.370E-31.450E-2Treatment;13C-Glc;unlabeled
Abscisic acid GLC ester-13C0[+Na]+ST000148AN0002355.820E-33.310E-2Treatment;13C-Glc;unlabeled
Abscisic acid GLC ester-13C16[+Na]+ST000148AN0002356.410E-33.520E-2Treatment;13C-Glc;unlabeled
alpha-Amylcinnamaldehyde-13C0[+QDA adduct]+ST000148AN0002356.010E-33.370E-2Treatment;13C-Glc;unlabeled
Anaferine-13C0[+13CD3 QDA]+ST000148AN0002354.860E-32.940E-2Treatment;13C-Glc;unlabeled
Benzoquinoneacetate-13C0[+QDA adduct]+ST000148AN0002353.130E-21.160E-1Treatment;13C-Glc;unlabeled
CAI-1-13C0[+13CD3 QDA]+ST000148AN0002354.410E-21.530E-1Treatment;13C-Glc;unlabeled
Capillone-13C0[+13CD3 QDA]+ST000148AN0002355.810E-33.310E-2Treatment;13C-Glc;unlabeled
Capillone-13C0[+QDA adduct]+ST000148AN0002351.700E-27.280E-2Treatment;13C-Glc;unlabeled
Capillone-13C1[+QDA adduct]+ST000148AN0002351.390E-26.250E-2Treatment;13C-Glc;unlabeled
Chloroacetoacetanilide-13C0[+QDA adduct+Na]+ST000148AN0002357.540E-33.930E-2Treatment;13C-Glc;unlabeled
Chloroacetoacetanilide-13C1[+QDA adduct+Na]+ST000148AN0002355.920E-33.340E-2Treatment;13C-Glc;unlabeled
Deoxydaunorubicin-13C0[+QDA adduct]+ST000148AN0002353.020E-47.150E-3Treatment;13C-Glc;unlabeled
Dihydrodaunorubicin-13C0[+13CD3 QDA]+ST000148AN0002353.340E-32.300E-2Treatment;13C-Glc;unlabeled
Flavonol 3-O-xylosylglycoside-13C1[+QDA adduct]+ST000148AN0002351.250E-105.430E-7Treatment;13C-Glc;unlabeled
Flavonol 3-O-xylosylglycoside-13C23[+QDA adduct]+ST000148AN0002351.610E-52.710E-3Treatment;13C-Glc;unlabeled
Geranylgeranylacetone-13C0[+QDA adduct]+ST000148AN0002353.640E-32.440E-2Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C0[+Na]+ST000148AN0002359.410E-34.640E-2Treatment;13C-Glc;unlabeled
Hydroxyandrosterone-13C0[+Na]+ST000148AN0002357.880E-34.060E-2Treatment;13C-Glc;unlabeled
Hydroxycinnamyl aldehyde-13C0[+Na]+ST000148AN0002357.890E-34.060E-2Treatment;13C-Glc;unlabeled
Hydroxykynurenamine-13C0[+13CD3 QDA]+ST000148AN0002353.600E-32.410E-2Treatment;13C-Glc;unlabeled
Hydroxynonenal-13C0[+13CD3 QDA]+ST000148AN0002358.770E-34.400E-2Treatment;13C-Glc;unlabeled
Hydroxynonenal-13C0[+QDA adduct]+ST000148AN0002352.300E-29.170E-2Treatment;13C-Glc;unlabeled
Hydroxynonenal-13C1[+QDA adduct]+ST000148AN0002354.190E-21.470E-1Treatment;13C-Glc;unlabeled
Hydroxynonenal-13C5[+QDA adduct]+ST000148AN0002352.390E-29.450E-2Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C0[+13CD3 QDA]+ST000148AN0002354.430E-21.530E-1Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C1[+13CD3 QDA]+ST000148AN0002359.130E-34.540E-2Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C5[+QDA adduct]+ST000148AN0002352.460E-29.630E-2Treatment;13C-Glc;unlabeled
Ketohexanoate-13C0[+QDA adduct+Na]+ST000148AN0002356.690E-33.630E-2Treatment;13C-Glc;unlabeled
Ketohexanoate-13C1[+QDA adduct+Na]+ST000148AN0002352.270E-29.100E-2Treatment;13C-Glc;unlabeled
Lankamycin-13C0[+Na]+ST000148AN0002356.600E-33.600E-2Treatment;13C-Glc;unlabeled
Leucomycin A3-13C0[+H]+ST000148AN0002351.050E-25.070E-2Treatment;13C-Glc;unlabeled
Manumycin A-13C0[+H]+ST000148AN0002357.440E-33.890E-2Treatment;13C-Glc;unlabeled
Manumycin A-13C16[+H]+ST000148AN0002353.460E-21.260E-1Treatment;13C-Glc;unlabeled
Manumycin A-13C17[+H]+ST000148AN0002351.110E-25.230E-2Treatment;13C-Glc;unlabeled
Methoxycinnamaldehyde-13C0[+QDA adduct]+ST000148AN0002352.010E-28.250E-2Treatment;13C-Glc;unlabeled
Methyl butenal-13C0[+13CD3 QDA]+ST000148AN0002351.460E-26.480E-2Treatment;13C-Glc;unlabeled
O-6-deoxy-a-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-D-Galactose-13C0[+13CD3 QDA]+ST000148AN0002354.660E-61.310E-3Treatment;13C-Glc;unlabeled
Oleandrosyl-oleandolide-13C0[+QDA adduct]+ST000148AN0002351.650E-31.610E-2Treatment;13C-Glc;unlabeled
Oleoylglycerone phosphate-13C0[+H]+ST000148AN0002352.350E-29.320E-2Treatment;13C-Glc;unlabeled
Oxidized Latia luciferin-13C0[+13CD3 QDA]+ST000148AN0002351.810E-27.610E-2Treatment;13C-Glc;unlabeled
Oxidized Latia luciferin-13C10[+QDA adduct]+ST000148AN0002351.550E-26.770E-2Treatment;13C-Glc;unlabeled
Oxidized Latia luciferin-13C1[+13CD3 QDA]+ST000148AN0002353.430E-21.250E-1Treatment;13C-Glc;unlabeled
Oxidized Latia luciferin-13C1[+QDA adduct]+ST000148AN0002354.030E-21.420E-1Treatment;13C-Glc;unlabeled
Oxodecanoate-13C0[+13CD3 QDA]+ST000148AN0002352.450E-29.600E-2Treatment;13C-Glc;unlabeled
Oxodecanoate-13C0[+QDA adduct]+ST000148AN0002351.060E-25.080E-2Treatment;13C-Glc;unlabeled
Oxodecanoate-13C1[+13CD3 QDA]+ST000148AN0002356.930E-33.720E-2Treatment;13C-Glc;unlabeled
Oxodecanoate-13C1[+QDA adduct]+ST000148AN0002354.170E-21.460E-1Treatment;13C-Glc;unlabeled
Oxodecanoate-13C3[+QDA adduct]+ST000148AN0002356.360E-33.510E-2Treatment;13C-Glc;unlabeled
Oxododecanoate-13C0[+13CD3 QDA]+ST000148AN0002354.190E-21.470E-1Treatment;13C-Glc;unlabeled
Oxododecanoate-13C0[+QDA adduct]+ST000148AN0002358.390E-34.250E-2Treatment;13C-Glc;unlabeled
Oxododecanoate-13C1[+QDA adduct]+ST000148AN0002353.210E-21.180E-1Treatment;13C-Glc;unlabeled
Oxononanoate-13C0[+13CD3 QDA]+ST000148AN0002352.360E-29.330E-2Treatment;13C-Glc;unlabeled
Oxononanoate-13C0[+QDA adduct]+ST000148AN0002353.360E-21.230E-1Treatment;13C-Glc;unlabeled
Oxononanoate-13C1[+13CD3 QDA]+ST000148AN0002354.760E-21.620E-1Treatment;13C-Glc;unlabeled
Oxononanoate-13C1[+QDA adduct]+ST000148AN0002352.240E-29.000E-2Treatment;13C-Glc;unlabeled
Oxooctanoate-13C0[+QDA adduct+Na]+ST000148AN0002353.030E-21.140E-1Treatment;13C-Glc;unlabeled
Oxooctanoate-13C1[+QDA adduct]+ST000148AN0002354.060E-21.430E-1Treatment;13C-Glc;unlabeled
Oxostearate-13C0[+Na]+ST000148AN0002352.370E-31.850E-2Treatment;13C-Glc;unlabeled
Oxytetracycline hydrochloride-13C0[+13CD3 QDA]+ST000148AN0002352.400E-29.470E-2Treatment;13C-Glc;unlabeled
Phenylglyoxylate-13C0[+13CD3 QDA]+ST000148AN0002357.610E-33.960E-2Treatment;13C-Glc;unlabeled
Phenylpyruviate-13C1[+13CD3 QDA]+ST000148AN0002356.480E-33.560E-2Treatment;13C-Glc;unlabeled
Phorbol 12-tiglate 13-decanoate-13C0[+Na]+ST000148AN0002356.110E-33.400E-2Treatment;13C-Glc;unlabeled
Phorbol butanoate-13C0[+QDA adduct]+ST000148AN0002351.900E-31.700E-2Treatment;13C-Glc;unlabeled
Picrasin C-13C0[+13CD3 QDA]+ST000148AN0002352.450E-29.610E-2Treatment;13C-Glc;unlabeled
Picrasin C-13C0[+QDA adduct]+ST000148AN0002351.080E-25.150E-2Treatment;13C-Glc;unlabeled
Picrasin C-13C1[+13CD3 QDA]+ST000148AN0002353.230E-53.240E-3Treatment;13C-Glc;unlabeled
Prohydrojasmon-13C0[+13CD3 QDA]+ST000148AN0002355.970E-33.350E-2Treatment;13C-Glc;unlabeled
Rimocidine-13C0[+H]+ST000148AN0002357.180E-33.810E-2Treatment;13C-Glc;unlabeled
Sphingosine(18:0)-13C0[+H]+ST000148AN0002359.610E-34.710E-2Treatment;13C-Glc;unlabeled
Sulfinopyruvate-13C0[+QDA adduct+Na]+ST000148AN0002352.290E-29.160E-2Treatment;13C-Glc;unlabeled
Sulfinopyruvate-13C1[+QDA adduct+Na]+ST000148AN0002355.760E-33.300E-2Treatment;13C-Glc;unlabeled
Tecomine-13C0[+13CD3 QDA]+NH4ST000148AN0002352.390E-31.850E-2Treatment;13C-Glc;unlabeled
U 0521-13C0[+QDA adduct]+NH4ST000148AN0002351.890E-31.700E-2Treatment;13C-Glc;unlabeled
Undecanone-13C0[+13CD3 QDA]+ST000148AN0002358.510E-34.300E-2Treatment;13C-Glc;unlabeled
Undecanone-13C0[+H]+ST000148AN0002357.430E-33.890E-2Treatment;13C-Glc;unlabeled
Undecanone-13C0[+QDA adduct]+ST000148AN0002351.250E-25.750E-2Treatment;13C-Glc;unlabeled
Undecanone-13C2[+QDA adduct]+ST000148AN0002354.130E-21.450E-1Treatment;13C-Glc;unlabeled
Undecanone-13C6[+QDA adduct]+ST000148AN0002353.280E-61.080E-3Treatment;13C-Glc;unlabeled
Uscharidin-13C0[+QDA adduct+Na]+ST000148AN0002351.720E-27.330E-2Treatment;13C-Glc;unlabeled
Xanthoxin-13C0[+QDA adduct]+ST000148AN0002352.540E-29.840E-2Treatment;13C-Glc;unlabeled
ValproateST000150AN0002375.750E-31.740E-1Patient;Patient 1;Patient 2;Patient 3;Patient 4
2-HB (2-hydroxybutyric acid)ST000166AN0002594.310E-31.410E-2Group;3M;Control;HF
3-AIB (a-amino[1-(14)C]isobutyric acid)ST000166AN0002591.280E-22.860E-2Group;3M;Control;HF
3-HB (3-hydroxybutyric acid)ST000166AN0002593.850E-26.650E-2Group;3M;Control;HF
myo-Inositol 1-phosphate/myo-Inositol 3-phosphateST000230AN0003436.990E-34.930E-2Tissue Type;HCC (Hepatocellular carcinoma);HCC-NT (surrounde...
Ile-Ala/Leu-AlaST000230AN0003446.890E-38.710E-2Tissue Type;HCC (Hepatocellular carcinoma);HCC-NT (surrounde...
11-Hydroxyeicosatetraenoate glyceryl esterST000241AN0003735.360E-59.230E-5Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
16b-HydroxystanozololST000241AN0003731.240E-31.770E-3Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
3-Hydroxyhexdecanedioyl-CoAST000241AN0003739.070E-41.330E-3Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4Alpha-hydroxymethyl-5alpha-cholesta-8-en-3beta-olST000241AN0003737.190E-81.800E-7Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-oxo-Retinoic acidST000241AN0003739.630E-125.570E-11Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-PhosphopantothenoylcysteineST000241AN0003735.210E-102.020E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
5b-PregnediolST000241AN0003732.240E-33.130E-3Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
5-Taurinomethyl-2-thiouridineST000241AN0003736.310E-123.760E-11Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
6-Hydroxy flavin adenine dinucleotideST000241AN0003736.150E-65.140E-5Concentration (uM);0;500
6-Hydroxy flavin adenine dinucleotideST000241AN0003731.380E-21.700E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
8-iso-15-keto-PGE2ST000241AN0003731.530E-131.480E-12Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Adenosylcobimide-GDPST000241AN0003733.240E-55.790E-5Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
CotinineglucuronideST000241AN0003732.240E-185.270E-17Concentration (uM);0;500
CotinineglucuronideST000241AN0003731.750E-119.140E-11Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Dimethylarsinous acidST000241AN0003731.330E-62.860E-6Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Disialyllacto-N-tetraoseST000241AN0003731.430E-95.060E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Disialyllacto-N-tetraoseST000241AN0003731.770E-28.770E-2Concentration (uM);0;500
Dolichyl beta-D-mannosyl phosphateST000241AN0003738.010E-102.980E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Estriol 3-sulfate 16-glucuronideST000241AN0003733.370E-88.730E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Galabiosylceramide (d18:1/26:0)ST000241AN0003736.080E-157.880E-14Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ganglioside GM3 (d18:0/16:0)ST000241AN0003731.360E-62.910E-6Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ganglioside GM3 (d18:0/24:0)ST000241AN0003731.470E-42.350E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ganglioside GT3 (d18:1/18:1(11Z))ST000241AN0003731.830E-107.660E-10Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Kinetensin 4-7ST000241AN0003731.550E-42.490E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
L-Aspartyl-4-phosphateST000241AN0003739.100E-92.650E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
L(-)-Nicotine pestalST000241AN0003731.010E-217.610E-20Concentration (uM);0;500
L(-)-Nicotine pestalST000241AN0003734.800E-156.450E-14Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
MG(18:0e/0:0/0:0)ST000241AN0003732.910E-99.670E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Molybdenum cofactor (sulfide)ST000241AN0003733.530E-246.640E-22Concentration (uM);0;500
Molybdenum cofactor (sulfide)ST000241AN0003731.180E-162.220E-15Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
O-(N-acetyl-a-neuraminosyl)-(2->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)- D-GlucST000241AN0003732.600E-86.890E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
O-(N-acetyl-a-neuraminosyl)-(2->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)- D-GlucST000241AN0003738.810E-46.020E-3Concentration (uM);0;500
PC(14:1(9Z)/P-16:0)ST000241AN0003732.280E-31.380E-2Concentration (uM);0;500
PC(14:1(9Z)/P-16:0)ST000241AN0003733.180E-34.350E-3Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PC(14:1(9Z)/P-18:1(11Z))ST000241AN0003739.260E-136.960E-12Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PC(22:0/P-18:1(11Z))ST000241AN0003731.980E-53.600E-5Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PC(24:1(15Z)/P-18:1(11Z))ST000241AN0003734.830E-134.220E-12Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PE(14:0/P-18:1(11Z))ST000241AN0003731.200E-62.630E-6Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PE(14:1(9Z)/P-16:0)ST000241AN0003732.680E-123.250E-11Concentration (uM);0;500
PE(14:1(9Z)/P-16:0)ST000241AN0003738.460E-92.510E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PE(16:0/P-18:1(11Z))ST000241AN0003737.990E-92.420E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PE(16:1(9Z)/P-18:1(11Z))ST000241AN0003734.310E-101.710E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PGF2a ethanolamideST000241AN0003732.030E-43.160E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PGP(18:0/18:1(11Z))ST000241AN0003734.490E-25.140E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PIP(16:0/20:1(11Z))ST000241AN0003737.200E-135.890E-12Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PregnetriolST000241AN0003731.090E-41.780E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Prostaglandin E2 ethanolamideST000241AN0003732.180E-22.620E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
(R)-3-Hydroxy-Octadecanoic acidST000241AN0003731.570E-42.500E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
S-AdenosylmethionimineST000241AN0003731.420E-173.870E-16Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Trihexosylceramide (d18:1/24:0)ST000241AN0003737.560E-71.680E-6Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Trihexosylceramide (d18:1/9Z-18:1)ST000241AN0003731.590E-118.670E-11Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
TriphosphateST000241AN0003733.510E-24.150E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
TriterpenoidST000241AN0003736.640E-92.030E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
AzythromycinST000241AN0003746.490E-101.640E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Lactosylceramide (d18:1/12:0)ST000241AN0003742.210E-39.300E-3Concentration (uM);0;500
Lactosylceramide (d18:1/12:0)ST000241AN0003741.630E-21.650E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Trihexosylceramide (d18:1/18:0)ST000241AN0003741.070E-23.970E-2Concentration (uM);0;500
Trihexosylceramide (d18:1/18:0)ST000241AN0003742.380E-22.380E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
2-Amino-3-methyl-1-butanolST000242AN0003751.860E-101.670E-9Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
2-Hydroxyiminodibenzyl glucuronideST000242AN0003751.220E-83.370E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
CitioloneST000242AN0003752.550E-64.590E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Cyclopiazonic AcidST000242AN0003754.050E-78.580E-7Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Digitoxigenin bisdigitoxosideST000242AN0003756.820E-92.040E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
FKGK 11ST000242AN0003755.550E-103.630E-9Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Kanokoside DST000242AN0003752.860E-91.140E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Malyngamide JST000242AN0003754.670E-91.530E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Met-Trp-OHST000242AN0003754.610E-126.640E-11Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-(4-benzenesulfonamide) arachidonoyl amineST000242AN0003751.130E-21.380E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Tyrphostin B44 (-)ST000242AN0003758.710E-41.180E-3Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
WestiellamideST000242AN0003755.420E-58.300E-5Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
F-Honaucin AST000242AN0003765.440E-45.930E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-Succinyl-L-diaminopimelic acidST000242AN0003764.500E-71.350E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
OxonitineST000242AN0003761.670E-76.660E-7Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Penicilloic G acidST000242AN0003764.330E-67.430E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Tyrphostin B44 (-)ST000242AN0003765.890E-71.410E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Digitoxigenin bisdigitoxosideST000242AN0003771.140E-71.490E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Digoxigenin bisdigitoxosideST000242AN0003774.600E-21.030E-1Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
ErgineST000242AN0003774.900E-21.070E-1Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
FKGK 11ST000242AN0003771.770E-24.940E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Gal?1-3Gal?1-4GlcNAc?-SpST000242AN0003771.120E-46.330E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
GlucocerebrosidesST000242AN0003773.060E-52.020E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
HexazinoneST000242AN0003774.390E-31.650E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
His-Thr-OHST000242AN0003772.520E-26.370E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Hydroxytetrabenazine glucuronideST000242AN0003771.160E-71.490E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Istamycin CST000242AN0003774.540E-74.840E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Istamycin C1ST000242AN0003771.010E-57.770E-5Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
LabriformidinST000242AN0003771.830E-37.970E-3Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Malyngamide JST000242AN0003778.870E-81.420E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
?-Methyltryptamine (AMT)ST000242AN0003771.330E-23.980E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-(3-pyridyl)-Indomethacin amideST000242AN0003772.820E-26.760E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Naloxone-3-glucuronideST000242AN0003779.460E-44.330E-3Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-methylundec-10-enamideST000242AN0003772.130E-38.880E-3Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Phosphatidyl glycerolST000242AN0003774.150E-101.590E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Spectinomycin adenylateST000242AN0003773.160E-52.020E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
UscharidinST000242AN0003771.210E-58.960E-5Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Yamogenin 3-O-neohesperidosideST000242AN0003771.210E-46.640E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
16-Oxo-palmitateST000248AN0003922.740E-27.260E-1Cell population;Fast-cycling cells;Slow-cyling cells
4-keto pentadecanoic acidST000248AN0003924.080E-27.260E-1Cell population;Fast-cycling cells;Slow-cyling cells
FumaricST000284AN0004524.470E-21.530E-1Patient group;CRC;Healthy;Polyp
gama-AminobutyrateST000284AN0004522.130E-21.150E-1Patient group;CRC;Healthy;Polyp
Hydroxyproline/AminolevulinateST000284AN0004529.630E-36.800E-2Patient group;CRC;Healthy;Polyp
Hyppuric AcidST000284AN0004523.160E-44.460E-3Patient group;CRC;Healthy;Polyp
KynorenateST000284AN0004522.580E-21.170E-1Patient group;CRC;Healthy;Polyp
(3-Arylcarbonyl)-alanineST000291AN0004644.050E-31.690E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
7-DeoxyloganetinST000291AN0004641.200E-23.760E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
(7R)-7-(5-Carboxy-5-oxopentanoyl)aminocephalosporinateST000291AN0004641.170E-66.990E-4Treatment ;Baseline urine;Urine after drinking apple juice;U...
CBS 113AST000291AN0004642.240E-25.970E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
DichlorophenST000291AN0004644.080E-28.100E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
ImazosulfuronST000291AN0004647.570E-81.350E-4Treatment ;Baseline urine;Urine after drinking apple juice;U...
IndanofanST000291AN0004645.960E-62.050E-3Treatment ;Baseline urine;Urine after drinking apple juice;U...
L-2-Amino-4-(hydroxymethylphosphinyl)butanoateST000291AN0004641.550E-24.620E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
M1ST000291AN0004643.330E-27.190E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
PhosphoagmatineST000291AN0004642.910E-31.420E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
(3-Arylcarbonyl)-alanineST000291AN0004653.910E-31.330E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
Ferrous lactateST000291AN0004653.460E-26.800E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
FuramizoleST000291AN0004655.790E-42.890E-2Treatment ;Baseline urine;Urine after drinking apple juice;U...
HeterocladolST000291AN0004655.270E-42.810E-2Treatment ;Baseline urine;Urine after drinking apple juice;U...
ValacyclovirST000291AN0004651.140E-35.000E-2Treatment ;Baseline urine;Urine after drinking apple juice;U...
2-Aceto-2-hydroxybutanoateST000292AN0004663.760E-39.180E-2Treatment ;Baseline plasma;Plasma after drinking apple juice...
3-(Methylthio)propanoateST000292AN0004661.610E-22.020E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
4-MaleylacetoacetateST000292AN0004661.680E-22.050E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
5-Guanidino-3-methyl-2-oxopentanoateST000292AN0004661.840E-22.060E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
5-Ureido-4-imidazole carboxylateST000292AN0004667.700E-131.790E-10Treatment ;Baseline plasma;Plasma after drinking apple juice...
Calcium salicylateST000292AN0004667.670E-43.090E-2Treatment ;Baseline plasma;Plasma after drinking apple juice...
CCCPST000292AN0004665.680E-31.200E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
Furfuryl alcoholST000292AN0004663.370E-38.440E-2Treatment ;Baseline plasma;Plasma after drinking apple juice...
MannopineST000292AN0004666.160E-31.220E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
MonodehydroascorbateST000292AN0004669.390E-31.530E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
N-(6-Aminohexanoyl)-6-aminohexanoateST000292AN0004662.960E-22.550E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
N-Amidino-L-glutamateST000292AN0004661.550E-21.970E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
Sodium ortho-phenylphenateST000292AN0004662.050E-22.180E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
Sulfacetamide sodium anhydrousST000292AN0004662.570E-52.380E-3Treatment ;Baseline plasma;Plasma after drinking apple juice...
Tolmetin sodiumST000292AN0004664.660E-23.250E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
Tos-Lys-CH2ClST000292AN0004664.730E-23.250E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
C6H12O6-HEXOSE/KETOSE/INOSITOLST000292AN0004671.350E-31.450E-2Treatment ;Baseline plasma;Plasma after drinking apple juice...
VanilloylglycineST000292AN0004671.970E-128.460E-11Treatment ;Baseline plasma;Plasma after drinking apple juice...
G3PST000301AN0004798.830E-88.240E-7Cell Line;L229;LN18;Pooled glioblastoma;U-138
Gl-OH3PST000301AN0004794.000E-38.300E-3Cell Line;L229;LN18;Pooled glioblastoma;U-138
MCOAST000301AN0004792.950E-25.160E-2Cell Line;L229;LN18;Pooled glioblastoma;U-138
FBPST000302AN0004801.520E-22.870E-2Labelint time (hours);0;1;24;3;48;72
G3PST000302AN0004801.210E-22.740E-2Labelint time (hours);0;1;24;3;48;72
1_iSTD PG (17:0/17:0)ST000342AN0005542.830E-36.330E-3Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
iSTD iSTD Ceramide (d18:1/17:0)ST000342AN0005542.100E-52.950E-4Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
iSTD iSTD FA (16:0)-d3ST000342AN0005543.350E-41.480E-3Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
iSTD iSTD MAG (17:0/0:0/0:0)ST000342AN0005547.630E-31.390E-2Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
iSTD iSTD PE (17:0/17:0)ST000342AN0005543.350E-36.870E-3Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
iSTD iSTD Ceramide (d18:1/17:0)ST000346AN0005622.790E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD FA (16:0)-d3ST000346AN0005621.590E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD MAG (17:0/0:0/0:0)ST000346AN0005621.900E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD PC (12:0/13:0)ST000346AN0005621.900E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD PG (17:0/17:0)ST000346AN0005621.470E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
2-amino-6-methylaminohexanoic acidST000355AN0005806.670E-32.440E-2Stage;1;2;3;4;-
2-oxo-4-methylvaleric acidST000355AN0005802.430E-31.070E-2Diagnosis;Breast cancer;Control
2-oxo-4-methylvaleric acidST000355AN0005804.490E-31.740E-2Stage;1;2;3;4;-
3-hydroxyoxyisovaleric acidST000355AN0005803.400E-31.360E-2Stage;1;2;3;4;-
6-deoxy-mannoseST000355AN0005803.100E-28.090E-2Stage;1;2;3;4;-
cis-3-HexenyllactateST000355AN0005804.660E-21.190E-1Diagnosis;Breast cancer;Control
glycolST000355AN0005808.320E-43.950E-3Stage;1;2;3;4;-
glycolST000355AN0005807.010E-32.720E-2Diagnosis;Breast cancer;Control
18-HydroxycorticosteroneST000355AN0005813.980E-29.380E-2Stage;1;2;3;4;-
6-Dehydrotestosterone glucuronideST000355AN0005812.430E-27.300E-2Stage;1;2;3;4;-
Bisnorcholic acidST000355AN0005813.690E-42.610E-3Stage;1;2;3;4;-
Bisnorcholic acidST000355AN0005818.200E-46.110E-3Diagnosis;Breast cancer;Control
PentosidineST000355AN0005811.370E-103.400E-9Diagnosis;Breast cancer;Control
PentosidineST000355AN0005812.550E-86.320E-7Stage;1;2;3;4;-
trans-Hexadec-2-enoyl carnitineST000355AN0005813.230E-28.950E-2Stage;1;2;3;4;-
1-stearoyl-rac-glycerolST000356AN0005826.550E-61.580E-5Diagnosis;breast cancer;control
1-stearoyl-rac-glycerolST000356AN0005821.140E-53.190E-5stage;-;2;3
2-oxo-3-methylvaleric acidST000356AN0005821.610E-271.800E-26Diagnosis;breast cancer;control
2-oxo-3-methylvaleric acidST000356AN0005822.980E-193.770E-18stage;-;2;3
2-oxo-4-methylvaleric acidST000356AN0005822.670E-283.370E-27Diagnosis;breast cancer;control
2-oxo-4-methylvaleric acidST000356AN0005826.850E-209.880E-19stage;-;2;3
2-pyrrolidone-5-carboxylic acidST000356AN0005822.020E-44.160E-4Diagnosis;breast cancer;control
2-pyrrolidone-5-carboxylic acidST000356AN0005821.270E-32.780E-3stage;-;2;3
3-hydroxyoxyisovaleric acidST000356AN0005824.060E-71.140E-6Diagnosis;breast cancer;control
3-hydroxyoxyisovaleric acidST000356AN0005821.550E-54.220E-5stage;-;2;3
(5-Amino-1H-tetraazol-1-yl)acetic acidST000356AN0005827.490E-133.150E-12Diagnosis;breast cancer;control
(5-Amino-1H-tetraazol-1-yl)acetic acidST000356AN0005827.550E-102.930E-9stage;-;2;3
Decosahexaenoic acidST000356AN0005822.700E-222.280E-21Diagnosis;breast cancer;control
Decosahexaenoic acidST000356AN0005828.270E-178.360E-16stage;-;2;3
ErythrotetrofuranoseST000356AN0005824.360E-71.190E-6Diagnosis;breast cancer;control
ErythrotetrofuranoseST000356AN0005822.070E-44.870E-4stage;-;2;3
Hydroxyglutaric acidST000356AN0005822.620E-66.620E-6Diagnosis;breast cancer;control
Hydroxyglutaric acidST000356AN0005823.590E-59.300E-5stage;-;2;3
L-2-aminobutyric acidST000356AN0005822.440E-23.980E-2Diagnosis;breast cancer;control
MethyltyrosineST000356AN0005827.610E-31.370E-2Diagnosis;breast cancer;control
MethyltyrosineST000356AN0005823.220E-25.800E-2stage;-;2;3
3-Methylglutaconic acidST000356AN0005831.110E-73.460E-7Diagnosis;breast cancer;control
3-Methylglutaconic acidST000356AN0005832.460E-57.640E-5stage;-;2;3
3-Pyridinebutanoic acidST000356AN0005831.940E-531.110E-51Diagnosis;breast cancer;control
3-Pyridinebutanoic acidST000356AN0005831.920E-301.100E-28stage;-;2;3
5-Amino-6-ribitylamino uracilST000356AN0005831.610E-444.580E-43Diagnosis;breast cancer;control
5-Amino-6-ribitylamino uracilST000356AN0005832.910E-266.220E-25stage;-;2;3
7b-HydroxydehydroepiandrosteroneST000356AN0005834.100E-71.250E-6Diagnosis;breast cancer;control
7b-HydroxydehydroepiandrosteroneST000356AN0005831.060E-32.590E-3stage;-;2;3
BiflorinST000356AN0005833.570E-427.620E-41Diagnosis;breast cancer;control
BiflorinST000356AN0005832.050E-265.020E-25stage;-;2;3
B-Sulfinyl pyruvateST000356AN0005835.230E-51.300E-4Diagnosis;breast cancer;control
B-Sulfinyl pyruvateST000356AN0005833.230E-48.510E-4stage;-;2;3
CoproporphyrinST000356AN0005833.960E-192.260E-18Diagnosis;breast cancer;control
CoproporphyrinST000356AN0005839.540E-166.270E-15stage;-;2;3
D-Alanyl-D-alanineST000356AN0005835.720E-41.170E-3Diagnosis;breast cancer;control
D-Alanyl-D-alanineST000356AN0005832.010E-34.650E-3stage;-;2;3
DimethylallylpyrophosphateST000356AN0005835.980E-41.200E-3Diagnosis;breast cancer;control
DimethylallylpyrophosphateST000356AN0005831.380E-22.580E-2stage;-;2;3
Histidylproline diketopiperazineST000356AN0005835.410E-51.320E-4Diagnosis;breast cancer;control
Histidylproline diketopiperazineST000356AN0005831.260E-33.030E-3stage;-;2;3
Isohomovanillic acidST000356AN0005834.110E-25.910E-2Diagnosis;breast cancer;control
Isohomovanillic acidST000356AN0005834.490E-27.390E-2stage;-;2;3
L-beta-aspartyl-L-phenylalanineST000356AN0005833.470E-161.690E-15Diagnosis;breast cancer;control
L-beta-aspartyl-L-phenylalanineST000356AN0005838.850E-134.880E-12stage;-;2;3
MethylnoradrenalineST000356AN0005836.850E-286.890E-27Diagnosis;breast cancer;control
MethylnoradrenalineST000356AN0005836.060E-196.480E-18stage;-;2;3
Se-MethylselenocysteineST000356AN0005833.580E-81.180E-7Diagnosis;breast cancer;control
Se-MethylselenocysteineST000356AN0005831.660E-76.310E-7stage;-;2;3
SertralineST000356AN0005831.090E-94.250E-9Diagnosis;breast cancer;control
SertralineST000356AN0005831.960E-88.160E-8stage;-;2;3
TetrahydroneopterinST000356AN0005838.300E-133.640E-12Diagnosis;breast cancer;control
TetrahydroneopterinST000356AN0005835.290E-92.260E-8stage;-;2;3
GQ1 d18:1 N18:0ST000362AN0005947.670E-78.820E-6Gender;1;2
GQ1 d18:1 N20:0ST000362AN0005948.170E-53.130E-4Gender;1;2
monohexsphST000362AN0005941.510E-45.210E-4Gender;1;2
monohexsphST000362AN0005942.420E-29.440E-1SmokingStatus;-;1
monohexsphST000362AN0005942.510E-21.310E-1Chronic_Bronchitis;1;-
OH-dihexcer d18:1 N16:0ST000362AN0005947.700E-31.060E-1Chronic_Bronchitis;1;-
OH-dihexcer d18:1 N18:0ST000362AN0005942.380E-36.540E-3Gender;1;2
OH-dihexcer d18:1 N18:0ST000362AN0005941.690E-21.260E-1Chronic_Bronchitis;1;-
OH-monohexcer d18:1 N16:0ST000362AN0005942.520E-51.340E-4Gender;1;2
OH-monohexcer d18:1 N16:0ST000362AN0005943.460E-31.630E-1GoldStage;3;4;2;1;-
OH-monohexcer d18:1 N18:0ST000362AN0005942.120E-34.880E-2Chronic_Bronchitis;1;-
OH-monohexcer d18:1 N20:0ST000362AN0005947.590E-31.540E-2Gender;1;2
OH-monohexcer d18:1 N24:0ST000362AN0005947.420E-31.540E-2Gender;1;2
sulfa d18:1 N16:0ST000362AN0005942.160E-36.220E-3Gender;1;2
sulfa d18:1 N20:0ST000362AN0005941.660E-21.260E-1Chronic_Bronchitis;1;-
sulfa d18:1 N20:0ST000362AN0005942.350E-24.150E-2Gender;1;2
sulfa d18:1 N22:0ST000362AN0005941.910E-51.220E-4Gender;1;2
sulfa d18:1 N22:0ST000362AN0005941.450E-34.880E-2Chronic_Bronchitis;1;-
sulfa d18:1 N22:0ST000362AN0005944.230E-26.260E-1Severe_Exacerbations;1;2;3;5;-
trihexcer d18:1 N16:0ST000362AN0005941.510E-22.820E-2Gender;1;2
Aminofructose 6-phosphate/Glucosamine 6-phosphate-13C3[-H+]-ST000367AN0006013.030E-29.720E-2Tissue type;nontumor;tumor
L-Glutamic-13C2[-H+]-ST000367AN0006013.160E-29.800E-2Tissue type;nontumor;tumor
L-Glutamic-13C3[-H+]-ST000367AN0006011.940E-29.070E-2Tissue type;nontumor;tumor
L-Glutamic-13C4[-H+]-ST000367AN0006011.210E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C1[-H+]-ST000367AN0006012.830E-29.640E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C2[-H+]-ST000367AN0006011.530E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C3[-H+]-ST000367AN0006011.950E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C4[-H+]-ST000367AN0006011.280E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C5[-H+]-ST000367AN0006011.430E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C6[-H+]-ST000367AN0006011.320E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C7[-H+]-ST000367AN0006011.510E-29.070E-2Tissue type;nontumor;tumor
SucroseAndDischarrides-13C11[-H+]-ST000367AN0006011.830E-29.070E-2Tissue type;nontumor;tumor
SucroseAndDischarrides-13C12[-H+]-ST000367AN0006014.690E-21.150E-1Tissue type;nontumor;tumor
SucroseAndDischarrides-13C6[-H+]-ST000367AN0006011.500E-29.070E-2Tissue type;nontumor;tumor
SucroseAndDischarrides-13C9[-H+]-ST000367AN0006012.450E-29.070E-2Tissue type;nontumor;tumor
2-deoxytetronic acid NISTST000368AN0006022.240E-44.050E-4Organ;Plasma;Serum;Serum or Plasma
5-hydroxynorvaline NISTST000368AN0006027.800E-51.500E-4Organ;Plasma;Serum;Serum or Plasma
acetophenone NISTST000368AN0006021.200E-31.880E-3Organ;Plasma;Serum;Serum or Plasma
beta-mannosylglycerateST000368AN0006021.210E-21.720E-2Organ;Plasma;Serum;Serum or Plasma
heptadecanoic acid NISTST000368AN0006021.250E-21.760E-2Organ;Plasma;Serum;Serum or Plasma
methylhexadecanoic acidST000368AN0006021.210E-99.110E-9Organ;Plasma;Serum;Serum or Plasma
2-oxogluconic acid NISTST000369AN0006032.370E-41.590E-3Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
2-oxogluconic acid NISTST000369AN0006033.590E-39.150E-3Organ;Plasma;Serum
2-oxogluconic acid NISTST000369AN0006031.500E-24.690E-2Gender;F;M;NA
2-oxogluconic acid NISTST000369AN0006032.660E-26.950E-2Smoker;Current;Former;NA
400671 carbohydrateST000369AN0006033.670E-31.670E-2Gender;F;M;NA
400671 carbohydrateST000369AN0006034.060E-31.500E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
400671 carbohydrateST000369AN0006037.310E-32.700E-2Smoker;Current;Former;NA
6-deoxyglucitol NISTST000369AN0006031.760E-39.370E-3Smoker;Current;Former;NA
6-deoxyglucitol NISTST000369AN0006035.020E-31.810E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
6-deoxyglucitol NISTST000369AN0006033.790E-29.390E-2Gender;F;M;NA
715929 carbohydrateST000369AN0006036.670E-42.050E-3Organ;Plasma;Serum
acetophenone NISTST000369AN0006039.910E-33.520E-2Gender;F;M;NA
cyano-L-alanineST000369AN0006031.380E-51.670E-4Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
cyano-L-alanineST000369AN0006031.060E-23.370E-2Smoker;Current;Former;NA
fucose + rhamnoseST000369AN0006031.020E-23.300E-2Smoker;Current;Former;NA
fucose + rhamnoseST000369AN0006033.300E-28.530E-2Gender;F;M;NA
glyoxalurea NISTST000369AN0006034.070E-72.210E-6Organ;Plasma;Serum
glyoxalurea NISTST000369AN0006033.670E-31.410E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
glyoxalurea NISTST000369AN0006032.850E-27.030E-2Smoker;Current;Former;NA
glyoxalurea NISTST000369AN0006033.250E-28.530E-2Gender;F;M;NA
heptadecanoic acid NISTST000369AN0006031.890E-35.180E-3Organ;Plasma;Serum
isolinoleic acid NISTST000369AN0006031.230E-33.600E-3Organ;Plasma;Serum
isolinoleic acid NISTST000369AN0006032.760E-27.030E-2Smoker;Current;Former;NA
lathosterol NISTST000369AN0006036.010E-44.350E-3Gender;F;M;NA
lathosterol NISTST000369AN0006031.650E-39.080E-3Smoker;Current;Former;NA
lathosterol NISTST000369AN0006033.990E-31.500E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
methylhexadecanoic acidST000369AN0006031.480E-38.350E-3Smoker;Current;Former;NA
methylhexadecanoic acidST000369AN0006031.510E-38.550E-3Gender;F;M;NA
methylhexadecanoic acidST000369AN0006035.670E-31.900E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
saccharic acidST000369AN0006033.350E-26.820E-2Organ;Plasma;Serum
trihydroxypyrazine NISTST000369AN0006031.160E-151.750E-14Organ;Plasma;Serum
butylamine NISTST000379AN0006132.450E-26.030E-2Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
cytidine-5-monophosphate NISTST000379AN0006131.980E-23.850E-2Time;10min;1hr;24hr;6hr
cytidine-5-monophosphate NISTST000379AN0006133.410E-27.700E-2Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
idonic acid NISTST000379AN0006135.530E-31.690E-2Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
idonic acid NISTST000379AN0006133.670E-26.590E-2Time;10min;1hr;24hr;6hr
lathosterol NISTST000379AN0006132.120E-35.090E-3Time;10min;1hr;24hr;6hr
lathosterol NISTST000379AN0006131.280E-23.620E-2Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
mannose-6-phosphate NISTST000379AN0006131.780E-48.390E-4Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
Taurine DimerST000380AN0006148.550E-126.600E-11Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
Taurine DimerST000380AN0006142.660E-34.350E-3Time;10min;1hr;24hr;6hr
acetophenone NISTST000381AN0006151.660E-24.550E-2Cohort;CSMC;INHA
enolpyruvate NISTST000381AN0006154.500E-31.700E-2Cohort;CSMC;INHA
furoylglycine NISTST000381AN0006151.960E-39.540E-3Cohort;CSMC;INHA
2-deoxyerythritol NISTST000383AN0006181.580E-32.790E-2Health Status;diabetic;non-diabetic
lathosterol NISTST000383AN0006182.330E-29.680E-1UCP-3 Polymorphism;g/a;g/g
2-deoxytetronic acid NISTST000385AN0006203.320E-156.390E-15Organ;Plasma;Serum;Serum or Plasma
2-deoxytetronic acid NISTST000385AN0006203.660E-41.800E-3Gender;F;M;NA
2-deoxytetronic acid NISTST000385AN0006207.350E-44.860E-3Smoking Status;Current;Former;NA
5-hydroxynorvaline NISTST000385AN0006201.060E-101.600E-10Organ;Plasma;Serum;Serum or Plasma
5-hydroxynorvaline NISTST000385AN0006202.510E-37.950E-3Health State;Adenocarcinoma;Healthy;NA
5-hydroxynorvaline NISTST000385AN0006208.620E-32.440E-2Smoking Status;Current;Former;NA
acetophenone NISTST000385AN0006204.190E-211.030E-20Organ;Plasma;Serum;Serum or Plasma
acetophenone NISTST000385AN0006201.910E-62.230E-5Health State;Adenocarcinoma;Healthy;NA
acetophenone NISTST000385AN0006203.190E-65.400E-5Smoking Status;Current;Former;NA
acetophenone NISTST000385AN0006203.230E-64.920E-5Gender;F;M;NA
beta-mannosylglycerateST000385AN0006208.300E-81.120E-7Organ;Plasma;Serum;Serum or Plasma
heptadecanoic acid NISTST000385AN0006206.370E-88.650E-8Organ;Plasma;Serum;Serum or Plasma
heptadecanoic acid NISTST000385AN0006204.730E-31.260E-2Health State;Adenocarcinoma;Healthy;NA
heptadecanoic acid NISTST000385AN0006201.710E-23.940E-2Smoking Status;Current;Former;NA
methylhexadecanoic acidST000385AN0006207.320E-416.180E-40Organ;Plasma;Serum;Serum or Plasma
methylhexadecanoic acidST000385AN0006202.270E-41.340E-3Gender;F;M;NA
methylhexadecanoic acidST000385AN0006201.500E-37.660E-3Smoking Status;Current;Former;NA
methylhexadecanoic acidST000385AN0006201.550E-35.630E-3Health State;Adenocarcinoma;Healthy;NA
N-acetylglycine NISTST000385AN0006208.230E-101.200E-9Organ;Plasma;Serum;Serum or Plasma
N-acetylglycine NISTST000385AN0006208.140E-31.770E-2Gender;F;M;NA
2-oxogluconic acid NISTST000386AN0006213.650E-31.830E-2Gender;F;M;NA
2-oxogluconic acid NISTST000386AN0006214.190E-31.100E-2Organ;Plasma;Serum
2-oxogluconic acid NISTST000386AN0006211.330E-24.720E-2Smoker;Current;Former;NA
2-oxogluconic acid NISTST000386AN0006215.000E-21.560E-1Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
400671 carbohydrateST000386AN0006214.030E-43.840E-3Gender;F;M;NA
400671 carbohydrateST000386AN0006215.050E-32.690E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
400671 carbohydrateST000386AN0006219.540E-33.840E-2Smoker;Current;Former;NA
6-deoxyglucitol NISTST000386AN0006213.660E-21.210E-1Gender;F;M;NA
715929 carbohydrateST000386AN0006218.300E-42.550E-3Organ;Plasma;Serum
acetophenone NISTST000386AN0006211.780E-26.200E-2Smoker;Current;Former;NA
glyoxalurea NISTST000386AN0006211.320E-77.960E-7Organ;Plasma;Serum
glyoxalurea NISTST000386AN0006212.410E-31.450E-2Gender;F;M;NA
glyoxalurea NISTST000386AN0006211.080E-24.170E-2Smoker;Current;Former;NA
glyoxalurea NISTST000386AN0006213.250E-21.180E-1Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
heptadecanoic acid NISTST000386AN0006212.360E-36.380E-3Organ;Plasma;Serum
isolinoleic acid NISTST000386AN0006211.270E-33.640E-3Organ;Plasma;Serum
lathosterol NISTST000386AN0006214.890E-32.460E-2Smoker;Current;Former;NA
lathosterol NISTST000386AN0006214.940E-32.290E-2Gender;F;M;NA
lathosterol NISTST000386AN0006212.010E-27.890E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
methylhexadecanoic acidST000386AN0006214.130E-32.210E-2Smoker;Current;Former;NA
methylhexadecanoic acidST000386AN0006215.360E-32.430E-2Gender;F;M;NA
methylhexadecanoic acidST000386AN0006212.410E-29.270E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
N-acetylglycine NISTST000386AN0006211.170E-24.340E-2Smoker;Current;Former;NA
saccharic acidST000386AN0006213.400E-27.070E-2Organ;Plasma;Serum
trihydroxypyrazine NISTST000386AN0006219.980E-151.640E-13Organ;Plasma;Serum
beta-mannosylglycerateST000389AN0006252.360E-25.000E-1Emphysema/COPD;No;Yes
methylhexadecanoic acidST000389AN0006253.350E-22.910E-1Group;Benign;Cancer
N-acetylglycine NISTST000389AN0006251.480E-25.000E-1Emphysema/COPD;No;Yes
5-hydroxynorvaline NISTST000390AN0006263.570E-22.040E-1Diagnosis;adenocarcinoma;adenocarcinoma w/ BAC;adenocarcinom...
cytidine-5-monophosphate NISTST000390AN0006261.290E-25.640E-2Tumor Present;No;Yes;-
fucose+ rhamnoseST000390AN0006269.210E-34.550E-2Tumor Present;No;Yes;-
2-ketoglucose dimethylacetal NISTST000392AN0006289.840E-84.570E-7Organ;Plasma;Serum;Serum or Plasma
2-ketoglucose dimethylacetal NISTST000392AN0006281.980E-31.960E-2Gender;F;M;-
2-ketoglucose dimethylacetal NISTST000392AN0006282.990E-33.370E-2Smoking Status;Current;Former;-
2-ketoglucose dimethylacetal NISTST000392AN0006283.120E-31.370E-2Disease State;cancer;control;-
5-hydroxynorvaline NISTST000392AN0006289.640E-45.440E-3Disease State;cancer;control;-
alloxanoic acid NISTST000392AN0006282.630E-162.590E-15Organ;Plasma;Serum;Serum or Plasma
alloxanoic acid NISTST000392AN0006288.830E-52.740E-3Gender;F;M;-
alloxanoic acid NISTST000392AN0006281.370E-43.620E-3Smoking Status;Current;Former;-
alloxanoic acid NISTST000392AN0006281.380E-41.360E-3Disease State;cancer;control;-
N-acetylglycine NISTST000392AN0006281.590E-24.050E-2Organ;Plasma;Serum;Serum or Plasma
inositol allo-ST000396AN0006332.180E-21.340E-1Age Group;45-49;50-54;55-59;60-64;65-69;70-74
isodeoxytetronic acidST000396AN0006336.810E-77.350E-5Sex;Male;Female
isodeoxytetronic acidST000396AN0006331.340E-21.080E-1Age Group;45-49;50-54;55-59;60-64;65-69;70-74
12-OPDAST000403AN0006426.590E-35.550E-2Glucose labelling;C13 glucose;unlabelled
12-OPDAST000403AN0006424.810E-24.280E-1timepoint;1 hour;20 hours
1-deoxynojirimycinST000403AN0006424.330E-22.180E-1Glucose labelling;C13 glucose;unlabelled
1-deoxyxylonojirimycinST000403AN0006424.600E-148.870E-13Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-3-deoxy-L-rhamnonateST000403AN0006421.390E-42.560E-3Glucose labelling;C13 glucose;unlabelled
3-(ADP)-2-phosphoglycerateST000403AN0006421.860E-54.880E-5Cell type;Mature erythrocyte;Reticulocyte
3-ButynoateST000403AN0006421.050E-117.380E-11Cell type;Mature erythrocyte;Reticulocyte
3-MethoxyanthranilateST000403AN0006429.590E-62.590E-5Cell type;Mature erythrocyte;Reticulocyte
4-(1-methyl-5-hydroxy-2-pyrrolidinyl)-3-oxobutanoate methyl esterST000403AN0006426.450E-35.520E-2Glucose labelling;C13 glucose;unlabelled
4-8dimethylnonanoylcarnitineST000403AN0006428.670E-31.500E-2Cell type;Mature erythrocyte;Reticulocyte
4-8dimethylnonanoylcarnitineST000403AN0006422.870E-21.680E-1Glucose labelling;C13 glucose;unlabelled
4-Hydroxy-4-methylglutamateST000403AN0006425.640E-41.160E-3Cell type;Mature erythrocyte;Reticulocyte
4-Imidazolone-5-propanoateST000403AN0006429.030E-141.370E-12Cell type;Mature erythrocyte;Reticulocyte
5-guanidino-3-methyl-2-oxo-pentanoateST000403AN0006424.850E-31.060E-1timepoint;1 hour;20 hours
5-guanidino-3-methyl-2-oxo-pentanoateST000403AN0006421.040E-21.780E-2Cell type;Mature erythrocyte;Reticulocyte
6-Acetamido-2-oxohexanoateST000403AN0006428.680E-51.830E-3Glucose labelling;C13 glucose;unlabelled
6-Acetamido-2-oxohexanoateST000403AN0006422.070E-23.380E-2Cell type;Mature erythrocyte;Reticulocyte
Ac-Tyr-OEtST000403AN0006421.110E-52.990E-5Cell type;Mature erythrocyte;Reticulocyte
a Cysteine adductST000403AN0006422.630E-34.970E-3Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Asp-GlnST000403AN0006421.850E-87.370E-8Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Cys-SerST000403AN0006426.390E-152.510E-13Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Pro-SerST000403AN0006426.650E-72.140E-6Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Lys-ProST000403AN0006421.580E-111.070E-10Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Thr-ProST000403AN0006423.070E-35.730E-3Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Thr-ProST000403AN0006422.700E-21.620E-1Glucose labelling;C13 glucose;unlabelled
Ala-Lys-Asn-HisST000403AN0006425.150E-123.900E-11Cell type;Mature erythrocyte;Reticulocyte
Ala-Met-Pro-TyrST000403AN0006426.500E-136.730E-12Cell type;Mature erythrocyte;Reticulocyte
alpha-MethylstyreneST000403AN0006423.800E-24.040E-1timepoint;1 hour;20 hours
alpha-MethylstyreneST000403AN0006424.350E-26.580E-2Cell type;Mature erythrocyte;Reticulocyte
Arg-Asn-Pro-HisST000403AN0006426.410E-124.720E-11Cell type;Mature erythrocyte;Reticulocyte
Arg-Asp-Asp-GlyST000403AN0006424.660E-148.870E-13Cell type;Mature erythrocyte;Reticulocyte
Arg-Leu-Asn-AspST000403AN0006421.640E-43.650E-4Cell type;Mature erythrocyte;Reticulocyte
Arg-Met-Asn-HisST000403AN0006429.720E-52.280E-4Cell type;Mature erythrocyte;Reticulocyte
Arg-Met-Val-AspST000403AN0006422.610E-57.330E-4Glucose labelling;C13 glucose;unlabelled
Asn-Asn-Pro-HisST000403AN0006423.260E-58.690E-4Glucose labelling;C13 glucose;unlabelled
Asn-Cys-Pro-SerST000403AN0006421.650E-111.090E-10Cell type;Mature erythrocyte;Reticulocyte
Asn-Leu-Asn-TyrST000403AN0006423.160E-122.620E-11Cell type;Mature erythrocyte;Reticulocyte
Asp-Gly-Pro-SerST000403AN0006421.540E-64.700E-6Cell type;Mature erythrocyte;Reticulocyte
AspidofractineST000403AN0006423.540E-21.900E-1Glucose labelling;C13 glucose;unlabelled
Asp-Leu-Ser-HisST000403AN0006426.180E-74.560E-5Glucose labelling;C13 glucose;unlabelled
Asp-Met-Pro-ProST000403AN0006429.620E-52.270E-4Cell type;Mature erythrocyte;Reticulocyte
Bis(glycerophospho)-glycerolST000403AN0006422.860E-163.380E-14Cell type;Mature erythrocyte;Reticulocyte
Boc-AsnST000403AN0006423.390E-91.530E-8Cell type;Mature erythrocyte;Reticulocyte
Casein KST000403AN0006421.660E-35.620E-2timepoint;1 hour;20 hours
CMP-N-trimethyl-2-aminoethylphosphonateST000403AN0006426.780E-136.900E-12Cell type;Mature erythrocyte;Reticulocyte
Cys-Lys-Met-GlnST000403AN0006422.490E-57.330E-4Glucose labelling;C13 glucose;unlabelled
Cys-Met-Tyr-TyrST000403AN0006424.440E-72.620E-4timepoint;1 hour;20 hours
Cys-Met-Tyr-TyrST000403AN0006423.830E-34.190E-2Glucose labelling;C13 glucose;unlabelled
Cys-Thr-Cys-CysST000403AN0006424.500E-34.660E-2Glucose labelling;C13 glucose;unlabelled
d1-piperidine-dicarboxylateST000403AN0006424.350E-51.090E-4Cell type;Mature erythrocyte;Reticulocyte
DiacetylhydrazineST000403AN0006421.330E-43.020E-4Cell type;Mature erythrocyte;Reticulocyte
DiacetylhydrazineST000403AN0006425.000E-24.280E-1timepoint;1 hour;20 hours
DiacetylmonoximeST000403AN0006421.660E-21.140E-1Glucose labelling;C13 glucose;unlabelled
di-n-UndecylamineST000403AN0006424.980E-152.260E-13Cell type;Mature erythrocyte;Reticulocyte
DL-Methionine sulfoneST000403AN0006424.960E-123.840E-11Cell type;Mature erythrocyte;Reticulocyte
DMNTST000403AN0006427.820E-31.370E-2Cell type;Mature erythrocyte;Reticulocyte
Erythrulose 1-phosphateST000403AN0006426.160E-92.620E-8Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(9:1)] 4-hydroxy-2-nonenalST000403AN0006423.890E-37.200E-3Cell type;Mature erythrocyte;Reticulocyte
FMLPST000403AN0006425.010E-102.570E-9Cell type;Mature erythrocyte;Reticulocyte
FructoselysineST000403AN0006422.200E-72.170E-5Glucose labelling;C13 glucose;unlabelled
[Fv] Desmosdumotin CST000403AN0006425.260E-31.110E-1timepoint;1 hour;20 hours
[Fv] Desmosdumotin CST000403AN0006421.260E-22.130E-2Cell type;Mature erythrocyte;Reticulocyte
[Fv] HomofleminginST000403AN0006421.490E-32.860E-3Cell type;Mature erythrocyte;Reticulocyte
[Fv] Ovalitenin AST000403AN0006422.200E-44.840E-4Cell type;Mature erythrocyte;Reticulocyte
Gln-Leu-Lys-HisST000403AN0006421.010E-31.980E-3Cell type;Mature erythrocyte;Reticulocyte
Gln-Leu-Lys-HisST000403AN0006424.890E-22.310E-1Glucose labelling;C13 glucose;unlabelled
Ile-Met-Met-ThrST000403AN0006422.850E-61.680E-4Glucose labelling;C13 glucose;unlabelled
indole-3-acetonitrile oxideST000403AN0006421.100E-32.140E-3Cell type;Mature erythrocyte;Reticulocyte
(-)-jasmonoyl-L-isoleucineST000403AN0006423.200E-46.830E-4Cell type;Mature erythrocyte;Reticulocyte
ketoconazolST000403AN0006423.180E-81.230E-7Cell type;Mature erythrocyte;Reticulocyte
L-1-Pyrroline-3-hydroxy-5-carboxylateST000403AN0006425.780E-61.650E-5Cell type;Mature erythrocyte;Reticulocyte
L-a-glutamyl-L-LysineST000403AN0006425.470E-135.860E-12Cell type;Mature erythrocyte;Reticulocyte
L-Glutamate methylesterST000403AN0006421.830E-44.040E-4Cell type;Mature erythrocyte;Reticulocyte
L-proline amideST000403AN0006421.520E-32.040E-2Glucose labelling;C13 glucose;unlabelled
L-proline amideST000403AN0006422.030E-22.720E-1timepoint;1 hour;20 hours
L-thiazolidine-4-carboxylateST000403AN0006423.460E-37.850E-2timepoint;1 hour;20 hours
Lys-Lys-Met-ProST000403AN0006421.020E-42.080E-3Glucose labelling;C13 glucose;unlabelled
Lys-Lys-Met-ProST000403AN0006423.330E-37.850E-2timepoint;1 hour;20 hours
Lys-Ser-Ser-SerST000403AN0006421.860E-72.170E-5Glucose labelling;C13 glucose;unlabelled
methiinST000403AN0006421.730E-33.310E-3Cell type;Mature erythrocyte;Reticulocyte
Met-Trp-Trp-TyrST000403AN0006425.900E-123.480E-9Glucose labelling;C13 glucose;unlabelled
Met-Trp-Trp-TyrST000403AN0006424.000E-24.140E-1timepoint;1 hour;20 hours
mildronateST000403AN0006423.930E-91.760E-8Cell type;Mature erythrocyte;Reticulocyte
N2-(D-1-Carboxyethyl)-L-arginineST000403AN0006425.190E-41.070E-3Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-ala-ala-ala-methylesterST000403AN0006423.510E-21.900E-1Glucose labelling;C13 glucose;unlabelled
N-dimethylethanolamineST000403AN0006429.500E-31.640E-2Cell type;Mature erythrocyte;Reticulocyte
N-(octanoyl)-L-homoserineST000403AN0006424.270E-81.610E-7Cell type;Mature erythrocyte;Reticulocyte
nornorcapsaicinST000403AN0006427.390E-36.060E-2Glucose labelling;C13 glucose;unlabelled
nornorcapsaicinST000403AN0006421.090E-21.830E-1timepoint;1 hour;20 hours
O-Acetylneuraminic acidST000403AN0006423.390E-58.690E-4Glucose labelling;C13 glucose;unlabelled
Ovothiol disulfideST000403AN0006427.720E-51.840E-4Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(CHO))ST000403AN0006421.480E-64.550E-6Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(COOH))ST000403AN0006421.200E-42.750E-4Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(COOH))ST000403AN0006428.610E-31.610E-1timepoint;1 hour;20 hours
PC(16:0/P-18:1(11Z))ST000403AN0006426.570E-72.140E-6Cell type;Mature erythrocyte;Reticulocyte
PC(18:0/P-18:1(11Z))ST000403AN0006422.770E-101.470E-9Cell type;Mature erythrocyte;Reticulocyte
[PC acetyl(16:1)] 1-(9Z-hexadecenoyl)-2-acetyl-sn-glycero-3-phosphocholineST000403AN0006421.290E-118.880E-11Cell type;Mature erythrocyte;Reticulocyte
psicoselysineST000403AN0006428.630E-63.920E-4Glucose labelling;C13 glucose;unlabelled
trans-Hexadec-2-enoylcarnitineST000403AN0006422.680E-101.440E-9Cell type;Mature erythrocyte;Reticulocyte
Trp-Trp-Tyr-TyrST000403AN0006421.080E-42.520E-4Cell type;Mature erythrocyte;Reticulocyte
Tyr-OEtST000403AN0006426.600E-72.140E-6Cell type;Mature erythrocyte;Reticulocyte
UrethaneST000403AN0006425.350E-61.540E-5Cell type;Mature erythrocyte;Reticulocyte
(Z)-4-Hydroxyphenylacetaldehyde-oximeST000403AN0006426.210E-35.450E-2Glucose labelling;C13 glucose;unlabelled
ZAPAST000403AN0006423.970E-34.260E-2Glucose labelling;C13 glucose;unlabelled
10-oxogeranialST000403AN0006431.180E-31.730E-2Glucose labelling;C13 glucose;unlabelled
2-(Acetamidomethylene)succinateST000403AN0006435.950E-92.900E-8Cell type;Mature erythrocyte;Reticulocyte
2(alpha-D-Mannosyl)-D-glycerateST000403AN0006438.890E-41.850E-3Cell type;Mature erythrocyte;Reticulocyte
2(alpha-D-Mannosyl)-D-glycerateST000403AN0006431.240E-27.960E-2Glucose labelling;C13 glucose;unlabelled
2-Aminomalonate semialdehydeST000403AN0006431.360E-64.210E-6Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-D-xylonateST000403AN0006438.500E-62.450E-5Cell type;Mature erythrocyte;Reticulocyte
2-Deoxymugineic acidST000403AN0006431.160E-32.350E-3Cell type;Mature erythrocyte;Reticulocyte
2-FormaminobenzoylacetateST000403AN0006434.460E-21.870E-1Glucose labelling;C13 glucose;unlabelled
2-hydroxymethanesulfonateST000403AN0006431.240E-43.020E-4Cell type;Mature erythrocyte;Reticulocyte
2-(Hydroxymethyl)-3-(acetamidomethylene)succinateST000403AN0006432.890E-151.410E-13Cell type;Mature erythrocyte;Reticulocyte
2-oxosuberateST000403AN0006434.130E-33.920E-2Glucose labelling;C13 glucose;unlabelled
2-(sulfomethyl)thiazolidine-4-carboxylateST000403AN0006433.320E-33.460E-2Glucose labelling;C13 glucose;unlabelled
3-acetyl pyridine adenine dinucleotideST000403AN0006434.440E-38.280E-3Cell type;Mature erythrocyte;Reticulocyte
3-acetyl pyridine adenine dinucleotideST000403AN0006432.310E-21.210E-1Glucose labelling;C13 glucose;unlabelled
3-(ADP)-glycerateST000403AN0006436.160E-125.460E-11Cell type;Mature erythrocyte;Reticulocyte
3-dimethylsulfoniopropionaldehydeST000403AN0006437.120E-111.930E-8Glucose labelling;C13 glucose;unlabelled
3-dimethylsulfoniopropionaldehydeST000403AN0006434.350E-37.140E-2timepoint;1 hour;20 hours
3-hydroxyacyl group of bacterial toxinST000403AN0006431.260E-28.030E-2Glucose labelling;C13 glucose;unlabelled
3-hydroxyacyl group of bacterial toxinST000403AN0006431.530E-21.920E-1timepoint;1 hour;20 hours
3-hydroxyacyl group of bacterial toxinST000403AN0006431.570E-22.640E-2Cell type;Mature erythrocyte;Reticulocyte
3-PhosphonopyruvateST000403AN0006434.440E-124.140E-11Cell type;Mature erythrocyte;Reticulocyte
3-SulfolactateST000403AN0006433.860E-71.280E-6Cell type;Mature erythrocyte;Reticulocyte
4-Amino-4-deoxychorismateST000403AN0006432.190E-45.100E-4Cell type;Mature erythrocyte;Reticulocyte
4-HydroxyphenylacetylglycineST000403AN0006433.040E-24.920E-2Cell type;Mature erythrocyte;Reticulocyte
4-Methylene-L-glutamateST000403AN0006433.370E-58.930E-5Cell type;Mature erythrocyte;Reticulocyte
4-Nitrophenyl-3-ketovalidamineST000403AN0006433.260E-101.890E-9Cell type;Mature erythrocyte;Reticulocyte
5-Dehydro-4-deoxy-D-glucarateST000403AN0006431.070E-21.450E-1timepoint;1 hour;20 hours
5-Deoxy-5-aminoshikimic acidST000403AN0006431.550E-163.490E-14Cell type;Mature erythrocyte;Reticulocyte
5-HydroxycotinineST000403AN0006433.550E-36.670E-3Cell type;Mature erythrocyte;Reticulocyte
6-Acetyl-D-glucoseST000403AN0006435.010E-81.900E-7Cell type;Mature erythrocyte;Reticulocyte
8-keto-7-aminoperlagonateST000403AN0006433.650E-33.590E-2Glucose labelling;C13 glucose;unlabelled
Abscisic acid glucose esterST000403AN0006432.580E-34.940E-3Cell type;Mature erythrocyte;Reticulocyte
Abscisic acid glucose esterST000403AN0006438.620E-31.230E-1timepoint;1 hour;20 hours
Abscisic acid glucose esterST000403AN0006433.810E-21.720E-1Glucose labelling;C13 glucose;unlabelled
A-KetoglutaricacidoximeST000403AN0006432.470E-45.660E-4Cell type;Mature erythrocyte;Reticulocyte
alpha-(Methylenecyclopropyl)glycineST000403AN0006431.470E-29.150E-2Glucose labelling;C13 glucose;unlabelled
Arg-Leu-Val-AsnST000403AN0006439.310E-166.290E-14Cell type;Mature erythrocyte;Reticulocyte
Asn-Asp-Asp-ProST000403AN0006431.240E-108.360E-10Cell type;Mature erythrocyte;Reticulocyte
Asn-Gln-Tyr-HisST000403AN0006433.710E-21.680E-1Glucose labelling;C13 glucose;unlabelled
Asp-Leu-Lys-LysST000403AN0006433.990E-151.660E-13Cell type;Mature erythrocyte;Reticulocyte
Asp-Met-Cys-CysST000403AN0006431.710E-159.270E-14Cell type;Mature erythrocyte;Reticulocyte
CAI-1ST000403AN0006433.240E-47.330E-4Cell type;Mature erythrocyte;Reticulocyte
Clitidine 5-phosphateST000403AN0006433.150E-71.060E-6Cell type;Mature erythrocyte;Reticulocyte
CMP-N-acetylneuraminateST000403AN0006436.630E-152.560E-13Cell type;Mature erythrocyte;Reticulocyte
Cys-Met-Met-PheST000403AN0006431.590E-43.800E-4Cell type;Mature erythrocyte;Reticulocyte
Cys-Met-Pro-HisST000403AN0006432.930E-33.230E-2Glucose labelling;C13 glucose;unlabelled
D-GalacturonateST000403AN0006435.830E-125.260E-11Cell type;Mature erythrocyte;Reticulocyte
Diethyl adipateST000403AN0006436.040E-31.100E-2Cell type;Mature erythrocyte;Reticulocyte
Diethyl adipateST000403AN0006432.170E-22.300E-1timepoint;1 hour;20 hours
dihomocitrateST000403AN0006433.880E-163.790E-14Cell type;Mature erythrocyte;Reticulocyte
dXMPST000403AN0006433.910E-123.710E-11Cell type;Mature erythrocyte;Reticulocyte
ethanedisulfonateST000403AN0006431.050E-32.150E-3Cell type;Mature erythrocyte;Reticulocyte
ethyl-(2R)-methyl-(3S)-hydroxybutanoateST000403AN0006433.080E-35.960E-2timepoint;1 hour;20 hours
ethyl-(2R)-methyl-(3S)-hydroxybutanoateST000403AN0006435.640E-34.790E-2Glucose labelling;C13 glucose;unlabelled
ethylpyruvateST000403AN0006437.770E-41.640E-3Cell type;Mature erythrocyte;Reticulocyte
[FA (10:1/2:0)] 2E-Decenedioic acidST000403AN0006431.600E-51.980E-3timepoint;1 hour;20 hours
[FA (10:1/2:0)] 2E-Decenedioic acidST000403AN0006434.700E-34.360E-2Glucose labelling;C13 glucose;unlabelled
[FA (8:1)] 2Z-octenoic acidST000403AN0006431.770E-33.540E-3Cell type;Mature erythrocyte;Reticulocyte
[FA (8:1)] 2Z-octenoic acidST000403AN0006431.770E-29.900E-2Glucose labelling;C13 glucose;unlabelled
[FA hydroxy(11:1)] 2-hydroxy-10-undecenoic acidST000403AN0006432.930E-46.690E-4Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(13:0)] 2-hydroxy-tridecanoic acidST000403AN0006434.990E-53.380E-3timepoint;1 hour;20 hours
[FA hydroxy(18:0)] 2S-hydroxy-octadecanoic acidST000403AN0006432.190E-77.510E-7Cell type;Mature erythrocyte;Reticulocyte
[FA methyl(14:0)] 12-methyl-tetradecanoic acidST000403AN0006432.180E-55.920E-5Cell type;Mature erythrocyte;Reticulocyte
[FA methyl(6:0)] 2-methyl-hexanoic acidST000403AN0006438.260E-42.530E-2timepoint;1 hour;20 hours
[FA oxo(7:0)] 2-oxo-heptanoic acidST000403AN0006434.420E-48.060E-3Glucose labelling;C13 glucose;unlabelled
[FA oxo(7:0)] 2-oxo-heptanoic acidST000403AN0006431.100E-21.450E-1timepoint;1 hour;20 hours
[FA oxo(8:0)] 3-oxo-octanoic acidST000403AN0006431.410E-31.870E-2Glucose labelling;C13 glucose;unlabelled
Furfural diethyl acetalST000403AN0006431.580E-31.940E-2Glucose labelling;C13 glucose;unlabelled
GalactinoldihydrateST000403AN0006433.700E-91.870E-8Cell type;Mature erythrocyte;Reticulocyte
Glu-Met-Cys-HisST000403AN0006432.400E-23.990E-2Cell type;Mature erythrocyte;Reticulocyte
Glu-Met-Met-HisST000403AN0006434.950E-34.460E-2Glucose labelling;C13 glucose;unlabelled
glutathione-sulfiteST000403AN0006436.610E-31.190E-2Cell type;Mature erythrocyte;Reticulocyte
[GP (16:0/18:1)] 1-hexadecanoyl-2-(11Z-octadecenoyl)-sn-glycero-3-phosphateST000403AN0006432.350E-77.960E-7Cell type;Mature erythrocyte;Reticulocyte
HEPESST000403AN0006431.340E-43.250E-4Cell type;Mature erythrocyte;Reticulocyte
His-Met-Trp-SerST000403AN0006434.330E-51.110E-3Glucose labelling;C13 glucose;unlabelled
hydrogen iodideST000403AN0006432.040E-122.250E-11Cell type;Mature erythrocyte;Reticulocyte
Icosadienoic acidST000403AN0006433.440E-47.750E-4Cell type;Mature erythrocyte;Reticulocyte
Icosatrienoic acidST000403AN0006432.050E-44.810E-4Cell type;Mature erythrocyte;Reticulocyte
indole-3-acetyl-valineST000403AN0006437.980E-41.680E-3Cell type;Mature erythrocyte;Reticulocyte
(-)-jasmonoyl-L-valineST000403AN0006431.880E-76.500E-7Cell type;Mature erythrocyte;Reticulocyte
L-2-Aminoadipate 6-semialdehydeST000403AN0006431.040E-27.310E-2Glucose labelling;C13 glucose;unlabelled
L-2-Aminoadipate 6-semialdehydeST000403AN0006434.560E-23.380E-1timepoint;1 hour;20 hours
L-Ala-L-GluST000403AN0006431.320E-108.580E-10Cell type;Mature erythrocyte;Reticulocyte
L-ArabinonateST000403AN0006431.990E-55.450E-5Cell type;Mature erythrocyte;Reticulocyte
L-ErythruloseST000403AN0006432.060E-88.490E-8Cell type;Mature erythrocyte;Reticulocyte
L-HypoglycinST000403AN0006432.510E-34.820E-3Cell type;Mature erythrocyte;Reticulocyte
L-HypoglycinST000403AN0006431.940E-21.060E-1Glucose labelling;C13 glucose;unlabelled
L-NoradrenalineST000403AN0006431.420E-22.420E-2Cell type;Mature erythrocyte;Reticulocyte
(-)-MedicocarpinST000403AN0006436.330E-61.860E-5Cell type;Mature erythrocyte;Reticulocyte
melibionateST000403AN0006433.670E-91.870E-8Cell type;Mature erythrocyte;Reticulocyte
MesaconateST000403AN0006434.440E-23.340E-1timepoint;1 hour;20 hours
Met-Met-Pro-TyrST000403AN0006431.660E-29.540E-2Glucose labelling;C13 glucose;unlabelled
N-Acetyl-D-glucosaminateST000403AN0006432.250E-45.210E-4Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-D-glucosamine 6-phosphateST000403AN0006431.650E-111.260E-10Cell type;Mature erythrocyte;Reticulocyte
N-Hydroxy-1-aminonaphthaleneST000403AN0006436.620E-31.190E-2Cell type;Mature erythrocyte;Reticulocyte
N-hydroxyisoleucineST000403AN0006431.220E-121.470E-11Cell type;Mature erythrocyte;Reticulocyte
nocardicin GST000403AN0006433.450E-81.350E-7Cell type;Mature erythrocyte;Reticulocyte
nonulose 9-phosphateST000403AN0006431.100E-107.600E-10Cell type;Mature erythrocyte;Reticulocyte
octulose 8-phosphateST000403AN0006438.110E-36.180E-2Glucose labelling;C13 glucose;unlabelled
octulose 8-phosphateST000403AN0006431.240E-22.110E-2Cell type;Mature erythrocyte;Reticulocyte
omega-Cyclohexylundecanoic acidST000403AN0006435.130E-71.660E-6Cell type;Mature erythrocyte;Reticulocyte
[PC (15:1)] 1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholineST000403AN0006432.250E-89.220E-8Cell type;Mature erythrocyte;Reticulocyte
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholineST000403AN0006431.170E-119.150E-11Cell type;Mature erythrocyte;Reticulocyte
P-DPDST000403AN0006432.360E-45.440E-4Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608ST000403AN0006436.090E-34.920E-2Glucose labelling;C13 glucose;unlabelled
perchlorateST000403AN0006439.390E-31.300E-1timepoint;1 hour;20 hours
PhenolsulfonphthaleinST000403AN0006438.450E-83.130E-7Cell type;Mature erythrocyte;Reticulocyte
phosphinomethylmalateST000403AN0006435.360E-39.830E-3Cell type;Mature erythrocyte;Reticulocyte
[PI (18:0)] 1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)ST000403AN0006432.240E-122.420E-11Cell type;Mature erythrocyte;Reticulocyte
[PR] 9-Hydroxy-helminthosporolST000403AN0006431.300E-74.620E-7Cell type;Mature erythrocyte;Reticulocyte
[PR] Citronellyl acetateST000403AN0006431.030E-63.220E-6Cell type;Mature erythrocyte;Reticulocyte
(R)-3-HydroxybutanoateST000403AN0006431.580E-29.310E-2Glucose labelling;C13 glucose;unlabelled
(R)-AMAAST000403AN0006434.500E-38.360E-3Cell type;Mature erythrocyte;Reticulocyte
sinapoyltyramineST000403AN0006434.210E-163.790E-14Cell type;Mature erythrocyte;Reticulocyte
(S)-Methylmalonate semialdehydeST000403AN0006431.300E-91.170E-7Glucose labelling;C13 glucose;unlabelled
sodium dodecyl sulfateST000403AN0006434.350E-37.140E-2timepoint;1 hour;20 hours
SulfoacetateST000403AN0006432.480E-22.460E-1timepoint;1 hour;20 hours
SulfoacetateST000403AN0006433.310E-25.340E-2Cell type;Mature erythrocyte;Reticulocyte
uridine-5-diphosphate bromoacetolST000403AN0006434.900E-39.080E-3Cell type;Mature erythrocyte;Reticulocyte
uridine-5-diphosphate bromoacetolST000403AN0006431.600E-29.310E-2Glucose labelling;C13 glucose;unlabelled
XylobioseST000403AN0006439.020E-73.050E-5Glucose labelling;C13 glucose;unlabelled
C12 / C12:1ST000405AN0006451.850E-25.990E-1Group;No PA;PA;PoolAll
C16 / C16:1ST000405AN0006453.390E-25.630E-1Vaginal Bleeding;N;UNK;Y;-
Cit / OrnST000405AN0006453.130E-35.630E-1Vaginal Bleeding;N;UNK;Y;-
PC aa C28:1 / PC aa C40:2ST000405AN0006454.470E-25.990E-1Group;No PA;PA;PoolAll
Total DMA / ArgST000405AN0006452.220E-25.990E-1Group;No PA;PA;PoolAll
N-acetyl-D-hexosamineST000412AN0006521.640E-96.370E-8Collection Time;1 Hr;2 Hr;3 Hr;-
oleamide NISTST000412AN0006521.310E-32.050E-3Treatment;fresh liver;nonwarm ischemic liver;steatotic liver...
saccharic acidST000412AN0006527.370E-72.380E-6Treatment;fresh liver;nonwarm ischemic liver;steatotic liver...
saccharic acidST000412AN0006524.560E-21.340E-1Collection Time;1 Hr;2 Hr;3 Hr;-
arachidiic acidST000416AN0006588.170E-55.520E-4Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
arachidiic acidST000416AN0006583.710E-21.430E-1Gender;Female;Male
creatine major dehydrated TMS3ST000416AN0006584.400E-52.380E-3Gender;Female;Male
creatine major dehydrated TMS3ST000416AN0006584.150E-31.270E-2Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
z dioctylphtalateST000416AN0006581.900E-24.280E-2Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
2-deoxytetronic acid nistST000420AN0006621.670E-74.790E-7Group;nonsmoker;smoker
3-hydroxybenzoic acid (likely)ST000420AN0006622.340E-33.820E-3Group;nonsmoker;smoker
4-hydroxypyridineST000420AN0006629.750E-131.020E-11Group;nonsmoker;smoker
5-aminovaleric acid lactameST000420AN0006627.540E-199.490E-17Group;nonsmoker;smoker
5-hydroxymethyl-2-furoic acid nistST000420AN0006622.880E-133.630E-12Group;nonsmoker;smoker
citraconic acid major TMS2ST000420AN0006626.740E-41.180E-3Group;nonsmoker;smoker
epsilon-caprolactam (likely)ST000420AN0006621.450E-22.120E-2Group;nonsmoker;smoker
glucose-6-phosphate minorST000420AN0006621.750E-32.890E-3Group;nonsmoker;smoker
phthalate esterST000420AN0006622.430E-55.280E-5Group;nonsmoker;smoker
possible sucroseST000420AN0006623.870E-25.480E-2Group;nonsmoker;smoker
ribitol (likely)ST000420AN0006624.220E-112.210E-10Group;nonsmoker;smoker
vanilylmandelic acidST000420AN0006621.530E-132.140E-12Group;nonsmoker;smoker
z mstfa artifactST000420AN0006621.140E-31.950E-3Group;nonsmoker;smoker
2-Amino-2-methyl-1-propanolST000421AN0006635.550E-31.210E-1treatment;ND;T1D poor glycemic control
2-Amino-3-methyl-1-butanol + 5.2393837ST000421AN0006634.020E-23.090E-1treatment;ND;T1D poor glycemic control
2-Oxovaleric acidST000421AN0006632.090E-22.140E-1treatment;ND;T1D poor glycemic control
4-Aminophenyl 1-thio-beta-D-glucuronide + 2.6188798ST000421AN0006633.120E-22.630E-1treatment;ND;T1D poor glycemic control
CarboxyibuprofenST000421AN0006631.410E-21.910E-1treatment;ND;T1D poor glycemic control
cefamandole nafateST000421AN0006639.560E-66.530E-4treatment;ND;T1D poor glycemic control
cefamandole nafate + 2.0600944ST000421AN0006632.640E-62.470E-4treatment;ND;T1D poor glycemic control
HYDROLYSIS PRODUCT OF BUSSEIN + 1.4680848ST000421AN0006631.530E-21.980E-1treatment;ND;T1D poor glycemic control
HYDROLYSIS PRODUCT OF BUSSEIN + 1.9674853ST000421AN0006631.360E-21.910E-1treatment;ND;T1D poor glycemic control
L-4-Hydroxy-3-methoxy-a-methylphenylalanineST000421AN0006633.170E-62.470E-4treatment;ND;T1D poor glycemic control
L-4-Hydroxy-3-methoxy-a-methylphenylalanine + 2.0514681ST000421AN0006637.690E-42.330E-2treatment;ND;T1D poor glycemic control
N-Didesethylquinagolide glucuronideST000421AN0006631.930E-22.080E-1treatment;ND;T1D poor glycemic control
OxprenololST000421AN0006632.480E-22.380E-1treatment;ND;T1D poor glycemic control
PropoxypheneST000421AN0006637.470E-31.460E-1treatment;ND;T1D poor glycemic control
URETHANEST000421AN0006633.130E-22.630E-1treatment;ND;T1D poor glycemic control
4-Hydroxybenzyl cyanideST000421AN0006641.040E-21.730E-1treatment;ND;T1D poor glycemic control
ANGOLENSIN (R)ST000421AN0006648.540E-31.730E-1treatment;ND;T1D poor glycemic control
Bifemelane (M4)ST000421AN0006641.340E-21.980E-1treatment;ND;T1D poor glycemic control
D1-2-Hydroxymethylethisterone - 1.9729741ST000421AN0006645.170E-31.710E-1treatment;ND;T1D poor glycemic control
DIMETHYLCAFFEIC ACIDST000421AN0006642.570E-75.100E-5treatment;ND;T1D poor glycemic control
GPEtnNMe(16:0/18:1(9Z))ST000421AN0006641.840E-22.150E-1treatment;ND;T1D poor glycemic control
HYDROLYSIS PRODUCT OF BUSSEINST000421AN0006643.080E-22.780E-1treatment;ND;T1D poor glycemic control
Mono-N-depropylprobenecidST000421AN0006641.400E-85.570E-6treatment;ND;T1D poor glycemic control
N-Acetyl-5-hydroxysulfapyridineST000421AN0006643.640E-31.710E-1treatment;ND;T1D poor glycemic control
ORTHOTHYMOTINIC ACIDST000421AN0006642.480E-22.520E-1treatment;ND;T1D poor glycemic control
SAPPANONE A 7-METHYL ETHERST000421AN0006643.590E-31.710E-1treatment;ND;T1D poor glycemic control
Sulfadoxine suflateST000421AN0006644.070E-23.270E-1treatment;ND;T1D poor glycemic control
SulfiteST000421AN0006644.380E-23.270E-1treatment;ND;T1D poor glycemic control
3-(a-Naphthoxy)lactic acid glucuronideST000421AN0006652.860E-24.500E-1treatment;ND;T1D poor glycemic control
AllotetrahydrocortisolST000421AN0006654.870E-24.500E-1treatment;ND;T1D poor glycemic control
Arachidonyl lysolecithin + 10.70548ST000421AN0006653.160E-24.500E-1treatment;ND;T1D poor glycemic control
Cerebroside CST000421AN0006652.360E-24.280E-1treatment;ND;T1D poor glycemic control
GemeprostST000421AN0006654.710E-24.500E-1treatment;ND;T1D poor glycemic control
Gemeprost + 11.412178ST000421AN0006654.410E-24.500E-1treatment;ND;T1D poor glycemic control
isoamyl nitriteST000421AN0006654.000E-24.500E-1treatment;ND;T1D poor glycemic control
Ivermectin B1aST000421AN0006655.140E-31.530E-1treatment;ND;T1D poor glycemic control
Ivermectin B1a + 11.394018ST000421AN0006653.750E-24.500E-1treatment;ND;T1D poor glycemic control
N-HISTIDYL-2-AMINONAPHTHALENE (betaNA)ST000421AN0006653.690E-24.500E-1treatment;ND;T1D poor glycemic control
Oleoyl amine + 12.276432ST000421AN0006651.480E-23.420E-1treatment;ND;T1D poor glycemic control
8R-hydroxy-9Z-octadecenoic acidST000421AN0006661.260E-22.190E-1treatment;ND;T1D poor glycemic control
gamma-Hydroxyphenylbutazone glucuronideST000421AN0006661.940E-31.900E-1treatment;ND;T1D poor glycemic control
TRIDESACETOXYKHIVORINST000421AN0006662.190E-22.330E-1treatment;ND;T1D poor glycemic control
4-Aminophenyl 1-thio-beta-D-glucuronideST000422AN0006671.190E-34.380E-2treatment;ND;T1D good glycemic control
Arachidonyl lysolecithinST000422AN0006673.640E-25.290E-1treatment;ND;T1D good glycemic control
beta-DIHYDROROTENONEST000422AN0006675.140E-71.420E-4treatment;ND;T1D good glycemic control
Bis (2-hydroxypropyl) amine + 5.4315743ST000422AN0006674.990E-26.020E-1treatment;ND;T1D good glycemic control
B-ureidoisobutyric acidST000422AN0006674.030E-42.240E-2treatment;ND;T1D good glycemic control
cefamandole nafateST000422AN0006673.310E-31.020E-1treatment;ND;T1D good glycemic control
deschlorobenzoyl IndomethacinST000422AN0006671.500E-23.190E-1treatment;ND;T1D good glycemic control
L-4-Hydroxy-3-methoxy-a-methylphenylalanineST000422AN0006674.050E-42.240E-2treatment;ND;T1D good glycemic control
Tetrahydrothiophene sulfoxideST000422AN0006674.530E-25.950E-1treatment;ND;T1D good glycemic control
3-(a-Naphthoxy)lactic acidST000422AN0006682.420E-22.680E-1treatment;ND;T1D good glycemic control
7-DeoxyadriamycinoneST000422AN0006681.670E-37.360E-2treatment;ND;T1D good glycemic control
7-Hydroxyfluphenazine glucuronideST000422AN0006681.580E-22.020E-1treatment;ND;T1D good glycemic control
D1-2-HydroxymethylethisteroneST000422AN0006682.670E-38.430E-2treatment;ND;T1D good glycemic control
deschlorobenzoyl IndomethacinST000422AN0006682.090E-22.440E-1treatment;ND;T1D good glycemic control
DIHYDROSPATHELIACHROMENEST000422AN0006683.650E-38.430E-2treatment;ND;T1D good glycemic control
DIMETHYLCAFFEIC ACIDST000422AN0006688.490E-31.350E-1treatment;ND;T1D good glycemic control
EDOXUDINEST000422AN0006683.500E-38.430E-2treatment;ND;T1D good glycemic control
FAMPRIDINEST000422AN0006682.430E-22.680E-1treatment;ND;T1D good glycemic control
KINETIN RIBOSIDEST000422AN0006683.480E-52.520E-3treatment;ND;T1D good glycemic control
L-Aspartic acid b-semialdehydeST000422AN0006683.450E-23.260E-1treatment;ND;T1D good glycemic control
Mono-N-depropylprobenecidST000422AN0006683.300E-52.520E-3treatment;ND;T1D good glycemic control
OBTUSAQUINONEST000422AN0006687.150E-31.290E-1treatment;ND;T1D good glycemic control
P-HydroxydesmethylgliquidoneST000422AN0006682.860E-22.930E-1treatment;ND;T1D good glycemic control
sodium chlorovulone IIIST000422AN0006681.810E-22.180E-1treatment;ND;T1D good glycemic control
Sulfate - 1.053629ST000422AN0006681.240E-21.690E-1treatment;ND;T1D good glycemic control
URSINIC ACIDST000422AN0006684.300E-23.560E-1treatment;ND;T1D good glycemic control
2-Propylisonicotinic acidST000422AN0006692.590E-21.000E+0treatment;ND;T1D good glycemic control
isoamyl nitriteST000422AN0006691.970E-21.000E+0treatment;ND;T1D good glycemic control
D1-2-Hydroxymethylethisterone - 13.49303ST000422AN0006701.610E-25.900E-1treatment;ND;T1D good glycemic control
D1-2-Hydroxymethylethisterone - 14.2670965ST000422AN0006702.860E-25.900E-1treatment;ND;T1D good glycemic control
Caffeine-D3ST000424AN0006733.630E-27.400E-1SEX;F;M
Creatine-D3ST000424AN0006734.250E-23.080E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
GLUCOSAMINE/MANNOSAMINEST000424AN0006733.280E-23.080E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
GLUCOSE/FRUCTOSE-PHOSPHATEST000424AN0006731.540E-22.970E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
HEXOSE-DISACCHARIDEST000424AN0006732.170E-23.080E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
L-Leucine-D10ST000424AN0006734.180E-23.080E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
c181hexcerumST000433AN0006831.480E-28.690E-2Group;Alzheimer disease dementia;Cognitively normal;Dementia...
c241hexcerumST000433AN0006833.160E-28.690E-2Group;Alzheimer disease dementia;Cognitively normal;Dementia...
cer160ST000433AN0006832.120E-28.690E-2Group;Alzheimer disease dementia;Cognitively normal;Dementia...
cer200ST000433AN0006832.870E-28.690E-2Group;Alzheimer disease dementia;Cognitively normal;Dementia...
AmmoniaST000435AN0006855.840E-42.790E-3treatment;ND;T1D good glycemic control;T1D poor glycemic con...
X3.Methylhistidine.ST000435AN0006856.610E-54.740E-4treatment;ND;T1D good glycemic control;T1D poor glycemic con...
Convallasaponin AST000437AN0006872.380E-53.760E-5Sample type;Spiked;Unknown
10-Hydroxy-octadec-12Z-enoate-9-beta-D-glucuronideST000444AN0006953.150E-25.280E-2Sample Treatment;Bubbled;Control
12-Hydroxynevirapine glucuronideST000444AN0006952.720E-25.210E-2Sample Treatment;Bubbled;Control
15beta-hydroxycyproterone acetateST000444AN0006951.560E-25.210E-2Sample Treatment;Bubbled;Control
16-a-HydroxypregnenoloneST000444AN0006952.600E-25.210E-2Sample Treatment;Bubbled;Control
17a-EthynylestradiolST000444AN0006951.720E-25.210E-2Sample Treatment;Bubbled;Control
2-Hydroxy-imipramine glucuronideST000444AN0006952.950E-25.280E-2Sample Treatment;Bubbled;Control
3-DechloroethylifosfamideST000444AN0006951.290E-25.210E-2Sample Treatment;Bubbled;Control
3-Hydroxytetradecanedioic acidST000444AN0006952.360E-25.210E-2Sample Treatment;Bubbled;Control
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronideST000444AN0006951.940E-25.210E-2Sample Treatment;Bubbled;Control
6beta-hydroxybudesonideST000444AN0006952.480E-25.210E-2Sample Treatment;Bubbled;Control
AcitretinST000444AN0006951.720E-25.210E-2Sample Treatment;Bubbled;Control
AFN911ST000444AN0006953.360E-25.280E-2Sample Treatment;Bubbled;Control
b-DihydrotetrabenazineST000444AN0006952.090E-25.210E-2Sample Treatment;Bubbled;Control
Buspirone N-oxideST000444AN0006952.370E-25.210E-2Sample Treatment;Bubbled;Control
CD 1790ST000444AN0006951.270E-25.210E-2Sample Treatment;Bubbled;Control
CyclopentolateST000444AN0006951.940E-25.210E-2Sample Treatment;Bubbled;Control
DeoxyartemsininST000444AN0006953.380E-25.280E-2Sample Treatment;Bubbled;Control
Deoxydihydro-artemisininST000444AN0006952.160E-25.210E-2Sample Treatment;Bubbled;Control
Dibucaine0cinchocaineST000444AN0006953.420E-25.280E-2Sample Treatment;Bubbled;Control
DimenhydrinateST000444AN0006952.990E-25.280E-2Sample Treatment;Bubbled;Control
DityrosineST000444AN0006953.680E-25.570E-2Sample Treatment;Bubbled;Control
EdrophoniumST000444AN0006953.230E-25.280E-2Sample Treatment;Bubbled;Control
GentamicinST000444AN0006952.060E-25.210E-2Sample Treatment;Bubbled;Control
LevonorgestrelST000444AN0006951.840E-25.210E-2Sample Treatment;Bubbled;Control
N-desmethylimatinibST000444AN0006953.230E-25.280E-2Sample Treatment;Bubbled;Control
NNAL-N-glucuronideST000444AN0006952.440E-25.210E-2Sample Treatment;Bubbled;Control
O-Desmethylverapamil (D-702)ST000444AN0006951.860E-25.210E-2Sample Treatment;Bubbled;Control
Tafluprost free acidST000444AN0006952.450E-25.210E-2Sample Treatment;Bubbled;Control
1-(6-[3]-ladderane-hexanyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerophosphocholineST000445AN0006962.320E-31.670E-2Treatment;FSH;LH
(3-sulfo)Galbeta-Cer(d18:0/18:0(2OH))ST000445AN0006962.270E-26.880E-2Treatment;FSH;LH
CaldarchaeolST000445AN0006967.930E-33.910E-2Treatment;FSH;LH
sn-caldarchaeo-1-phosphoethanolamineST000445AN0006961.410E-25.500E-2Treatment;FSH;LH
Ceramide(d18:1/23:0) or Ceramide(d18:1/22:1 OH)ST000450AN0007052.110E-31.700E-2Disease;CFS;Normal
CoQ10H2ST000450AN0007052.210E-24.300E-2gender;Female;Male
GC(18:2/16:0)ST000450AN0007055.570E-92.170E-8gender;Female;Male
Hydroxycholesterol speciesST000450AN0007053.440E-21.410E-1Disease;CFS;Normal
2-deoxyglucose-6-phosphateST000450AN0007061.680E-42.490E-4gender;Female;Male
Deoxyribose phosphateST000450AN0007061.510E-323.070E-31gender;Female;Male
Hexose Diphosphate PoolST000450AN0007062.950E-211.400E-20gender;Female;Male
Hexose Disaccharide PoolST000450AN0007062.540E-54.020E-5gender;Female;Male
Hexose Monophosphate PoolST000450AN0007062.610E-421.460E-40gender;Female;Male
Hexose PoolST000450AN0007063.650E-108.670E-10gender;Female;Male
Octulose-monophosphateST000450AN0007062.010E-251.600E-24gender;Female;Male
Plasmalogen(20:4/p18:1)ST000450AN0007069.850E-61.620E-5gender;Female;Male
Plasmalogen(p18:0/20:4)ST000450AN0007064.610E-36.190E-3gender;Female;Male
SM(d18:1/25:0) or SM(d18:1/24:1 OH)ST000450AN0007065.060E-243.530E-23gender;Female;Male
Hexose PoolST000465AN0007262.410E-21.340E-1Treatment;Control;Englerin (100 nM)
SM(d18:1/25:0) or SM(d18:1/24:1 OH)ST000465AN0007261.640E-35.870E-2Treatment;Control;Englerin (100 nM)
Hydroxycholesterol SpeciesST000465AN0007272.030E-34.330E-2Treatment;Control;Englerin (100 nM)
ALANINE/SARCOSINEST000475AN0007395.190E-61.780E-5Treatment;-;MDH inhib
ALDO/KETO-HEXOSEST000475AN0007392.150E-33.600E-3Treatment;-;MDH inhib
GLUCOSAMINE/MANNOSAMINEST000475AN0007397.440E-41.370E-3Treatment;-;MDH inhib
HEXOSE-DISACCHARIDEST000475AN0007392.280E-23.560E-2Treatment;-;MDH inhib
L-VALINE/5-AMINOPENTANOATE/L-NORVALINEST000475AN0007391.300E-68.480E-6Treatment;-;MDH inhib
N-ACETYL-HEXOSAMINEST000475AN0007396.130E-74.910E-6Treatment;-;MDH inhib
DISACCHARIDE (6C/6C)/2-alpha-D-glucosyl-D-glucoseST000475AN0007401.370E-22.160E-2Treatment;-;MDH inhib
GLYCERALDEHYDE/LACTATEST000475AN0007403.080E-61.400E-5Treatment;-;MDH inhib
SARCOSINE/BETA-ALANINEST000475AN0007401.370E-69.790E-6Treatment;-;MDH inhib
SeratoninST000490AN0007561.250E-24.980E-2Disease;cardiovascular disease;sleep apnea
cis Aconitate M0ST000507AN0007762.560E-57.230E-5Time (incubation);24 hours;72 hours
Fummarate M0ST000507AN0007762.780E-35.790E-3Time (incubation);24 hours;72 hours
Fummarate M+4ST000507AN0007761.680E-33.690E-3Time (incubation);24 hours;72 hours
Isocitrate M0ST000507AN0007761.150E-22.260E-2Time (incubation);24 hours;72 hours
KG M+1ST000507AN0007765.130E-51.270E-4Time (incubation);24 hours;72 hours
KG M+5ST000507AN0007762.890E-81.380E-7Time (incubation);24 hours;72 hours
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000523AN0007982.450E-42.160E-3Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000523AN0007987.460E-41.050E-2Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000523AN0007989.070E-44.410E-3Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000523AN0007982.220E-41.310E-3Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000523AN0007983.490E-46.160E-3Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000523AN0007981.010E-35.910E-3Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000523AN0007981.380E-48.810E-4Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000523AN0007983.040E-46.130E-3Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000523AN0007989.000E-45.520E-3Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000523AN0007991.920E-82.090E-7Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000523AN0007992.590E-75.180E-6Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000523AN0007993.330E-74.990E-6Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
SALICYLATE #2 (M-H)-ST000523AN0007992.030E-62.710E-5Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
SALICYLATE #2 (M-H)-ST000523AN0007997.210E-31.970E-2Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
SALICYLATE #2 (M-H)-ST000523AN0007992.090E-27.390E-2Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
ZEATIN [ISTD] (M+Cl)-ST000523AN0007993.330E-27.870E-2Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
IS Ceramide; [M-H2O]+ST000523AN0008001.000E-52.540E-5Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
IS Ceramide; [M-H2O]+ST000523AN0008001.080E-23.330E-2Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
IS Ceramide; [M-H2O]+ST000523AN0008003.850E-21.250E-1Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
IS D31-TAGST000523AN0008008.330E-153.640E-13Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
IS D31-TAGST000523AN0008001.310E-38.170E-3Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
IS D31-TAGST000523AN0008002.920E-29.930E-2Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
IS d5-DAGST000523AN0008002.090E-22.890E-2Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
IS SM 35:1; [M+H]+ST000523AN0008007.780E-105.810E-9Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
IS SM 35:1; [M+H]+ST000523AN0008003.810E-31.790E-2Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
12-OPDAST000539AN0008183.500E-37.280E-3Cell type;Mature erythrocyte;Reticulocyte
1-5-diazabicyclononaneST000539AN0008185.240E-37.400E-2timepoint;1 hour;20 hours
1-5-diazabicyclononane 2ST000539AN0008185.240E-37.400E-2timepoint;1 hour;20 hours
1-deoxyxylonojirimycinST000539AN0008185.460E-152.870E-13Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-2-phosphoglycerateST000539AN0008185.400E-31.080E-2Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-2-phosphoglycerateST000539AN0008182.700E-21.840E-1timepoint;1 hour;20 hours
3-ButynoateST000539AN0008187.200E-72.740E-6Cell type;Mature erythrocyte;Reticulocyte
3-MethoxyanthranilateST000539AN0008181.150E-43.100E-4Cell type;Mature erythrocyte;Reticulocyte
3-nitro-2-pentanolST000539AN0008184.330E-26.750E-2Cell type;Mature erythrocyte;Reticulocyte
4-Hydroxy-4-methylglutamateST000539AN0008187.380E-93.650E-8Cell type;Mature erythrocyte;Reticulocyte
4-Imidazolone-5-propanoateST000539AN0008182.430E-123.810E-11Cell type;Mature erythrocyte;Reticulocyte
4-PIOLST000539AN0008183.430E-22.110E-1timepoint;1 hour;20 hours
5-guanidino-3-methyl-2-oxo-pentanoateST000539AN0008183.400E-36.160E-2timepoint;1 hour;20 hours
Ac-Tyr-OEtST000539AN0008181.990E-21.600E-1timepoint;1 hour;20 hours
a Cysteine adductST000539AN0008181.010E-32.380E-3Cell type;Mature erythrocyte;Reticulocyte
a Cysteine adduct 2ST000539AN0008181.010E-32.380E-3Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Asp-GlnST000539AN0008181.810E-99.710E-9Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Cys-GlyST000539AN0008185.680E-63.650E-4timepoint;1 hour;20 hours
Ala-Asp-Cys-SerST000539AN0008189.050E-167.530E-14Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Pro-SerST000539AN0008181.070E-32.510E-3Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Lys-ProST000539AN0008188.160E-62.680E-5Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Thr-ProST000539AN0008183.910E-26.190E-2Cell type;Mature erythrocyte;Reticulocyte
Ala-Lys-Asn-HisST000539AN0008187.940E-116.390E-10Cell type;Mature erythrocyte;Reticulocyte
Ala-Met-Pro-TyrST000539AN0008187.510E-128.390E-11Cell type;Mature erythrocyte;Reticulocyte
Arg-Asn-Pro-HisST000539AN0008187.740E-93.800E-8Cell type;Mature erythrocyte;Reticulocyte
Arg-Asp-Asp-GlyST000539AN0008187.570E-104.760E-9Cell type;Mature erythrocyte;Reticulocyte
Arg-Leu-Asn-AspST000539AN0008181.560E-44.090E-4Cell type;Mature erythrocyte;Reticulocyte
Arg-Met-Asn-HisST000539AN0008182.800E-24.630E-2Cell type;Mature erythrocyte;Reticulocyte
Arg-Met-Asn-HisST000539AN0008183.400E-24.110E-1Glucose labelling;C13 glucose;unlabelled
Asn-Cys-Pro-SerST000539AN0008181.740E-66.360E-6Cell type;Mature erythrocyte;Reticulocyte
Asn-Leu-Asn-TyrST000539AN0008184.180E-139.310E-12Cell type;Mature erythrocyte;Reticulocyte
Asp-Gly-Arg 2ST000539AN0008185.020E-92.570E-8Cell type;Mature erythrocyte;Reticulocyte
Asp-Gly-Pro-SerST000539AN0008181.670E-33.750E-3Cell type;Mature erythrocyte;Reticulocyte
AspidofractineST000539AN0008182.450E-35.340E-3Cell type;Mature erythrocyte;Reticulocyte
AspidofractineST000539AN0008183.250E-22.020E-1timepoint;1 hour;20 hours
Asp-Met-Pro-ProST000539AN0008184.020E-38.230E-3Cell type;Mature erythrocyte;Reticulocyte
Bis(glycerophospho)-glycerolST000539AN0008182.390E-136.300E-12Cell type;Mature erythrocyte;Reticulocyte
Boc-AsnST000539AN0008188.790E-83.660E-7Cell type;Mature erythrocyte;Reticulocyte
Casein KST000539AN0008181.850E-34.130E-3Cell type;Mature erythrocyte;Reticulocyte
Casein KST000539AN0008182.340E-21.650E-1timepoint;1 hour;20 hours
Casein K 2ST000539AN0008181.850E-34.130E-3Cell type;Mature erythrocyte;Reticulocyte
Casein K 2ST000539AN0008182.340E-21.650E-1timepoint;1 hour;20 hours
CMP-N-trimethyl-2-aminoethylphosphonateST000539AN0008181.090E-108.460E-10Cell type;Mature erythrocyte;Reticulocyte
CTABST000539AN0008182.340E-45.910E-4Cell type;Mature erythrocyte;Reticulocyte
Cyclo(deltaAla-L-Val)ST000539AN0008189.080E-39.920E-2timepoint;1 hour;20 hours
Cys-Met-Tyr-TyrST000539AN0008181.520E-41.100E-2Glucose labelling;C13 glucose;unlabelled
Cys-Met-Tyr-TyrST000539AN0008182.260E-41.010E-2timepoint;1 hour;20 hours
Cys-Thr-Cys-CysST000539AN0008182.800E-58.280E-5Cell type;Mature erythrocyte;Reticulocyte
d1-piperidine-dicarboxylateST000539AN0008188.580E-31.640E-2Cell type;Mature erythrocyte;Reticulocyte
D-2-Amino-hexano-6-lactamST000539AN0008186.490E-38.070E-2timepoint;1 hour;20 hours
D-2-Amino-hexano-6-lactamST000539AN0008184.690E-27.220E-2Cell type;Mature erythrocyte;Reticulocyte
DiacetylhydrazineST000539AN0008181.290E-33.450E-2timepoint;1 hour;20 hours
DiacetylmonoximeST000539AN0008185.930E-31.730E-1Glucose labelling;C13 glucose;unlabelled
DiacetylmonoximeST000539AN0008182.250E-23.790E-2Cell type;Mature erythrocyte;Reticulocyte
DiacetylmonoximeST000539AN0008184.010E-22.330E-1timepoint;1 hour;20 hours
di-n-UndecylamineST000539AN0008186.430E-115.390E-10Cell type;Mature erythrocyte;Reticulocyte
DL-Methionine sulfoneST000539AN0008183.750E-61.320E-5Cell type;Mature erythrocyte;Reticulocyte
Erythrulose 1-phosphateST000539AN0008183.740E-51.090E-4Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(9:1)] 4-hydroxy-2-nonenalST000539AN0008183.970E-36.760E-2timepoint;1 hour;20 hours
FMLPST000539AN0008181.260E-43.360E-4Cell type;Mature erythrocyte;Reticulocyte
FructoselysineST000539AN0008182.090E-23.580E-2Cell type;Mature erythrocyte;Reticulocyte
Fructoselysine 2ST000539AN0008182.090E-23.580E-2Cell type;Mature erythrocyte;Reticulocyte
[Fv] Desmosdumotin CST000539AN0008181.650E-169.540E-14timepoint;1 hour;20 hours
[Fv] Desmosdumotin CST000539AN0008183.850E-24.280E-1Glucose labelling;C13 glucose;unlabelled
[Fv] HomofleminginST000539AN0008184.010E-41.660E-2timepoint;1 hour;20 hours
[Fv] Ovalitenin AST000539AN0008188.120E-89.410E-6timepoint;1 hour;20 hours
GentianaineST000539AN0008183.480E-37.280E-3Cell type;Mature erythrocyte;Reticulocyte
GentianaineST000539AN0008182.270E-21.640E-1timepoint;1 hour;20 hours
GentianaineST000539AN0008182.400E-23.640E-1Glucose labelling;C13 glucose;unlabelled
Gln-Leu-Lys-HisST000539AN0008181.030E-21.920E-2Cell type;Mature erythrocyte;Reticulocyte
Gln-Leu-Lys-HisST000539AN0008184.790E-22.570E-1timepoint;1 hour;20 hours
indole-3-acetonitrile oxideST000539AN0008181.750E-23.070E-2Cell type;Mature erythrocyte;Reticulocyte
(-)-jasmonoyl-L-isoleucineST000539AN0008182.170E-23.670E-2Cell type;Mature erythrocyte;Reticulocyte
ketoconazolST000539AN0008182.680E-24.470E-2Cell type;Mature erythrocyte;Reticulocyte
L-1-Pyrroline-3-hydroxy-5-carboxylateST000539AN0008182.140E-23.630E-2Cell type;Mature erythrocyte;Reticulocyte
L-1-Pyrroline-3-hydroxy-5-carboxylate 2ST000539AN0008182.140E-23.630E-2Cell type;Mature erythrocyte;Reticulocyte
L-a-glutamyl-L-LysineST000539AN0008182.030E-175.890E-15Cell type;Mature erythrocyte;Reticulocyte
L-Glutamate methylesterST000539AN0008185.380E-37.420E-2timepoint;1 hour;20 hours
L-Glutamate methylesterST000539AN0008185.450E-31.080E-2Cell type;Mature erythrocyte;Reticulocyte
L-Glutamate methylesterST000539AN0008184.780E-25.120E-1Glucose labelling;C13 glucose;unlabelled
L-proline amideST000539AN0008181.450E-33.450E-2timepoint;1 hour;20 hours
L-proline amideST000539AN0008184.370E-26.770E-2Cell type;Mature erythrocyte;Reticulocyte
Lys-Lys-Met-ProST000539AN0008182.430E-52.340E-3Glucose labelling;C13 glucose;unlabelled
Lys-Lys-Met-ProST000539AN0008181.000E-44.840E-3timepoint;1 hour;20 hours
metabolite 1ST000539AN0008181.740E-23.050E-2Cell type;Mature erythrocyte;Reticulocyte
metabolite 2ST000539AN0008185.140E-37.400E-2timepoint;1 hour;20 hours
metabolite 3ST000539AN0008189.090E-81.750E-5Glucose labelling;C13 glucose;unlabelled
methiinST000539AN0008184.420E-41.090E-3Cell type;Mature erythrocyte;Reticulocyte
Met-Trp-Trp-TyrST000539AN0008181.780E-101.030E-7Glucose labelling;C13 glucose;unlabelled
Met-Trp-Trp-TyrST000539AN0008184.320E-22.360E-1timepoint;1 hour;20 hours
mildronateST000539AN0008182.150E-101.540E-9Cell type;Mature erythrocyte;Reticulocyte
N2-(D-1-Carboxyethyl)-L-arginineST000539AN0008183.330E-48.350E-4Cell type;Mature erythrocyte;Reticulocyte
N5-acetyl-N5-hydroxy-L-ornithineST000539AN0008185.650E-37.440E-2timepoint;1 hour;20 hours
N5-acetyl-N5-hydroxy-L-ornithineST000539AN0008189.170E-32.120E-1Glucose labelling;C13 glucose;unlabelled
N5-acetyl-N5-hydroxy-L-ornithineST000539AN0008182.750E-24.560E-2Cell type;Mature erythrocyte;Reticulocyte
N-acetyl -D- glucosaminitolST000539AN0008181.200E-43.220E-4Cell type;Mature erythrocyte;Reticulocyte
N-acetyl -D- glucosaminitol 2ST000539AN0008181.200E-43.220E-4Cell type;Mature erythrocyte;Reticulocyte
nitrocyclohexaneST000539AN0008181.060E-22.350E-1Glucose labelling;C13 glucose;unlabelled
nitrocyclohexaneST000539AN0008181.920E-23.340E-2Cell type;Mature erythrocyte;Reticulocyte
N-(octanoyl)-L-homoserineST000539AN0008182.910E-61.030E-5Cell type;Mature erythrocyte;Reticulocyte
O-Acetylneuraminic acidST000539AN0008185.740E-31.730E-1Glucose labelling;C13 glucose;unlabelled
Ovothiol disulfideST000539AN0008186.860E-82.880E-7Cell type;Mature erythrocyte;Reticulocyte
[PC (16:0/3:0)] 1-hexadecanoyl-2-(2E-propionyl)-sn-glycero-3-phosphocholineST000539AN0008189.610E-31.800E-2Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(CHO))ST000539AN0008181.360E-43.590E-4Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(COOH))ST000539AN0008181.170E-22.410E-1Glucose labelling;C13 glucose;unlabelled
PC(16:0/5:0(COOH))ST000539AN0008181.410E-21.410E-1timepoint;1 hour;20 hours
PC(18:0/P-18:1(11Z))ST000539AN0008184.990E-126.720E-11Cell type;Mature erythrocyte;Reticulocyte
[PC acetyl(16:1)] 1-(9Z-hexadecenoyl)-2-acetyl-sn-glycero-3-phosphocholineST000539AN0008185.660E-37.440E-2timepoint;1 hour;20 hours
psicoselysineST000539AN0008181.800E-22.970E-1Glucose labelling;C13 glucose;unlabelled
trans-Hexadec-2-enoylcarnitineST000539AN0008181.960E-135.670E-12Cell type;Mature erythrocyte;Reticulocyte
Trp-Trp-Tyr-TyrST000539AN0008181.070E-53.400E-5Cell type;Mature erythrocyte;Reticulocyte
Tyr-OEtST000539AN0008182.780E-46.990E-4Cell type;Mature erythrocyte;Reticulocyte
UrethaneST000539AN0008183.420E-37.180E-3Cell type;Mature erythrocyte;Reticulocyte
Urethane 2ST000539AN0008183.420E-37.180E-3Cell type;Mature erythrocyte;Reticulocyte
ZAPAST000539AN0008186.880E-51.950E-4Cell type;Mature erythrocyte;Reticulocyte
2-(Acetamidomethylene)succinateST000539AN0008191.910E-89.860E-8Cell type;Mature erythrocyte;Reticulocyte
2(alpha-D-Mannosyl)-D-glycerateST000539AN0008194.830E-71.990E-5Glucose labelling;C13 glucose;unlabelled
2(alpha-D-Mannosyl)-D-glycerateST000539AN0008192.740E-22.040E-1timepoint;1 hour;20 hours
2-Aminomalonate semialdehydeST000539AN0008194.620E-72.010E-6Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-D-xylonateST000539AN0008192.270E-33.790E-2Glucose labelling;C13 glucose;unlabelled
2-Dehydro-D-xylonateST000539AN0008193.460E-25.700E-2Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-D-xylonate 2ST000539AN0008192.270E-33.790E-2Glucose labelling;C13 glucose;unlabelled
2-Dehydro-D-xylonate 2ST000539AN0008193.460E-25.700E-2Cell type;Mature erythrocyte;Reticulocyte
2-Deoxymugineic acidST000539AN0008191.230E-54.150E-5Cell type;Mature erythrocyte;Reticulocyte
2-FormaminobenzoylacetateST000539AN0008193.020E-34.620E-2Glucose labelling;C13 glucose;unlabelled
2-FormaminobenzoylacetateST000539AN0008197.680E-31.230E-1timepoint;1 hour;20 hours
2-FormaminobenzoylacetateST000539AN0008194.390E-27.140E-2Cell type;Mature erythrocyte;Reticulocyte
2-hydroxymethanesulfonateST000539AN0008194.850E-72.100E-6Cell type;Mature erythrocyte;Reticulocyte
2-(Hydroxymethyl)-3-(acetamidomethylene)succinateST000539AN0008191.040E-42.990E-4Cell type;Mature erythrocyte;Reticulocyte
2-oxosuberateST000539AN0008192.270E-33.790E-2Glucose labelling;C13 glucose;unlabelled
(2S)-2-{[1-(R)-Carboxyethyl]amino}pentanoateST000539AN0008192.340E-45.700E-3Glucose labelling;C13 glucose;unlabelled
(2S)-2-{[1-(R)-Carboxyethyl]amino}pentanoate 2ST000539AN0008192.340E-45.700E-3Glucose labelling;C13 glucose;unlabelled
2-(sulfomethyl)thiazolidine-4-carboxylateST000539AN0008198.730E-52.550E-4Cell type;Mature erythrocyte;Reticulocyte
3-acetyl pyridine adenine dinucleotideST000539AN0008191.580E-33.030E-2Glucose labelling;C13 glucose;unlabelled
3-(ADP)-glycerateST000539AN0008198.120E-62.830E-5Cell type;Mature erythrocyte;Reticulocyte
3-dimethylsulfoniopropionaldehydeST000539AN0008191.450E-123.880E-10Glucose labelling;C13 glucose;unlabelled
3-dimethylsulfoniopropionaldehydeST000539AN0008192.700E-22.040E-1timepoint;1 hour;20 hours
3-hydroxyacyl group of bacterial toxinST000539AN0008191.670E-77.590E-7Cell type;Mature erythrocyte;Reticulocyte
3-PhosphonopyruvateST000539AN0008191.440E-44.100E-4Cell type;Mature erythrocyte;Reticulocyte
3-SulfolactateST000539AN0008191.840E-56.010E-5Cell type;Mature erythrocyte;Reticulocyte
3-sulfopropanoateST000539AN0008194.220E-38.840E-3Cell type;Mature erythrocyte;Reticulocyte
4-Amino-4-deoxychorismateST000539AN0008197.990E-31.550E-2Cell type;Mature erythrocyte;Reticulocyte
4-Methylene-L-glutamateST000539AN0008192.700E-24.570E-2Cell type;Mature erythrocyte;Reticulocyte
4-Nitrophenyl-3-ketovalidamineST000539AN0008191.470E-76.740E-7Cell type;Mature erythrocyte;Reticulocyte
5-Acetamidopentanoate 2ST000539AN0008193.570E-47.970E-3Glucose labelling;C13 glucose;unlabelled
5-Deoxy-5-aminoshikimic acidST000539AN0008191.020E-42.940E-4Cell type;Mature erythrocyte;Reticulocyte
6-Acetyl-D-glucoseST000539AN0008195.090E-131.050E-11Cell type;Mature erythrocyte;Reticulocyte
6-Acetyl-D-glucose 2ST000539AN0008195.090E-131.050E-11Cell type;Mature erythrocyte;Reticulocyte
A-KetoglutaricacidoximeST000539AN0008194.150E-113.830E-10Cell type;Mature erythrocyte;Reticulocyte
Arg-Cys-Gln-TyrST000539AN0008195.430E-31.110E-2Cell type;Mature erythrocyte;Reticulocyte
Arg-Leu-Val-AsnST000539AN0008198.810E-204.720E-17Cell type;Mature erythrocyte;Reticulocyte
Asn-Asp-Asp-ProST000539AN0008197.460E-116.060E-10Cell type;Mature erythrocyte;Reticulocyte
Asp-Leu-Lys-LysST000539AN0008198.390E-156.420E-13Cell type;Mature erythrocyte;Reticulocyte
Asp-Met-Cys-CysST000539AN0008199.280E-143.820E-12Cell type;Mature erythrocyte;Reticulocyte
CAI-1ST000539AN0008193.490E-42.230E-2timepoint;1 hour;20 hours
Clitidine 5-phosphateST000539AN0008198.300E-129.670E-11Cell type;Mature erythrocyte;Reticulocyte
CMP-N-acetylneuraminateST000539AN0008195.770E-114.910E-10Cell type;Mature erythrocyte;Reticulocyte
Cys-Met-Met-PheST000539AN0008191.900E-34.450E-3Cell type;Mature erythrocyte;Reticulocyte
Cys-Met-Pro-HisST000539AN0008192.080E-21.890E-1Glucose labelling;C13 glucose;unlabelled
Cys-Thr-Ser-TyrST000539AN0008197.860E-31.230E-1timepoint;1 hour;20 hours
Cys-Thr-Ser-TyrST000539AN0008191.220E-22.230E-2Cell type;Mature erythrocyte;Reticulocyte
D-Alanyl-D-alanineST000539AN0008192.630E-39.520E-2timepoint;1 hour;20 hours
D-Alanyl-D-alanineST000539AN0008191.950E-21.860E-1Glucose labelling;C13 glucose;unlabelled
D-GalacturonateST000539AN0008192.110E-112.060E-10Cell type;Mature erythrocyte;Reticulocyte
Diethyl adipateST000539AN0008191.120E-76.010E-5timepoint;1 hour;20 hours
dihomocitrateST000539AN0008193.710E-113.480E-10Cell type;Mature erythrocyte;Reticulocyte
dXMPST000539AN0008191.580E-111.590E-10Cell type;Mature erythrocyte;Reticulocyte
ethanedisulfonateST000539AN0008194.700E-92.770E-8Cell type;Mature erythrocyte;Reticulocyte
ethyl-(2R)-methyl-(3S)-hydroxybutanoateST000539AN0008193.390E-25.620E-2Cell type;Mature erythrocyte;Reticulocyte
ethyl-(2R)-methyl-(3S)-hydroxybutanoateST000539AN0008193.480E-22.630E-1Glucose labelling;C13 glucose;unlabelled
ethylpyruvateST000539AN0008194.670E-41.250E-3Cell type;Mature erythrocyte;Reticulocyte
[FA (10:1/2:0)] 2E-Decenedioic acidST000539AN0008194.970E-27.880E-2Cell type;Mature erythrocyte;Reticulocyte
[FA (8:1)] 2Z-octenoic acidST000539AN0008197.730E-41.990E-3Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(11:1)] 2-hydroxy-10-undecenoic acidST000539AN0008191.320E-22.400E-2Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(13:0)] 2-hydroxy-tridecanoic acidST000539AN0008198.060E-44.320E-2timepoint;1 hour;20 hours
[FA hydroxy(18:0)] 2S-hydroxy-octadecanoic acidST000539AN0008191.190E-22.180E-2Cell type;Mature erythrocyte;Reticulocyte
[FA methyl(14:0)] 12-methyl-tetradecanoic acidST000539AN0008191.120E-97.330E-9Cell type;Mature erythrocyte;Reticulocyte
[FA methyl(6:0)] 2-methyl-hexanoic acidST000539AN0008191.140E-22.110E-2Cell type;Mature erythrocyte;Reticulocyte
[FA oxo(7:0)] 2-oxo-heptanoic acidST000539AN0008191.410E-22.550E-2Cell type;Mature erythrocyte;Reticulocyte
[FA oxo(8:0)] 3-oxo-octanoic acidST000539AN0008195.530E-51.700E-4Cell type;Mature erythrocyte;Reticulocyte
Furfural diethyl acetalST000539AN0008191.250E-33.030E-3Cell type;Mature erythrocyte;Reticulocyte
GalactinoldihydrateST000539AN0008191.590E-66.250E-6Cell type;Mature erythrocyte;Reticulocyte
Glu-Cys-Cys 2ST000539AN0008199.280E-84.400E-7Cell type;Mature erythrocyte;Reticulocyte
Glu-Met-Cys-HisST000539AN0008196.740E-31.330E-2Cell type;Mature erythrocyte;Reticulocyte
Glu-Met-Met-HisST000539AN0008191.250E-21.460E-1timepoint;1 hour;20 hours
Glu-Met-Met-HisST000539AN0008193.160E-25.270E-2Cell type;Mature erythrocyte;Reticulocyte
glutathione-sulfiteST000539AN0008192.660E-39.520E-2timepoint;1 hour;20 hours
[GP (16:0/18:1)] 1-hexadecanoyl-2-(11Z-octadecenoyl)-sn-glycero-3-phosphateST000539AN0008191.340E-98.540E-9Cell type;Mature erythrocyte;Reticulocyte
HEPESST000539AN0008193.360E-124.860E-11Cell type;Mature erythrocyte;Reticulocyte
hydrogen iodideST000539AN0008194.480E-114.070E-10Cell type;Mature erythrocyte;Reticulocyte
Icosadienoic acidST000539AN0008194.930E-27.860E-2Cell type;Mature erythrocyte;Reticulocyte
Icosatrienoic acidST000539AN0008191.370E-33.290E-3Cell type;Mature erythrocyte;Reticulocyte
indole-3-acetyl-valineST000539AN0008193.020E-48.210E-4Cell type;Mature erythrocyte;Reticulocyte
(-)-jasmonoyl-L-valineST000539AN0008194.970E-31.030E-2Cell type;Mature erythrocyte;Reticulocyte
L-2-Aminoadipate 6-semialdehydeST000539AN0008193.270E-34.870E-2Glucose labelling;C13 glucose;unlabelled
L-Ala-L-GluST000539AN0008197.920E-42.010E-3Cell type;Mature erythrocyte;Reticulocyte
L-Ala-L-Glu 2ST000539AN0008197.920E-42.010E-3Cell type;Mature erythrocyte;Reticulocyte
L-ArabinonateST000539AN0008194.330E-92.580E-8Cell type;Mature erythrocyte;Reticulocyte
LaudanosineST000539AN0008195.220E-37.360E-2Glucose labelling;C13 glucose;unlabelled
LaudanosineST000539AN0008191.770E-23.090E-2Cell type;Mature erythrocyte;Reticulocyte
L-ErythruloseST000539AN0008191.020E-64.290E-6Cell type;Mature erythrocyte;Reticulocyte
L-HypoglycinST000539AN0008192.270E-45.700E-3Glucose labelling;C13 glucose;unlabelled
L-NoradrenalineST000539AN0008194.470E-27.200E-2Cell type;Mature erythrocyte;Reticulocyte
(-)-MedicocarpinST000539AN0008195.600E-51.720E-4Cell type;Mature erythrocyte;Reticulocyte
melibionateST000539AN0008198.950E-117.060E-10Cell type;Mature erythrocyte;Reticulocyte
MesaconateST000539AN0008191.660E-21.810E-1Glucose labelling;C13 glucose;unlabelled
metabolite 1ST000539AN0008191.910E-21.860E-1Glucose labelling;C13 glucose;unlabelled
metabolite 1ST000539AN0008193.140E-25.260E-2Cell type;Mature erythrocyte;Reticulocyte
metabolite 2ST000539AN0008192.780E-101.860E-8Glucose labelling;C13 glucose;unlabelled
Methyl 2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-p-toluateST000539AN0008197.630E-31.230E-1timepoint;1 hour;20 hours
N2-Acetyl-L-aminoadipate 2ST000539AN0008191.240E-64.990E-6Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-D-glucosaminateST000539AN0008192.220E-81.120E-7Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-D-glucosamine 6-phosphateST000539AN0008192.410E-141.440E-12Cell type;Mature erythrocyte;Reticulocyte
N-Hydroxy-1-aminonaphthaleneST000539AN0008191.990E-45.500E-4Cell type;Mature erythrocyte;Reticulocyte
N-hydroxyisoleucineST000539AN0008194.350E-103.030E-9Cell type;Mature erythrocyte;Reticulocyte
nocardicin GST000539AN0008195.290E-72.270E-6Cell type;Mature erythrocyte;Reticulocyte
nonulose 9-phosphateST000539AN0008195.380E-93.070E-8Cell type;Mature erythrocyte;Reticulocyte
nonulose 9-phosphate 2ST000539AN0008195.380E-93.070E-8Cell type;Mature erythrocyte;Reticulocyte
O-Acetyl-L-homoserine 2ST000539AN0008193.040E-22.170E-1timepoint;1 hour;20 hours
octulose 8-phosphateST000539AN0008192.980E-22.420E-1Glucose labelling;C13 glucose;unlabelled
omega-Cyclohexylundecanoic acidST000539AN0008191.720E-122.800E-11Cell type;Mature erythrocyte;Reticulocyte
[PC (15:1)] 1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholineST000539AN0008191.370E-33.290E-3Cell type;Mature erythrocyte;Reticulocyte
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholineST000539AN0008191.190E-21.410E-1timepoint;1 hour;20 hours
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholineST000539AN0008191.220E-22.230E-2Cell type;Mature erythrocyte;Reticulocyte
P-DPDST000539AN0008191.380E-33.290E-3Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608ST000539AN0008193.680E-37.790E-3Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608ST000539AN0008192.340E-21.950E-1timepoint;1 hour;20 hours
penem CGP31608 2ST000539AN0008193.680E-37.790E-3Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608 2ST000539AN0008192.340E-21.950E-1timepoint;1 hour;20 hours
PhenolsulfonphthaleinST000539AN0008193.570E-71.580E-6Cell type;Mature erythrocyte;Reticulocyte
[PI (18:0)] 1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)ST000539AN0008197.170E-104.740E-9Cell type;Mature erythrocyte;Reticulocyte
[PR] 9-Hydroxy-helminthosporolST000539AN0008193.870E-38.130E-3Cell type;Mature erythrocyte;Reticulocyte
[PR] Citronellyl acetateST000539AN0008191.560E-55.150E-5Cell type;Mature erythrocyte;Reticulocyte
(R)-3-HydroxybutanoateST000539AN0008193.030E-25.100E-2Cell type;Mature erythrocyte;Reticulocyte
(R)-AMAAST000539AN0008192.540E-35.690E-3Cell type;Mature erythrocyte;Reticulocyte
(R)-AMAAST000539AN0008193.740E-22.360E-1timepoint;1 hour;20 hours
(R)-AMAAST000539AN0008193.850E-22.830E-1Glucose labelling;C13 glucose;unlabelled
sinapoyltyramineST000539AN0008191.310E-133.910E-12Cell type;Mature erythrocyte;Reticulocyte
(S)-Methylmalonate semialdehydeST000539AN0008195.900E-133.160E-10Glucose labelling;C13 glucose;unlabelled
(S)-Methylmalonate semialdehydeST000539AN0008193.550E-22.310E-1timepoint;1 hour;20 hours
sodium dodecyl sulfateST000539AN0008194.740E-31.070E-1timepoint;1 hour;20 hours
SulfoacetateST000539AN0008196.190E-31.240E-2Cell type;Mature erythrocyte;Reticulocyte
uridine-5-diphosphate bromoacetolST000539AN0008199.140E-52.210E-2timepoint;1 hour;20 hours
XylobioseST000539AN0008191.920E-67.360E-5Glucose labelling;C13 glucose;unlabelled
ADMA / ArgST000544AN0008266.110E-156.930E-14Sample Type;Control;Replicate
Arg/(Arg+Orn)ST000544AN0008268.220E-32.790E-2Sample Type;Control;Replicate
Cit / ArgST000544AN0008263.430E-21.020E-1Sample Type;Control;Replicate
Cit / OrnST000544AN0008264.950E-21.400E-1Sample Type;Control;Replicate
DOPA/TyrST000544AN0008262.740E-31.030E-2Sample Type;Control;Replicate
Fisher ratioST000544AN0008267.830E-32.790E-2Sample Type;Control;Replicate
GlutaminolysisST000544AN0008262.320E-153.950E-14Sample Type;Control;Replicate
Orn / SerST000544AN0008261.690E-25.230E-2Sample Type;Control;Replicate
Putrescine / OrnST000544AN0008262.420E-122.060E-11Sample Type;Control;Replicate
SDMA / ArgST000544AN0008263.530E-82.180E-7Sample Type;Control;Replicate
Spermidine / PutrescineST000544AN0008262.630E-31.030E-2Sample Type;Control;Replicate
Total DMA / ArgST000544AN0008261.430E-111.080E-10Sample Type;Control;Replicate
C12 / C10ST000544AN0008272.610E-82.790E-7Sample Type;Control;Replicate
C12 / C8ST000544AN0008274.990E-74.560E-6Sample Type;Control;Replicate
C14:1-OH / C10ST000544AN0008278.700E-34.180E-2Sample Type;Control;Replicate
C2 / C0ST000544AN0008278.590E-34.180E-2Sample Type;Control;Replicate
C3 / C4ST000544AN0008273.230E-42.070E-3Sample Type;Control;Replicate
C4 / C5ST000544AN0008273.530E-124.520E-11Sample Type;Control;Replicate
C9 / C10:2ST000544AN0008276.450E-33.350E-2Sample Type;Control;Replicate
C9 / C14ST000544AN0008274.120E-187.910E-17Sample Type;Control;Replicate
C9 / C14:1-OHST000544AN0008279.930E-226.360E-20Sample Type;Control;Replicate
C9 / C16:1-OHST000544AN0008271.600E-142.360E-13Sample Type;Control;Replicate
CPT-I ratioST000544AN0008272.360E-31.370E-2Sample Type;Control;Replicate
Total AC / C0ST000544AN0008279.800E-34.590E-2Sample Type;Control;Replicate
Total AC-DC / Total ACST000544AN0008272.290E-41.570E-3Sample Type;Control;Replicate
Total AC-OH / Total ACST000544AN0008272.280E-51.810E-4Sample Type;Control;Replicate
Total SM / Total PCST000544AN0008272.350E-51.810E-4Sample Type;Control;Replicate
Total SM / Total (SM+PC)ST000544AN0008273.260E-52.320E-4Sample Type;Control;Replicate
ADMA / ArgST000545AN0008292.590E-33.560E-2Sample Type;Control;Replicate
DOPA/TyrST000545AN0008292.740E-33.560E-2Sample Type;Control;Replicate
Fisher ratioST000545AN0008291.970E-41.470E-2Sample Type;Control;Replicate
Kynurenine / TrpST000545AN0008299.110E-37.600E-2Sample Type;Control;Replicate
Met-SO / MetST000545AN0008298.730E-37.600E-2Sample Type;Control;Replicate
Putrescine / OrnST000545AN0008292.850E-33.560E-2Sample Type;Control;Replicate
SDMA / ArgST000545AN0008292.180E-21.360E-1Sample Type;Control;Replicate
Serotonin / TrpST000545AN0008292.620E-33.560E-2Sample Type;Control;Replicate
Spermidine / PutrescineST000545AN0008291.970E-33.560E-2Sample Type;Control;Replicate
Spermine / SpermidineST000545AN0008294.900E-22.400E-1Sample Type;Control;Replicate
Total DMA / ArgST000545AN0008291.410E-21.060E-1Sample Type;Control;Replicate
C12 / C10ST000545AN0008307.060E-89.800E-7Sample Type;Control;Replicate
C12 / C8ST000545AN0008307.890E-31.120E-2Sample Type;Control;Replicate
C14:1-OH / C10ST000545AN0008301.390E-32.170E-3Sample Type;Control;Replicate
C3 / C4ST000545AN0008304.040E-35.980E-3Sample Type;Control;Replicate
C4 / C0ST000545AN0008301.590E-32.470E-3Sample Type;Control;Replicate
C4 / C5ST000545AN0008302.180E-54.120E-5Sample Type;Control;Replicate
C9 / C10:2ST000545AN0008309.810E-31.380E-2Sample Type;Control;Replicate
CPT-I ratioST000545AN0008302.360E-33.580E-3Sample Type;Control;Replicate
lysoPC a C16:0 / lysoPC a C16:1ST000545AN0008302.270E-68.290E-6Sample Type;Control;Replicate
lysoPC a C20:4 / lysoPC a C20:3ST000545AN0008303.020E-55.450E-5Sample Type;Control;Replicate
MUFA (PC)ST000545AN0008301.860E-67.970E-6Sample Type;Control;Replicate
MUFA (PC) / SFA (PC)ST000545AN0008302.270E-122.170E-10Sample Type;Control;Replicate
PC aa C40:3 / PC aa C42:5ST000545AN0008306.050E-51.050E-4Sample Type;Control;Replicate
PC aa C40:5 / PC aa C42:5ST000545AN0008304.960E-61.210E-5Sample Type;Control;Replicate
PC ae C44:5 / PC ae C42:5ST000545AN0008307.720E-51.300E-4Sample Type;Control;Replicate
PUFA (PC)ST000545AN0008302.420E-68.290E-6Sample Type;Control;Replicate
PUFA (PC) / MUFA (PC)ST000545AN0008307.370E-61.550E-5Sample Type;Control;Replicate
PUFA (PC) / SFA (PC)ST000545AN0008305.060E-123.220E-10Sample Type;Control;Replicate
SFA (PC)ST000545AN0008302.590E-23.560E-2Sample Type;Control;Replicate
Total AC / C0ST000545AN0008305.690E-38.170E-3Sample Type;Control;Replicate
Total AC-DC / Total ACST000545AN0008301.100E-52.190E-5Sample Type;Control;Replicate
Total AC-OH / Total ACST000545AN0008302.280E-54.240E-5Sample Type;Control;Replicate
Total lysoPCST000545AN0008302.360E-71.880E-6Sample Type;Control;Replicate
Total lysoPC / Total PCST000545AN0008303.160E-55.630E-5Sample Type;Control;Replicate
Total PCST000545AN0008303.140E-68.880E-6Sample Type;Control;Replicate
Total PC aaST000545AN0008303.250E-68.880E-6Sample Type;Control;Replicate
Total PC aeST000545AN0008302.340E-68.290E-6Sample Type;Control;Replicate
Total (PC+SM)ST000545AN0008302.900E-68.880E-6Sample Type;Control;Replicate
Total SMST000545AN0008301.960E-67.970E-6Sample Type;Control;Replicate
Total SM-non OHST000545AN0008301.920E-67.970E-6Sample Type;Control;Replicate
Total SM-OHST000545AN0008301.400E-66.860E-6Sample Type;Control;Replicate
Total SM / Total PCST000545AN0008303.210E-68.880E-6Sample Type;Control;Replicate
Total SM / Total (SM+PC)ST000545AN0008307.360E-61.550E-5Sample Type;Control;Replicate
O-Acetyl-Lcarnitine:HCl (N-methyl-D3)ST000552AN0008433.230E-29.420E-1VTE;no;yes
2-O-ethyl PAF C-16ST000553AN0008451.140E-114.390E-11Sample type;Plasma;Urine
2-O-methyl PAF C16ST000553AN0008457.740E-48.890E-4Sample type;Plasma;Urine
ArachidonoylPAF-C16ST000553AN0008453.110E-85.090E-8Sample type;Plasma;Urine
Butanoyl-PAFST000553AN0008456.650E-135.980E-12Sample type;Plasma;Urine
Cyclo(leucylprolyl)ST000553AN0008451.890E-116.380E-11Sample type;Plasma;Urine
Docosahexaenoyl PAF C-16ST000553AN0008453.720E-109.140E-10Sample type;Plasma;Urine
Eicosapentaenoyl PAF C-16ST000553AN0008452.900E-121.570E-11Sample type;Plasma;Urine
gamma-Muricholic acidST000553AN0008453.390E-108.720E-10Sample type;Plasma;Urine
HWESASXXST000553AN0008453.470E-111.100E-10Sample type;Plasma;Urine
Lovastatin Hydroxy AcidST000553AN0008453.850E-34.330E-3Sample type;Plasma;Urine
PAF C-16ST000553AN0008451.110E-82.000E-8Sample type;Plasma;Urine
PAF C-18ST000553AN0008452.050E-94.250E-9Sample type;Plasma;Urine
Phe-Ala-Phe-AlaST000553AN0008451.670E-82.830E-8Sample type;Plasma;Urine
POV-PCST000553AN0008451.410E-62.000E-6Sample type;Plasma;Urine
Sphinganine-phosphate (d18:0)ST000553AN0008451.120E-131.210E-12Sample type;Plasma;Urine
?-TocotrienolST000553AN0008452.520E-22.780E-2Sample type;Plasma;Urine
17?-Ethinyl estradiolST000553AN0008461.860E-72.320E-7Sample type;Plasma;Urine
1-Oleoyl Lysophosphatidic AcidST000553AN0008461.430E-115.590E-11Sample type;Plasma;Urine
2-O-methyl PAF C-16ST000553AN0008466.290E-77.410E-7Sample type;Plasma;Urine
Arachidonoyl PAF C-16ST000553AN0008467.090E-91.340E-8Sample type;Plasma;Urine
Butanoyl-PAFST000553AN0008466.370E-88.950E-8Sample type;Plasma;Urine
Dihomo-?-Linolenic AcidST000553AN0008461.740E-131.280E-12Sample type;Plasma;Urine
Dihydro Cer (d18:0/16:0)ST000553AN0008461.990E-83.120E-8Sample type;Plasma;Urine
DimethylallylaminopurineST000553AN0008461.920E-104.880E-10Sample type;Plasma;Urine
Docosahexaenoyl PAF C-16ST000553AN0008466.510E-91.260E-8Sample type;Plasma;Urine
Eicosapentaenoyl PAF C-16ST000553AN0008462.740E-121.210E-11Sample type;Plasma;Urine
gamma-Muricholic acidST000553AN0008463.000E-107.080E-10Sample type;Plasma;Urine
HWESASXXST000553AN0008464.720E-132.830E-12Sample type;Plasma;Urine
PAF C-16ST000553AN0008462.400E-52.510E-5Sample type;Plasma;Urine
PAF C-18ST000553AN0008461.650E-72.100E-7Sample type;Plasma;Urine
Sphinganine-phosphate (d18:0)ST000553AN0008462.200E-94.400E-9Sample type;Plasma;Urine
2-DeoxyinosineST000553AN0008475.700E-111.470E-10Sample type;Plasma;Urine
Assymetrical dimethylarginineST000553AN0008471.730E-62.430E-6Sample type;Plasma;Urine
BenzylserineST000553AN0008479.400E-71.400E-6Sample type;Plasma;Urine
Beta-alanine methyl esterST000553AN0008477.090E-111.740E-10Sample type;Plasma;Urine
MethylhippurateST000553AN0008472.750E-117.880E-11Sample type;Plasma;Urine
MethylpicolinateST000553AN0008478.070E-81.360E-7Sample type;Plasma;Urine
Na-methylhistamineST000553AN0008472.390E-84.360E-8Sample type;Plasma;Urine
PyroglutamylglycineST000553AN0008471.420E-41.670E-4Sample type;Plasma;Urine
Theobromine /TheophyllineST000553AN0008471.330E-92.680E-9Sample type;Plasma;Urine
Threonine /HomoserineST000553AN0008477.040E-101.510E-9Sample type;Plasma;Urine
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoic acidST000566AN0008698.180E-32.670E-2group;Old-Curcumin;Old-Placebo;young
2-PyridylthioamideST000566AN0008691.730E-33.390E-3Time point;Post;Pre;Baseline
4-Hydroxylevamisole GlucuronideST000566AN0008692.040E-33.820E-3Time point;Post;Pre;Baseline
4-Methylumbelliferyl ?-D-glucuronideST000566AN0008691.990E-37.970E-3group;Old-Curcumin;Old-Placebo;young
5?-Androstan-3?-ol-17-one sulfateST000566AN0008692.100E-201.230E-19Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfateST000566AN0008691.460E-58.030E-5group;Old-Curcumin;Old-Placebo;young
5?-Androstan-3?-ol-17-one sulfate - 7.5459185ST000566AN0008691.700E-157.880E-15Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfate - 7.5459185ST000566AN0008691.810E-37.580E-3group;Old-Curcumin;Old-Placebo;young
5?-Androstan-3?-ol-17-one sulfate - 7.7291727ST000566AN0008692.700E-251.830E-24Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfate - 7.7291727ST000566AN0008692.730E-61.720E-5group;Old-Curcumin;Old-Placebo;young
5?-Androstan-3?-ol-17-one sulfate - 8.185043ST000566AN0008697.010E-316.170E-30Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfate - 8.185043ST000566AN0008691.360E-91.990E-8group;Old-Curcumin;Old-Placebo;young
5-Dehydro-4-deoxy-D-glucarateST000566AN0008691.420E-24.310E-2group;Old-Curcumin;Old-Placebo;young
5-O-Feruloylquinic acidST000566AN0008695.700E-39.830E-3Time point;Post;Pre;Baseline
Allopregnanalone sulfateST000566AN0008695.090E-381.120E-36Time point;Post;Pre;Baseline
Allopregnanalone sulfateST000566AN0008693.980E-83.500E-7group;Old-Curcumin;Old-Placebo;young
FluroxypyrST000566AN0008696.080E-51.530E-4Time point;Post;Pre;Baseline
HydroxyibuprofenST000566AN0008695.680E-91.850E-8Time point;Post;Pre;Baseline
MarinobufageninST000566AN0008693.080E-121.230E-11Time point;Post;Pre;Baseline
MarinobufageninST000566AN0008692.490E-39.530E-3group;Old-Curcumin;Old-Placebo;young
Phenyl beta-D-glucopyranosideST000566AN0008691.020E-34.490E-3group;Old-Curcumin;Old-Placebo;young
Steryl sulfateST000566AN0008695.390E-202.960E-19Time point;Post;Pre;Baseline
Steryl sulfateST000566AN0008692.790E-72.230E-6group;Old-Curcumin;Old-Placebo;young
Sulfinpyrazone sulfoneST000566AN0008692.700E-23.970E-2Time point;Post;Pre;Baseline
Tris(2-chloroethyl)phosphateST000566AN0008694.530E-101.590E-9Time point;Post;Pre;Baseline
2-Amino-3-methyl-1-butanolST000566AN0008702.430E-71.220E-6Time point;Post;Pre;Baseline
2-Oxo-10-methylthiodecanoic acidST000566AN0008702.280E-54.430E-5Time point;Post;Pre;Baseline
2-oxo-3-methylvaleric acidST000566AN0008702.520E-54.640E-5Time point;Post;Pre;Baseline
2-oxo-3-methylvaleric acidST000566AN0008704.700E-21.410E-1group;Old-Curcumin;Old-Placebo;young
3-ButynoateST000566AN0008708.460E-41.100E-3Time point;Post;Pre;Baseline
3-O-Methyl-myo-inositolST000566AN0008704.660E-34.450E-2group;Old-Curcumin;Old-Placebo;young
3-O-Methyl-myo-inositolST000566AN0008701.840E-22.020E-2Time point;Post;Pre;Baseline
5-Formiminotetrahydrofolic acidST000566AN0008709.050E-73.060E-6Time point;Post;Pre;Baseline
5-Formiminotetrahydrofolic acidST000566AN0008703.830E-21.300E-1group;Old-Curcumin;Old-Placebo;young
AzaserineST000566AN0008701.060E-41.680E-4Time point;Post;Pre;Baseline
C4 N O4 SST000566AN0008705.760E-87.450E-7Time point;Post;Pre;Baseline
C7 N O6 SST000566AN0008708.060E-87.450E-7Time point;Post;Pre;Baseline
CeliprololST000566AN0008701.790E-29.110E-2group;Old-Curcumin;Old-Placebo;young
CeliprololST000566AN0008703.110E-23.260E-2Time point;Post;Pre;Baseline
Corey PG-Lactone DiolST000566AN0008705.840E-59.890E-5Time point;Post;Pre;Baseline
Corey PG-Lactone DiolST000566AN0008704.120E-21.350E-1group;Old-Curcumin;Old-Placebo;young
Corey PG-Lactone Diol + 6.739769ST000566AN0008709.270E-41.190E-3Time point;Post;Pre;Baseline
Desmethylmianserin glucuronideST000566AN0008705.590E-61.200E-5Time point;Post;Pre;Baseline
Desmethylmianserin glucuronideST000566AN0008703.270E-21.230E-1group;Old-Curcumin;Old-Placebo;young
Diethyl OxalpropionateST000566AN0008701.670E-48.790E-3group;Old-Curcumin;Old-Placebo;young
Diethyl OxalpropionateST000566AN0008704.510E-24.640E-2Time point;Post;Pre;Baseline
DL-?-Lipoic AcidST000566AN0008701.160E-31.470E-3Time point;Post;Pre;Baseline
HBAST000566AN0008704.510E-46.080E-4Time point;Post;Pre;Baseline
Levobunolol glucuronideST000566AN0008702.450E-32.960E-3Time point;Post;Pre;Baseline
L-Glutamic acid dibutyl esterST000566AN0008702.610E-43.750E-4Time point;Post;Pre;Baseline
L-Glutamic acid dibutyl esterST000566AN0008705.570E-41.400E-2group;Old-Curcumin;Old-Placebo;young
L-Glutamic acid n-butyl esterST000566AN0008701.160E-63.590E-6Time point;Post;Pre;Baseline
L-Glutamic acid n-butyl esterST000566AN0008708.980E-35.240E-2group;Old-Curcumin;Old-Placebo;young
L-Glutamic acid n-butyl ester + 1.5990624ST000566AN0008701.050E-63.340E-6Time point;Post;Pre;Baseline
L-Glutamic acid n-butyl ester + 1.5990624ST000566AN0008707.530E-34.910E-2group;Old-Curcumin;Old-Placebo;young
Mycalamide AST000566AN0008707.440E-34.910E-2group;Old-Curcumin;Old-Placebo;young
Mycalamide AST000566AN0008703.210E-23.330E-2Time point;Post;Pre;Baseline
Myxothiazol ZST000566AN0008701.830E-65.050E-6Time point;Post;Pre;Baseline
N-HydroxymethylnicotinamideST000566AN0008702.500E-22.670E-2Time point;Post;Pre;Baseline
N-HydroxymethylnicotinamideST000566AN0008703.130E-21.220E-1group;Old-Curcumin;Old-Placebo;young
N-Oleoyl-L-SerineST000566AN0008707.520E-51.250E-4Time point;Post;Pre;Baseline
N-Oleoyl-L-SerineST000566AN0008701.640E-32.150E-2group;Old-Curcumin;Old-Placebo;young
SenecivernineST000566AN0008702.910E-71.330E-6Time point;Post;Pre;Baseline
TiletamineST000566AN0008701.350E-42.060E-4Time point;Post;Pre;Baseline
(Z)-N-(2-hydroxyethyl)hexadec-7-enamideST000566AN0008701.410E-52.910E-5Time point;Post;Pre;Baseline
16-FeruloyloxypalmitateST000567AN0008712.230E-191.990E-18Time point;Post;Pre;Baseline
16-FeruloyloxypalmitateST000567AN0008718.750E-69.630E-5groups;Old-Curcumin;Old-Placebo;young
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoic acidST000567AN0008715.870E-31.710E-2groups;Old-Curcumin;Old-Placebo;young
4-Sulfobenzyl alcoholST000567AN0008719.560E-32.530E-2groups;Old-Curcumin;Old-Placebo;young
5?-Androstan-3?-ol-17-one sulfateST000567AN0008717.040E-228.390E-21Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfateST000567AN0008717.010E-55.570E-4groups;Old-Curcumin;Old-Placebo;young
5-?-Hydroxybutyl HydantoinST000567AN0008718.440E-93.020E-8Time point;Post;Pre;Baseline
Ascorbate 2-sulfateST000567AN0008717.270E-43.540E-3groups;Old-Curcumin;Old-Placebo;young
C16-OH SulfatideST000567AN0008711.030E-167.760E-16Time point;Post;Pre;Baseline
C16-OH SulfatideST000567AN0008712.730E-38.860E-3groups;Old-Curcumin;Old-Placebo;young
cyclo-Dopa-glucuronylglucosideST000567AN0008717.360E-291.750E-27Time point;Post;Pre;Baseline
cyclo-Dopa-glucuronylglucosideST000567AN0008711.400E-51.250E-4groups;Old-Curcumin;Old-Placebo;young
Dehydro-L-(+)-ascorbic acid dimerST000567AN0008716.820E-82.270E-7Time point;Post;Pre;Baseline
DiphenylmethylphosphineST000567AN0008716.890E-72.140E-6Time point;Post;Pre;Baseline
EpoxomicinST000567AN0008711.250E-84.370E-8Time point;Post;Pre;Baseline
EuparinST000567AN0008711.910E-41.240E-3groups;Old-Curcumin;Old-Placebo;young
FurmecycloxST000567AN0008711.210E-63.700E-6Time point;Post;Pre;Baseline
HydroxyibuprofenST000567AN0008717.970E-42.000E-3Time point;Post;Pre;Baseline
Laurencione diacetateST000567AN0008716.200E-261.270E-24Time point;Post;Pre;Baseline
Laurencione diacetateST000567AN0008713.070E-91.460E-7groups;Old-Curcumin;Old-Placebo;young
MarinobufageninST000567AN0008717.610E-251.360E-23Time point;Post;Pre;Baseline
MarinobufageninST000567AN0008711.090E-51.120E-4groups;Old-Curcumin;Old-Placebo;young
MethylprednisoneST000567AN0008715.880E-123.000E-11Time point;Post;Pre;Baseline
MethylprednisoneST000567AN0008717.540E-32.110E-2groups;Old-Curcumin;Old-Placebo;young
NVP-BEZ235ST000567AN0008713.280E-27.570E-2groups;Old-Curcumin;Old-Placebo;young
Phenyl beta-D-glucopyranosideST000567AN0008711.270E-35.030E-3groups;Old-Curcumin;Old-Placebo;young
Pregnanolone sulfateST000567AN0008716.830E-301.950E-28Time point;Post;Pre;Baseline
Pregnanolone sulfateST000567AN0008717.860E-69.360E-5groups;Old-Curcumin;Old-Placebo;young
SC-514ST000567AN0008711.690E-96.710E-9Time point;Post;Pre;Baseline
SC-514ST000567AN0008712.900E-26.810E-2groups;Old-Curcumin;Old-Placebo;young
YM-201636ST000567AN0008712.430E-38.260E-3groups;Old-Curcumin;Old-Placebo;young
17-phenyl trinor Prostaglandin E2 serinol amideST000567AN0008728.050E-51.660E-4Time point;Post;Pre;Baseline
2E-methyl-glutaconic acidST000567AN0008721.040E-31.500E-3Time point;Post;Pre;Baseline
2-MethylbutanalST000567AN0008723.780E-72.890E-6Time point;Post;Pre;Baseline
2-Oxo-7-methylthioheptanoic acidST000567AN0008721.150E-53.050E-5Time point;Post;Pre;Baseline
4-Hydroxy-6-methylpyran-2-oneST000567AN0008721.370E-31.930E-3Time point;Post;Pre;Baseline
5-(3-Pyridyl)-2-hydroxytetrahydrofuranST000567AN0008721.020E-31.190E-2groups;Old-Curcumin;Old-Placebo;young
5-(3-Pyridyl)-2-hydroxytetrahydrofuranST000567AN0008721.290E-21.410E-2Time point;Post;Pre;Baseline
7?-Hydroxy-3-oxo-4-cholestenoateST000567AN0008726.540E-74.050E-6Time point;Post;Pre;Baseline
C29 N O20 S2ST000567AN0008725.290E-73.620E-6Time point;Post;Pre;Baseline
C4 N O4 SST000567AN0008729.850E-81.860E-6Time point;Post;Pre;Baseline
C7 N O6 SST000567AN0008724.500E-81.860E-6Time point;Post;Pre;Baseline
CycloleucineST000567AN0008722.700E-44.340E-4Time point;Post;Pre;Baseline
CycloleucineST000567AN0008722.790E-21.070E-1groups;Old-Curcumin;Old-Placebo;young
D-2-Amino-hexano-6-lactamST000567AN0008722.680E-61.130E-5Time point;Post;Pre;Baseline
DecylubiquinolST000567AN0008725.330E-47.870E-4Time point;Post;Pre;Baseline
DecylubiquinolST000567AN0008721.160E-25.370E-2groups;Old-Curcumin;Old-Placebo;young
delta-Guanidinovaleric acidST000567AN0008727.390E-73.200E-5groups;Old-Curcumin;Old-Placebo;young
delta-Guanidinovaleric acidST000567AN0008726.660E-62.060E-5Time point;Post;Pre;Baseline
(E)-2-Butenyl-4-methyl-threonineST000567AN0008723.670E-45.310E-3groups;Old-Curcumin;Old-Placebo;young
(E)-2-Butenyl-4-methyl-threonineST000567AN0008723.790E-45.730E-4Time point;Post;Pre;Baseline
Galabiosylceramide (d18:1/16:0)ST000567AN0008724.960E-35.940E-3Time point;Post;Pre;Baseline
HBAST000567AN0008727.050E-74.160E-6Time point;Post;Pre;Baseline
N(alpha)-t-Butoxycarbonyl-L-leucineST000567AN0008721.230E-66.070E-6Time point;Post;Pre;Baseline
Neomenthyl acetateST000567AN0008721.590E-42.950E-4Time point;Post;Pre;Baseline
Neomenthyl acetateST000567AN0008726.590E-33.570E-2groups;Old-Curcumin;Old-Placebo;young
farnesolST000568AN0008741.660E-112.850E-11Genotype;AA;AC;CC
Dicyclohexyl phthalateST000583AN0008942.620E-21.850E-1time;12-weeks;baseline
Dicyclohexyl phthalateST000583AN0008943.340E-22.650E-1caries status;caries-active;caries-free
Dipropylene glycolST000583AN0008943.360E-42.620E-2caries status;caries-active;caries-free
TexanolST000583AN0008943.330E-37.050E-2caries status;caries-active;caries-free
Dinoterb (herbicide)ST000583AN0008953.410E-21.830E-1time;12-weeks;baseline
GLYCEROL 2-PHOSPHATE/SN-GLYCEROL 3-PHOSPHATEST000583AN0008954.180E-37.350E-2time;12-weeks;baseline
N-ACETYL-HEXOSAMINEST000583AN0008953.780E-21.940E-1time;12-weeks;baseline
2-Ketoleucine/ketoisoleucineST000586AN0009012.300E-371.960E-36Plasma Volume;0 uL;150 uL;700 uL
2-KetovalineST000586AN0009013.340E-107.630E-10Plasma Volume;0 uL;150 uL;700 uL
3-(4-Hydroxyphenyl)propionic acidST000586AN0009013.310E-23.870E-2Plasma Volume;0 uL;150 uL;700 uL
3-Indolelactic acid/tryptophanST000586AN0009011.420E-62.530E-6Plasma Volume;0 uL;150 uL;700 uL
5-alpha-Coprostanol or similar oxysterolST000586AN0009013.290E-23.870E-2Plasma Volume;0 uL;150 uL;700 uL
6-DeoxyhexoseST000586AN0009016.940E-333.420E-32Plasma Volume;0 uL;150 uL;700 uL
AldopentosesST000586AN0009011.750E-297.450E-29Plasma Volume;0 uL;150 uL;700 uL
Cholic acid or similar bile acidST000586AN0009012.220E-43.260E-4Plasma Volume;0 uL;150 uL;700 uL
DisaccharideST000586AN0009015.980E-374.570E-36Plasma Volume;0 uL;150 uL;700 uL
Ethanol diglycine (EDTA decomposition product)ST000586AN0009017.510E-282.800E-27Plasma Volume;0 uL;150 uL;700 uL
Flavonoid or short-chain cholesterol esterST000586AN0009012.210E-63.710E-6Plasma Volume;0 uL;150 uL;700 uL
Gluconic acid or similar sugar acidST000586AN0009011.190E-414.470E-40Plasma Volume;0 uL;150 uL;700 uL
Gluconic acid or similar sugar acid 2ST000586AN0009019.870E-355.810E-34Plasma Volume;0 uL;150 uL;700 uL
Heptadecanoic acid/Octadecanol 2ST000586AN0009011.530E-62.630E-6Plasma Volume;0 uL;150 uL;700 uL
HydroxyprolinesST000586AN0009015.510E-71.020E-6Plasma Volume;0 uL;150 uL;700 uL
Methyl eicosatrienoateST000586AN0009013.530E-76.670E-7Plasma Volume;0 uL;150 uL;700 uL
Methyl palmitateST000586AN0009011.720E-351.100E-34Plasma Volume;0 uL;150 uL;700 uL
Myoinositol-2-phosphateST000586AN0009017.020E-131.790E-12Plasma Volume;0 uL;150 uL;700 uL
N-Methylalanine/2-Aminobutanoic acid/N-EthylglycineST000586AN0009013.900E-66.490E-6Plasma Volume;0 uL;150 uL;700 uL
Pentonic acidsST000586AN0009014.330E-141.120E-13Plasma Volume;0 uL;150 uL;700 uL
Prunetin or similar isoflavoneST000586AN0009011.230E-21.540E-2Plasma Volume;0 uL;150 uL;700 uL
Sucrose and similar disaccharidesST000586AN0009018.950E-162.450E-15Plasma Volume;0 uL;150 uL;700 uL
TrisaccharideST000586AN0009018.180E-81.580E-7Plasma Volume;0 uL;150 uL;700 uL
2-KetoleucineST000589AN0009043.070E-727.600E-72Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
2-KetovalineST000589AN0009049.360E-622.060E-61Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
3-Indolelactic acidST000589AN0009047.810E-1213.550E-120Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
4-HydroxypyridineST000589AN0009041.590E-131.880E-13Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
6-DeoxyhexoseST000589AN0009043.150E-808.530E-80Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
AldopentosesST000589AN0009042.110E-363.340E-36Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Cholic acid or similar bile acidST000589AN0009045.310E-186.870E-18Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
DisaccharideST000589AN0009043.570E-1261.800E-125Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
HydroxyprolinesST000589AN0009047.190E-291.040E-28Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Methyl eicosatrienoateST000589AN0009043.390E-1161.260E-115Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Methyl palmitateST000589AN0009046.410E-611.390E-60Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Myoinositol-2-phosphateST000589AN0009045.880E-369.210E-36Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Pentonic acidsST000589AN0009041.050E-271.510E-27Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Prunetin or similar isoflavoneST000589AN0009042.090E-22.160E-2Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Tartronic acidST000589AN0009044.310E-508.090E-50Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
TetrasaccharideST000589AN0009047.160E-239.520E-23Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
TrisaccharideST000589AN0009047.830E-611.670E-60Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
CerH2O(d18:1/16:0)ST000608AN0009295.650E-269.290E-25Sample_Type;blotter;serum
CerH2O(d18:1/24:0)ST000608AN0009291.030E-41.390E-4Sample_Type;blotter;serum
CerH2O(d18:1/24:0);CerH2O(d19:1/23:0)ST000608AN0009294.620E-42.250E-3Factor;case;control
CerH2O(d18:1/26:0);CerH2O(d20:1/24:0)ST000608AN0009299.130E-215.580E-20Sample_Type;blotter;serum
CerH2O(d18:1/26:1)ST000608AN0009291.870E-263.280E-25Sample_Type;blotter;serum
CerH2O(d18:2/22:0)ST000608AN0009292.710E-84.340E-8Sample_Type;blotter;serum
CerH2O(d18:2/23:0)ST000608AN0009292.340E-73.570E-7Sample_Type;blotter;serum
CerH2O(d19:1/24:0)ST000608AN0009298.300E-121.670E-11Sample_Type;blotter;serum
PC(16:0/11:0(CHO))ST000608AN0009294.250E-244.650E-23Sample_Type;blotter;serum
PC(16:0/5:0(CHO))ST000608AN0009291.080E-206.470E-20Sample_Type;blotter;serum
PC(16:0/7:0(CHO))ST000608AN0009291.520E-143.850E-14Sample_Type;blotter;serum
PC(18:0/5:0(COOH))ST000608AN0009295.650E-78.540E-7Sample_Type;blotter;serum
PC(18:0/8:0(COOH))ST000608AN0009291.040E-142.690E-14Sample_Type;blotter;serum
PC(18:0/9:0(CHO))ST000608AN0009293.670E-244.190E-23Sample_Type;blotter;serum
PC(18:0/9:0(COOH))ST000608AN0009298.220E-193.860E-18Sample_Type;blotter;serum
alloxanoic acidST000608AN0009317.420E-333.190E-32Sample_Type;blotter;serum
biphosphoglyceric acidST000608AN0009319.730E-421.670E-40Sample_Type;blotter;serum
Sphinganine-phosphateST000612AN0009372.330E-22.560E-1Condition;Control;Glaucomatous
Ethylmalonate/Methyl MalonateST000614AN0009391.140E-61.720E-6Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Ethylmalonate/Methyl MalonateST000614AN0009396.340E-61.060E-5Diagonsis;Benign;Cancer;Normal
Glucosamine/GalactosamineST000614AN0009394.400E-186.780E-17Diagonsis;Benign;Cancer;Normal
Glucosamine/GalactosamineST000614AN0009391.670E-171.830E-16Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
L-ZeatineST000614AN0009393.870E-482.980E-46Diagonsis;Benign;Cancer;Normal
L-ZeatineST000614AN0009392.100E-471.620E-45Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
N-Acetyl LysineST000614AN0009391.250E-31.560E-3Diagonsis;Benign;Cancer;Normal
N-Acetyl LysineST000614AN0009392.490E-32.870E-3Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Octonyl CarnitineST000614AN0009391.340E-51.840E-5Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Octonyl CarnitineST000614AN0009391.430E-52.240E-5Diagonsis;Benign;Cancer;Normal
Frctose-6-PhosphateST000614AN0009403.460E-35.100E-3Diagonsis;Benign;Cancer;Normal
Frctose-6-PhosphateST000614AN0009409.140E-31.130E-2Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
HBAST000614AN0009402.410E-22.670E-2Diagonsis;Benign;Cancer;Normal
HBAST000614AN0009402.500E-22.980E-2Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
4aminobenzaldehyde1ST000614AN0009418.690E-81.300E-7Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
4aminobenzaldehyde1ST000614AN0009415.580E-49.120E-4Diagonsis;Benign;Cancer;Normal
benzi(ghi)perylene1ST000614AN0009413.600E-33.600E-3Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
benzi(ghi)perylene1ST000614AN0009411.440E-21.730E-2Diagonsis;Benign;Cancer;Normal
cotinine1ST000614AN0009412.830E-161.700E-15Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Methyl methoxyacetateST000614AN0009413.760E-141.350E-13Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Methyl methoxyacetateST000614AN0009411.750E-71.050E-6Diagonsis;Benign;Cancer;Normal
o-toluidene2ST000614AN0009414.200E-107.550E-10Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
o-toluidene2ST000614AN0009419.180E-51.840E-4Diagonsis;Benign;Cancer;Normal
PantathonicacidST000614AN0009426.430E-61.160E-5Diagonsis;Benign;Cancer;Normal
PantathonicacidST000614AN0009422.170E-53.250E-5Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Aminophosphovaleric acidST000614AN0009431.460E-41.900E-4Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Aminophosphovaleric acidST000614AN0009431.870E-32.920E-3Diagonsis;Benign;Cancer;Normal
benzi(ghi)peryleneST000614AN0009431.200E-83.120E-8Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
benzi(ghi)peryleneST000614AN0009434.790E-36.030E-3Diagonsis;Benign;Cancer;Normal
CotineST000614AN0009434.370E-124.260E-11Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
CotineST000614AN0009438.500E-53.320E-4Diagonsis;Benign;Cancer;Normal
Cotinine-goodST000614AN0009433.160E-99.490E-9Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Cotinine-goodST000614AN0009438.400E-41.550E-3Diagonsis;Benign;Cancer;Normal
D-Erythronic acid ?-lactoneST000614AN0009433.050E-87.420E-8Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
D-Erythronic acid ?-lactoneST000614AN0009433.870E-83.770E-7Diagonsis;Benign;Cancer;Normal
Methyl deoxyadenosineST000614AN0009433.230E-101.260E-9Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Methyl deoxyadenosineST000614AN0009431.370E-44.440E-4Diagonsis;Benign;Cancer;Normal
Methyl GuanineST000614AN0009432.650E-111.720E-10Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Methyl GuanineST000614AN0009432.730E-46.650E-4Diagonsis;Benign;Cancer;Normal
Napthyl amineST000614AN0009431.280E-31.560E-3Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Napthyl amineST000614AN0009432.670E-23.060E-2Diagonsis;Benign;Cancer;Normal
o-toluideneST000614AN0009439.800E-92.730E-8Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
o-toluideneST000614AN0009435.980E-41.170E-3Diagonsis;Benign;Cancer;Normal
para-toluideneST000614AN0009435.340E-79.060E-7Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
para-toluideneST000614AN0009433.050E-34.110E-3Diagonsis;Benign;Cancer;Normal
SM(d18:1/25:0) or SM(d18:1/24:1 OH)ST000617AN0009463.450E-23.110E-1Treatment;CFS;Control
PC(16:0/15:1(14))ST000624AN0009561.190E-51.290E-4Condition;Control;Glaucomatous
PC(O-12:0/O-1:0)ST000624AN0009561.470E-26.320E-2Condition;Control;Glaucomatous
C8-Ceramide m0ST000644AN0009761.180E-82.610E-8tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m0ST000644AN0009768.590E-42.490E-3time;48 hr;0 hr
C8-Ceramide m0ST000644AN0009762.290E-23.600E-1group ID;PHGDH;PSAT;PSPH
C8-Ceramide m+1ST000644AN0009765.500E-59.300E-5tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+1ST000644AN0009763.200E-41.170E-3time;48 hr;0 hr
C8-Ceramide m+10ST000644AN0009761.750E-251.100E-24tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+10ST000644AN0009763.090E-41.150E-3time;48 hr;0 hr
C8-Ceramide m+11ST000644AN0009762.320E-426.590E-41tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+11ST000644AN0009761.460E-48.430E-4time;48 hr;0 hr
C8-Ceramide m+12ST000644AN0009762.500E-149.210E-14tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+12ST000644AN0009761.550E-34.070E-3time;48 hr;0 hr
C8-Ceramide m+13ST000644AN0009762.330E-469.470E-45tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+13ST000644AN0009761.370E-48.430E-4time;48 hr;0 hr
C8-Ceramide m+14ST000644AN0009762.780E-96.630E-9tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+14ST000644AN0009766.370E-31.260E-2time;48 hr;0 hr
C8-Ceramide m+14ST000644AN0009762.560E-23.600E-1group ID;PHGDH;PSAT;PSPH
C8-Ceramide m+15ST000644AN0009761.790E-456.340E-44tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+15ST000644AN0009761.390E-48.430E-4time;48 hr;0 hr
C8-Ceramide m+17ST000644AN0009762.590E-261.750E-25tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+17ST000644AN0009762.890E-41.100E-3time;48 hr;0 hr
C8-Ceramide m+6ST000644AN0009767.860E-153.020E-14tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+6ST000644AN0009761.390E-33.710E-3time;48 hr;0 hr
C8-Ceramide m+7ST000644AN0009764.830E-344.570E-33tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+7ST000644AN0009761.850E-48.470E-4time;48 hr;0 hr
C8-Ceramide m+8ST000644AN0009765.670E-284.020E-27tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+8ST000644AN0009762.550E-41.050E-3time;48 hr;0 hr
C8-Ceramide m+9ST000644AN0009761.830E-393.460E-38tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+9ST000644AN0009761.560E-48.430E-4time;48 hr;0 hr
IS Ceramide;[M-H20]+ST000661AN0010091.000E-337.770E-33Study;CHOICE;CSU-143;POOLED
IS Ceramide;[M-H20]+ST000661AN0010091.000E-337.770E-33Type;Clinical;Preclinical;POOLED
IS Ceramide;[M-H20]+ST000661AN0010093.620E-312.710E-30Treatment;Ornish;Southbeach;Baseline;Gainer (ad lib);Loser (...
IS Ceramide;[M-H20]+ST000661AN0010091.630E-281.110E-27Time_Point;1 Month;6 Months;Baseline;0 Days;27 Days;29 Days;...
IS Ceramide;[M-H20]+ST000661AN0010096.350E-111.760E-10Sample_Source;Plasma;POOLED;Mammary gland
IS Ceramide;[M-H20]+ST000661AN0010096.530E-119.870E-11Species;Homo sapiens;Rattus
IS Ceramide;[M-H20]+ST000661AN0010092.440E-22.710E-2Sample type;Plasma;Tissues
IS SM 35:1;[M+H]+ST000661AN0010095.210E-302.960E-29Study;CHOICE;CSU-143;POOLED
IS SM 35:1;[M+H]+ST000661AN0010095.210E-302.960E-29Type;Clinical;Preclinical;POOLED
IS SM 35:1;[M+H]+ST000661AN0010095.690E-293.440E-28Treatment;Ornish;Southbeach;Baseline;Gainer (ad lib);Loser (...
IS SM 35:1;[M+H]+ST000661AN0010092.030E-251.030E-24Time_Point;1 Month;6 Months;Baseline;0 Days;27 Days;29 Days;...
IS SM 35:1;[M+H]+ST000661AN0010097.300E-131.280E-12Species;Homo sapiens;Rattus
IS SM 35:1;[M+H]+ST000661AN0010099.430E-122.960E-11Sample_Source;Plasma;POOLED;Mammary gland
IS SM 35:1;[M+H]+ST000661AN0010099.830E-51.240E-4Sample type;Plasma;Tissues
plasmenyl-PC 19:0; [M+Na]+@2.31ST000665AN0010175.020E-34.350E-2Cell line;HepG2;HuH-7
IS Ceramide;[M-H20]+ST000669AN0010252.230E-21.790E-1Matrix;Plasma;SRF;CB
IS D31-TAGST000669AN0010259.210E-32.530E-1Disease;AS-Control-P;AS-Control-S;Coats;JB-Coats-P
IS D31-TAGST000669AN0010251.050E-21.690E-1Matrix;Plasma;SRF;CB
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000689AN0010632.330E-39.890E-3Construct;-;Control lentivirus;Noxa knockdown
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000689AN0010631.190E-37.300E-3Construct;-;Control lentivirus;Noxa knockdown
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000689AN0010631.230E-37.300E-3Construct;-;Control lentivirus;Noxa knockdown
D-MANNOSAMINE (CAS# 14307-02-9); (M+H)+[-H2O]ST000689AN0010641.520E-37.720E-3Construct;-;Control lentivirus;Noxa knockdown
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M+H)+ST000689AN0010642.610E-31.200E-2Construct;-;Control lentivirus;Noxa knockdown
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000689AN0010642.320E-42.250E-3Construct;-;Control lentivirus;Noxa knockdown
URSODIOL-2 WATERST000691AN0010672.780E-23.250E-2Progression;Pooled plasma;Y
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (CAS# 41613-14-3); (M+HCOO)-ST000695AN0010759.320E-34.630E-2Race;Black;White;POOLED
IBUPROFEN CARBOXYLIC ACID (CAS# 15935-54-3); (M+CL)-ST000695AN0010759.320E-34.630E-2Race;Black;White;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010752.260E-21.350E-1Chemotherapy;N;Y;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010752.650E-21.780E-1Taxane;N;Y;-
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010752.790E-21.850E-1CASE_CONTROL;Case;Control;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010752.910E-21.850E-1TIMEPOINT;3 Month;Baseline;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010753.350E-21.400E-1Race;Black;White;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010753.770E-22.060E-1Tamoxyfen;N;Y;-
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010754.090E-22.620E-1Drug;Exemestane;Letrozole;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010752.530E-61.330E-4Race;Black;White;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010754.010E-62.630E-4Tamoxyfen;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010754.980E-63.280E-4Drug;Exemestane;Letrozole;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010755.030E-63.310E-4Taxane;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010755.100E-62.850E-4TIMEPOINT;3 Month;Baseline;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010755.320E-63.500E-4Chemotherapy;N;Y;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010755.580E-63.670E-4CASE_CONTROL;Case;Control;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010756.870E-62.590E-4Race;Black;White;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010758.590E-63.770E-4Tamoxyfen;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.180E-54.450E-4Chemotherapy;N;Y;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.180E-54.450E-4Taxane;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.230E-55.390E-4Drug;Exemestane;Letrozole;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.350E-55.960E-4CASE_CONTROL;Case;Control;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.460E-55.490E-4TIMEPOINT;3 Month;Baseline;POOLED
L-ARGININE-(GUANIDINEIMINO-15N2) [ISTD] (CAS# ); (M+H)+ST000695AN0010766.260E-32.270E-1Taxane;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010763.040E-53.870E-3Taxane;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010766.690E-51.090E-2Drug;Exemestane;Letrozole;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010768.830E-58.600E-3TIMEPOINT;3 Month;Baseline;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010761.100E-41.460E-2Chemotherapy;N;Y;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010761.200E-41.210E-2CASE_CONTROL;Case;Control;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010761.570E-41.100E-2Race;Black;White;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010761.890E-41.840E-2Tamoxyfen;N;Y;-
BOC-ALA-OH (CAS# 15761-38-3); (M-H)-ST000697AN0010819.200E-37.550E-2Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000697AN0010816.190E-51.200E-3Cell Type;BS4;HAHA;PAK;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000697AN0010816.500E-52.970E-3Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000697AN0010811.870E-55.430E-4Cell Type;BS4;HAHA;PAK;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000697AN0010813.700E-52.950E-3Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000697AN0010826.590E-39.120E-2Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000697AN0010828.540E-35.750E-2Cell Type;BS4;HAHA;PAK;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000698AN0010833.690E-21.440E-1KD#2;yes;no;Pooled melanoma
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000698AN0010833.690E-22.040E-1KD#1;no;yes;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000698AN0010835.200E-34.890E-2KD#1;no;yes;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000698AN0010838.840E-34.870E-2KD#2;yes;no;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000698AN0010832.250E-21.080E-1Condition;no;Pooled melanoma;yes
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000698AN0010834.260E-42.410E-2KD#1;no;yes;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000698AN0010837.460E-41.120E-2KD#2;yes;no;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000698AN0010831.650E-32.490E-2Condition;no;Pooled melanoma;yes
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000698AN0010843.880E-164.790E-14KD#1;no;yes;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000698AN0010841.160E-151.440E-13KD#2;yes;no;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000698AN0010841.180E-151.460E-13Condition;no;Pooled melanoma;yes
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000708AN0011004.240E-21.570E-1GROUP;POOLED;Standard;VLED
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000708AN0011004.270E-21.940E-1VISIT;POOLED;visit 1;visit 2
ZEATIN [ISTD] (M+CL)-ST000711AN0011101.380E-38.610E-2NTM pulmonary disease;no;yes
ZEATIN [ISTD] (M-H)-ST000711AN0011101.930E-38.610E-2NTM pulmonary disease;no;yes
ZEATIN [ISTD] (M+H)+ST000711AN0011111.470E-34.130E-2NTM pulmonary disease;no;yes
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000713AN0011131.660E-97.930E-8malignant transformation;No;yes;Yes
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000713AN0011132.400E-31.810E-2level of dysplasia;HGD;HGD & PDA;LGD;N/A
SALICYLATE #2 (M-H)-ST000713AN0011132.000E-63.580E-5level of dysplasia;HGD;HGD & PDA;LGD;N/A
ZEATIN [ISTD] (M+CL)-ST000713AN0011132.770E-32.480E-2malignant transformation;No;yes;Yes
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000713AN0011142.910E-75.500E-6malignant transformation;No;yes;Yes
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000713AN0011148.160E-41.040E-2level of dysplasia;HGD;HGD & PDA;LGD;N/A
ACETAMINOPHEN (TN TYLENOL) (M+NA)+ST000713AN0011146.100E-69.600E-5malignant transformation;No;yes;Yes
ACETAMINOPHEN (TN TYLENOL) (M+NA)+ST000713AN0011148.230E-41.040E-2level of dysplasia;HGD;HGD & PDA;LGD;N/A
ZEATIN [ISTD] (M+H)+ST000721AN0011274.380E-22.480E-1Gender;Male;Female
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000721AN0011281.570E-24.850E-1GOSE;4;5;6;7;8;NA
IBUPROFEN CARBOXYLIC ACID (M-H)-ST000721AN0011283.070E-23.590E-1CT findings;Abnormal only;Normal
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000721AN0011282.190E-61.260E-5Injury;1 month;3 months
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000725AN0011372.680E-35.560E-1gender;Female;Male
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000726AN0011386.390E-31.210E-1AGE;12;13;14;15;16;17
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000726AN0011384.060E-21.400E-1Assay;BC TP;OGTT
ZEATIN [ISTD] (M+CL)-ST000726AN0011382.250E-97.500E-9Timepoint;-;270;120;30;90
ZEATIN [ISTD] (M+CL)-ST000726AN0011384.170E-22.170E-1DISEASE_STATE;Control;PCOS
ZEATIN [ISTD] (M-H)-ST000726AN0011387.700E-34.490E-2Assay;BC TP;OGTT
ZEATIN [ISTD] (M-H)-ST000726AN0011381.260E-21.100E-1DISEASE_STATE;Control;PCOS
ETHYL 3-UREIDOPROPIONATE (M+H)+ST000726AN0011394.570E-34.400E-2DISEASE_STATE;Control;PCOS
ETHYL 3-UREIDOPROPIONATE (M+H)+ST000726AN0011393.190E-26.770E-2Timepoint;-;270;120;30;90
ZEATIN [ISTD] (M+H)+ST000726AN0011396.280E-51.660E-3DISEASE_STATE;Control;PCOS
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000741AN0011559.450E-42.990E-2subject type;Healthy control;Mild disease;POOLED;Severe dise...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000741AN0011551.220E-71.790E-5subject type;Healthy control;Mild disease;POOLED;Severe dise...
1-PHENYLETHANOL (CAS# 1445-91-6); (M+H)+[-H2O]ST000741AN0011562.640E-21.290E-1subject type;Healthy control;Mild disease;POOLED;Severe dise...
PROCOLLAGEN 5-HYDROXY-L-LYSINE (CAS# 1190-94-9); (M+H)+ST000741AN0011563.950E-21.740E-1subject type;Healthy control;Mild disease;POOLED;Severe dise...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000741AN0011561.660E-53.600E-4subject type;Healthy control;Mild disease;POOLED;Severe dise...
ACETAMINOPHEN (TN TYLENOL) (M+NA)+ST000742AN0011584.760E-28.080E-2Species;Homo sapiens;Mus musculus;-
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+ST000742AN0011584.600E-28.070E-2Species;Homo sapiens;Mus musculus;-
IBUPROFEN CARBOXYLIC ACID (M-H)-ST000743AN0011602.820E-25.870E-1Gender;female;male
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (M+NA)+ST000744AN0011637.070E-32.000E-1Gender;female;male
ZEATIN [ISTD] (M+H)+ST000744AN0011633.470E-24.360E-1Gender;female;male
BENZOIC ACID #2 (M-H)-ST000748AN0011724.570E-24.930E-2Sample type;Cells;Culture Media
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000748AN0011726.440E-68.550E-6Sample type;Cells;Culture Media
SALICYLATE #2 (M-H)-ST000748AN0011721.580E-124.630E-12Sample type;Cells;Culture Media
ZEATIN [ISTD] (M+CL)-ST000748AN0011723.110E-96.040E-9Sample type;Cells;Culture Media
ZEATIN [ISTD] (M-H)-ST000748AN0011724.000E-97.450E-9Sample type;Cells;Culture Media
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000763AN0012011.410E-25.720E-2Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
MANDELIC ACID #2 (M-H)-ST000763AN0012019.540E-102.200E-8Type;Cath;Non-invasive
MANDELIC ACID #2 (M-H)-ST000763AN0012019.180E-81.810E-6Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
MANDELIC ACID #2 (M-H)-ST000763AN0012013.480E-51.600E-3Exercise;No;Yes
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000763AN0012024.600E-32.350E-2Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
ACETAMINOPHEN (TN TYLENOL) (M+NA)+ST000763AN0012028.610E-33.560E-2Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
ZEATIN [ISTD] (M+H)+ST000763AN0012023.000E-31.730E-2Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
ZEATIN [ISTD] (M+H)+ST000763AN0012024.600E-21.570E-1Type;Cath;Non-invasive
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+ST000768AN0012154.840E-23.320E-1Media;3N media;E8 media
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+ST000768AN0012154.840E-23.320E-1Type;neurons;stem cells
AC1MIY4GST000770AN0012173.410E-21.660E-1Timepoint;T0;T55
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000775AN0012223.290E-31.630E-2Treatment response;No;Yes;Pooled
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000775AN0012224.260E-33.110E-2Timepoint;T0;T2;Pooled
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000775AN0012221.720E-27.160E-2Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000775AN0012224.240E-72.470E-5Treatment response;No;Yes;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000775AN0012223.350E-61.950E-4Timepoint;T0;T2;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000775AN0012225.340E-63.110E-4Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000775AN0012221.520E-71.770E-5Treatment response;No;Yes;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000775AN0012221.230E-61.430E-4Timepoint;T0;T2;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000775AN0012221.260E-54.880E-4Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (CAS# 41613-14-3); (M+H)+ST000775AN0012232.270E-44.790E-3Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
PROCOLLAGEN 5-HYDROXY-L-LYSINE (CAS# 1190-94-9); (M+H)+ST000775AN0012231.510E-21.160E-1Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000775AN0012231.290E-66.460E-5Treatment response;No;Yes;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000775AN0012232.280E-61.370E-4Timepoint;T0;T2;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000775AN0012236.260E-52.350E-3Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
CerP 21:0; [M-H]-@2.12ST000775AN0012244.770E-21.270E-1Treatment response;No;Yes;Pooled
Nitro-Tyr1)ST000783AN0012393.570E-27.020E-1RACE;AA;EA
trans-OH-ProST000783AN0012391.570E-32.920E-1RACE;AA;EA
ARACHIDONATE #2 (M-H)-ST000818AN0012961.820E-54.940E-5Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
ARACHIDONATE #2 (M-H)-ST000818AN0012963.950E-51.140E-4Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
ARACHIDONATE #2 (M-H)-ST000818AN0012961.220E-33.860E-3Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
ARACHIDONATE #2 (M-H)-ST000818AN0012962.880E-29.120E-2Sex;F;M;nan
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (M+Cl)-ST000818AN0012964.020E-26.850E-2Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
ZEATIN [ISTD] (M+Cl)-ST000818AN0012961.990E-1051.890E-103Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
ZEATIN [ISTD] (M+Cl)-ST000818AN0012964.770E-704.530E-68Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
ZEATIN [ISTD] (M+Cl)-ST000818AN0012961.260E-271.190E-25Country;Ethiopia;Tanzania;Botswana
ZEATIN [ISTD] (M+Cl)-ST000818AN0012965.160E-211.630E-19Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
ZEATIN [ISTD] (M-H)-ST000818AN0012964.610E-1012.190E-99Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
ZEATIN [ISTD] (M-H)-ST000818AN0012961.690E-688.050E-67Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
ZEATIN [ISTD] (M-H)-ST000818AN0012964.320E-261.370E-24Country;Ethiopia;Tanzania;Botswana
ZEATIN [ISTD] (M-H)-ST000818AN0012967.320E-211.740E-19Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000818AN0012973.070E-224.100E-21Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000818AN0012971.090E-151.060E-14Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000818AN0012971.050E-68.560E-6Country;Ethiopia;Tanzania;Botswana
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000818AN0012971.960E-38.470E-3Country;Ethiopia;Tanzania;Botswana
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000818AN0012973.340E-26.130E-2Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
CALCIDIOL (M+H)+[-H2O]ST000818AN0012974.040E-41.120E-3Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Unknown_742.54(-)@5.61ST000818AN0012984.840E-88.070E-8Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
Unknown_742.54(-)@5.61ST000818AN0012982.650E-54.310E-5Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Unknown_742.54(-)@5.61ST000818AN0012984.970E-26.530E-2Country;Ethiopia;Tanzania;Botswana
Unknown_742.54(-)@6.25ST000818AN0012982.110E-104.500E-10Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
Unknown_742.54(-)@6.25ST000818AN0012981.050E-85.050E-8Country;Ethiopia;Tanzania;Botswana
Unknown_742.54(-)@6.25ST000818AN0012989.880E-82.210E-7Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Unknown_742.54(-)@6.25ST000818AN0012981.810E-32.940E-3Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
PROCOLLAGEN 5-HYDROXY-L-LYSINE (M+H)+ST000823AN0013077.090E-34.330E-1Dysplasia;LGD;N/A
PROCOLLAGEN 5-HYDROXY-L-LYSINE (M+H)+ST000823AN0013073.450E-27.330E-1Diagnosis;IPMN;MCN;SCA
ZEATIN [ISTD] (M+H)+ST000823AN0013072.670E-24.330E-1Dysplasia;LGD;N/A
SALICYLATE #2 (M-H)-ST000841AN0013492.830E-33.280E-2Subject group;HIGH-FA;LOW-FA;MID-FA;N/A
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000842AN0013569.570E-183.990E-17Sample type;Muscles;Plasma;Pooled sample
MANDELIC ACID #2 (M-H)-ST000842AN0013565.800E-109.350E-10Sample type;Muscles;Plasma;Pooled sample
SALICYLATE #2 (M-H)-ST000842AN0013568.540E-51.080E-4Sample type;Muscles;Plasma;Pooled sample
ZEATIN [ISTD] (M+Cl)-ST000842AN0013564.840E-233.230E-22Sample type;Muscles;Plasma;Pooled sample
ZEATIN [ISTD] (M+H)+ST000842AN0013573.400E-533.940E-51Sample type;Muscles;Plasma;Pooled sample
AC1MIY4GST000842AN0013605.020E-85.220E-8Sample type;Muscles;Plasma;Pooled sample
AC1MIY4GST000842AN0013611.870E-295.350E-29Sample type;Muscles;Plasma;Pooled sample
glycine-d5 deuteratedST000865AN0013902.310E-356.470E-34Patient group;CIRR;HCC;Pool CIRR;Pool HCC;POSSIBLE CASE;-
glycine-d5 deuteratedST000865AN0013903.090E-354.540E-34RACE;AA;Asian;EA;Hisp;Other;-
L-pyroglutamic acid/ glutamic acidST000865AN0013904.180E-261.800E-25Patient group;CIRR;HCC;Pool CIRR;Pool HCC;POSSIBLE CASE;-
L-pyroglutamic acid/ glutamic acidST000865AN0013907.370E-252.750E-24RACE;AA;Asian;EA;Hisp;Other;-
3-OH-DL-KYNURENINEST000876AN0014134.390E-23.200E-1L-serine (mg/kg/day);100;200;300;400;50;-
Aminodipic AcidST000876AN0014138.870E-31.000E-1L-serine (mg/kg/day);100;200;300;400;50;-
arachidiic acidST000417AN0014482.230E-35.260E-3Group;AIR;NO2PM;PM
creatine major dehydrated TMS3ST000417AN0014482.680E-51.950E-4Group;AIR;NO2PM;PM
phthalate esterST000417AN0014488.910E-69.890E-5Group;AIR;NO2PM;PM
succinic acid2ST000417AN0014483.390E-52.020E-4Group;AIR;NO2PM;PM
z dioctylphtalateST000417AN0014481.470E-22.680E-2Group;AIR;NO2PM;PM
z dioctylphtalateST000417AN0014482.800E-26.220E-1Collection Time;24HRPOST;Post;Pre
2-oxindole-3-acetateST000899AN0014621.320E-24.930E-2Type;Control;Crohn disease;Ulcerative Colitis
gamma-glutamyl-2-aminobutyrateST000899AN0014621.960E-53.930E-4Type;Control;Crohn disease;Ulcerative Colitis
N6-carboxymethyllysineST000899AN0014627.020E-44.880E-3Type;Control;Crohn disease;Ulcerative Colitis
thioprolineST000899AN0014625.610E-32.570E-2Type;Control;Crohn disease;Ulcerative Colitis
docosahexaenoylcholineST000899AN0014632.130E-36.650E-3Type;Control;Crohn disease;Ulcerative Colitis
2-hydroxyoctanoateST000899AN0014643.400E-26.860E-2Type;Control;Crohn disease;Ulcerative Colitis
2-methylcitrate/homocitrateST000899AN0014643.670E-27.320E-2Type;Control;Crohn disease;Ulcerative Colitis
3-methoxycatechol sulfate (2)ST000899AN0014641.040E-22.550E-2Type;Control;Crohn disease;Ulcerative Colitis
3-methyl catechol sulfate (1)ST000899AN0014641.130E-33.830E-3Type;Control;Crohn disease;Ulcerative Colitis
4-ethylphenylsulfateST000899AN0014642.330E-24.890E-2Type;Control;Crohn disease;Ulcerative Colitis
4-hydroxychlorothalonilST000899AN0014642.970E-51.920E-4Type;Control;Crohn disease;Ulcerative Colitis
4-methylcatechol sulfateST000899AN0014641.190E-59.760E-5Type;Control;Crohn disease;Ulcerative Colitis
acisogaST000899AN0014643.410E-52.170E-4Type;Control;Crohn disease;Ulcerative Colitis
C-glycosyltryptophanST000899AN0014641.220E-91.890E-7Type;Control;Crohn disease;Ulcerative Colitis
gamma-CEHC glucuronideST000899AN0014643.230E-41.380E-3Type;Control;Crohn disease;Ulcerative Colitis
methyl-4-hydroxybenzoate sulfateST000899AN0014641.730E-23.780E-2Type;Control;Crohn disease;Ulcerative Colitis
N-acetylisoleucineST000899AN0014642.050E-24.340E-2Type;Control;Crohn disease;Ulcerative Colitis
o-cresol sulfateST000899AN0014641.610E-23.580E-2Type;Control;Crohn disease;Ulcerative Colitis
O-methylcatechol sulfateST000899AN0014641.740E-35.470E-3Type;Control;Crohn disease;Ulcerative Colitis
propyl 4-hydroxybenzoate sulfateST000899AN0014641.910E-24.070E-2Type;Control;Crohn disease;Ulcerative Colitis
sulfateST000899AN0014641.940E-51.370E-4Type;Control;Crohn disease;Ulcerative Colitis
2-hydroxybutyrate/2-hydroxyisobutyrateST000899AN0014653.890E-54.480E-4Type;Control;Crohn disease;Ulcerative Colitis
1-monoheptadecanoyl glyceride NISTST000910AN0014803.330E-22.390E-1Diagnosis;MECFS;MS;ND
isobutene glycol NISTST000910AN0014801.540E-21.610E-1Diagnosis;MECFS;MS;ND
AcetominophenST000913AN0014831.360E-23.310E-1Diagnosis;MECFS;MS;ND
AcetominophenST000913AN0014832.550E-24.280E-1Sex;FEMALE;MALE
ChlordiazepoxideST000913AN0014833.440E-24.400E-1Sex;FEMALE;MALE
CocamidopropylBetaineST000913AN0014832.650E-23.990E-1Diagnosis;MECFS;MS;ND
CrotetamideST000913AN0014835.870E-96.810E-7Diagnosis;MECFS;MS;ND
L-beta-HomoleucineST000913AN0014834.910E-24.480E-1Diagnosis;MECFS;MS;ND
20cooh AAST000916AN0014915.140E-123.960E-10Diagnosis;Cirrhosis;NASH;Normal;Steatosis
5-HETrEST000916AN0014919.860E-56.320E-4Diagnosis;Cirrhosis;NASH;Normal;Steatosis
8-HETrEST000916AN0014911.500E-24.110E-2Diagnosis;Cirrhosis;NASH;Normal;Steatosis
tetranor 12-HETEST000916AN0014918.660E-103.330E-8Diagnosis;Cirrhosis;NASH;Normal;Steatosis
14-demethyl-14-dehydrolanosterolST000916AN0014924.350E-53.690E-4Diagnosis;Cirrhosis;NASH;Normal;Steatosis
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATEST000919AN0015066.090E-34.240E-2Gender;Female;Male
L-Leucine-D10ST000919AN0015064.190E-45.590E-3Gender;Female;Male
L-VALINE/5-AMINOPENTANOATE/L-NORVALINEST000919AN0015069.240E-35.910E-2Gender;Female;Male
Source Fragment TRPST000919AN0015062.580E-32.420E-2Gender;Female;Male
BillirubinST000919AN0015073.150E-32.370E-2Response;NR;R
C6H12O6-HEXOSE/KETOSE/INOSITOLST000919AN0015073.200E-21.310E-1Response;NR;R
Caffeine-D3ST000919AN0015073.770E-44.200E-3Response;NR;R
Caffeine-D3ST000919AN0015078.000E-35.400E-2Gender;Female;Male
SARCOSINE/BETA-ALANINEST000919AN0015079.210E-65.430E-4Gender;Female;Male
2-deoxycytidineST000923AN0015132.430E-27.810E-2sex;Female;Male
2-deoxycytidineST000923AN0015134.660E-27.100E-2Diagnosis;CD;nonIBD;UC
4-hydroxy-3-methylacetophenoneST000923AN0015132.670E-41.470E-3Diagnosis;CD;nonIBD;UC
4-hydroxy-3-methylacetophenoneST000923AN0015132.930E-28.360E-2sex;Female;Male
ADMA/SDMAST000923AN0015139.040E-61.450E-4Diagnosis;CD;nonIBD;UC
aminoisobutyric acid/GABAST000923AN0015132.290E-41.310E-3Diagnosis;CD;nonIBD;UC
aminoisobutyric acid/GABAST000923AN0015133.010E-32.130E-2sex;Female;Male
diacetylspermineST000923AN0015136.100E-55.680E-4Diagnosis;CD;nonIBD;UC
NMMAST000923AN0015131.680E-23.420E-2Diagnosis;CD;nonIBD;UC
threosphingosineST000923AN0015138.280E-43.460E-3Diagnosis;CD;nonIBD;UC
trimethylbenzeneST000923AN0015134.950E-31.460E-2Diagnosis;CD;nonIBD;UC
urobilin - targetedST000923AN0015139.370E-198.800E-17Diagnosis;CD;nonIBD;UC
urobilin - targetedST000923AN0015131.270E-31.180E-2sex;Female;Male
1-3-7-trimethylurateST000923AN0015141.360E-34.870E-3Diagnosis;CD;nonIBD;UC
3-methyladipate/pimelateST000923AN0015147.130E-76.840E-6Diagnosis;CD;nonIBD;UC
azelateST000923AN0015146.440E-64.630E-5Diagnosis;CD;nonIBD;UC
tetrahydro-1-methyl-beta-carboline-3-carboxylateST000923AN0015145.430E-31.420E-2Diagnosis;CD;nonIBD;UC
valerate/isovalerateST000923AN0015149.270E-55.910E-4Diagnosis;CD;nonIBD;UC
10-nonadecenoateST000923AN0015156.500E-31.690E-2Diagnosis;CD;nonIBD;UC
1.2.3.4-tetrahydro-beta-carboline-1.3-dicarboxylateST000923AN0015155.430E-42.080E-3Diagnosis;CD;nonIBD;UC
1.2.3.4-tetrahydro-beta-carboline-1.3-dicarboxylateST000923AN0015154.560E-22.960E-1sex;Female;Male
acetytyrosineST000923AN0015153.560E-27.040E-2Diagnosis;CD;nonIBD;UC
azelateST000923AN0015151.000E-56.070E-5Diagnosis;CD;nonIBD;UC
carboxyibuprofenST000923AN0015152.940E-22.430E-1sex;Female;Male
hydroxymyristateST000923AN0015156.220E-31.660E-2Diagnosis;CD;nonIBD;UC
ketodeoxycholateST000923AN0015157.390E-53.830E-4Diagnosis;CD;nonIBD;UC
masilinateST000923AN0015157.150E-31.800E-2Diagnosis;CD;nonIBD;UC
undecanedionateST000923AN0015155.970E-42.170E-3Diagnosis;CD;nonIBD;UC
palmithoylethanolamideST000923AN0015163.680E-25.370E-2Diagnosis;CD;nonIBD;UC
13C-aminoadipicST000947AN0015553.560E-343.560E-34Time point;120;135;150;-15;165;180;-30;-45;-60;60;baseline
13C-aminoadipicST000947AN0015552.680E-78.040E-7Group;control;PCOS
13C-aminoadipicST000948AN0015573.030E-24.540E-2Time point;120;135;150;-15;165;180;-30;-45;-60;60;baseline
bOHbutyrate-13C00ST000951AN0015602.720E-29.040E-1cell_type;CD8_T_memory;CD8_T_naive;NK
6C-SUGAR ALCOHOLST000954AN0015642.490E-31.160E-1ethnicity;1;2;-
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATEST000954AN0015641.080E-21.560E-1race;1;2
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATEST000954AN0015644.450E-24.160E-1ethnicity;1;2;-
C5-SUGAR ALCOHOLST000954AN0015642.390E-44.610E-2ethnicity;1;2;-
Creatine-D3ST000954AN0015641.800E-27.810E-1diplotype;1;2
Lactose+KST000954AN0015643.380E-26.520E-1daily_dose;2;3;4;1
L-Leucine-D10ST000954AN0015644.560E-24.160E-1ethnicity;1;2;-
L-VALINE/5-AMINOPENTANOATE/L-NORVALINEST000954AN0015642.960E-23.180E-1ethnicity;1;2;-
N-ACETYL-HEXOSAMINEST000954AN0015642.640E-21.820E-1race;1;2
N-BOC-L-TryptophanST000954AN0015646.870E-31.320E-1race;1;2
Phenylalanine-HCOOHST000954AN0015644.390E-22.340E-1race;1;2
Source Fragment TRPST000954AN0015643.170E-31.020E-1race;1;2
4-oxoproline;5-OXO-L-PROLINEST000954AN0015651.260E-21.550E-1race;1;2
LACTATE-dimerST000954AN0015653.750E-22.880E-1race;1;2
L-GLUTAMIC ACID;N-METHYL-D-ASPARTIC ACID;O-ACETYL-L-SERINE;O-Acetyl-L-SerineST000954AN0015652.210E-24.710E-1ethnicity;1;2;-
Mannitol;HEXOSE ALCOHOLST000954AN0015655.860E-34.360E-1ethnicity;1;2;-
Monoethyl phthalate (mEP)ST000954AN0015653.160E-37.280E-2daily_dose;2;3;4;1
2-hydroxyglutarate+NaST000956AN0015685.930E-41.620E-3Treatment;Condition-1;Condition-2;Condition-3;Control
2-Hydroxyphenylalanine;L-TYROSINEST000956AN0015689.100E-31.710E-2Treatment;Condition-1;Condition-2;Condition-3;Control
4-AMINOBUTANOATE (GABA);2-AMINO-2-METHYLPROPANOATE;3-AMINOISOBUTANOATEST000956AN0015683.600E-105.560E-9Treatment;Condition-1;Condition-2;Condition-3;Control
ALANINE/SARCOSINEST000956AN0015681.550E-56.340E-5Treatment;Condition-1;Condition-2;Condition-3;Control
ALDO/KETO-HEXOSEST000956AN0015681.190E-22.210E-2Treatment;Condition-1;Condition-2;Condition-3;Control
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE;L-2-Aminoadipic AcidST000956AN0015686.230E-73.090E-6Treatment;Condition-1;Condition-2;Condition-3;Control
Caffeine-D3ST000956AN0015687.430E-31.440E-2Treatment;Condition-1;Condition-2;Condition-3;Control
Citrate+Na;CITRATEST000956AN0015681.270E-33.160E-3Treatment;Condition-1;Condition-2;Condition-3;Control
Citrate+NH3ST000956AN0015681.870E-34.180E-3Treatment;Condition-1;Condition-2;Condition-3;Control
Citrate source fragment (+H and + NH3)ST000956AN0015681.050E-32.700E-3Treatment;Condition-1;Condition-2;Condition-3;Control
D-Ribose;ALDOPENTOSEST000956AN0015685.250E-41.460E-3Treatment;Condition-1;Condition-2;Condition-3;Control
GLUCOSE/FRUCTOSE-PHOSPHATEST000956AN0015681.260E-44.070E-4Treatment;Condition-1;Condition-2;Condition-3;Control
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE;BETAINEST000956AN0015681.330E-89.260E-8Treatment;Condition-1;Condition-2;Condition-3;Control
N-ACETYL-HEXOSAMINEST000956AN0015685.580E-51.990E-4Treatment;Condition-1;Condition-2;Condition-3;Control
N-ACETYL-L-ALANINE;3-AMINO-5-HYDROXYBENZOIC ACIDST000956AN0015688.720E-109.320E-9Treatment;Condition-1;Condition-2;Condition-3;Control
URACIL;UracilST000956AN0015681.700E-68.170E-6Treatment;Condition-1;Condition-2;Condition-3;Control
2-AMINOETHYL DIHYDROGEN PHOSPHATE;ETHANOLAMINE PHOSPHATEST000956AN0015691.660E-34.880E-3Treatment;Condition-1;Condition-2;Condition-3;Control
C5-SUGAR ALCOHOLST000956AN0015694.470E-31.120E-2Treatment;Condition-1;Condition-2;Condition-3;Control
DISACCHARIDE (6C/6C)/2-alpha-D-glucosyl-D-glucoseST000956AN0015691.320E-34.000E-3Treatment;Condition-1;Condition-2;Condition-3;Control
GLYCEROL 2-PHOSPHATE/SN-GLYCEROL 3-PHOSPHATEST000956AN0015695.770E-42.210E-3Treatment;Condition-1;Condition-2;Condition-3;Control
LACTATE-dimerST000956AN0015694.590E-27.280E-2Treatment;Condition-1;Condition-2;Condition-3;Control
L-GLUTAMIC ACID;N-METHYL-D-ASPARTIC ACID;O-ACETYL-L-SERINE;O-Acetyl-L-SerineST000956AN0015691.170E-22.330E-2Treatment;Condition-1;Condition-2;Condition-3;Control
MALATE;OXALOACETATE+2H-HST000956AN0015697.480E-53.740E-4Treatment;Condition-1;Condition-2;Condition-3;Control
Mannitol;HEXOSE ALCOHOLST000956AN0015691.110E-22.310E-2Treatment;Condition-1;Condition-2;Condition-3;Control
N-ACETYL-HEXOSAMINEST000956AN0015693.130E-25.580E-2Treatment;Condition-1;Condition-2;Condition-3;Control
N-METHYL-L-GLUTAMATE;ALPHA-AMINOADIPATE;L-2-Aminoadipic AcidST000956AN0015691.210E-45.480E-4Treatment;Condition-1;Condition-2;Condition-3;Control
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATEST000957AN0015702.940E-21.960E-1Milk fraction;fat;skim;whole
HEXANESULFONIC ACID-SulfateST000957AN0015711.270E-21.380E-1Milk fraction;fat;skim;whole
1-(14 or 15-methyl)palmitoyl-GPC (a17:0 or i17:0)*ST000974AN0015951.840E-21.840E-1GROUP;case;control
16a-hydroxy DHEA 3-sulfateST000974AN0015954.900E-22.140E-1GENDER;F;M
1-arachidonoylglyercophosphateST000974AN0015951.190E-101.280E-9REGION;AHRI;MRC;SUN
1-dihomo-linoleoylglycerophosphocholine (20:2n6)*ST000974AN0015954.400E-21.980E-1GENDER;F;M
21-hydroxypregnenolone monosulfate (1)ST000974AN0015952.670E-31.080E-2REGION;AHRI;MRC;SUN
2-ethylphenylsulfateST000974AN0015955.410E-34.500E-2GENDER;F;M
2-hydroxyoctanoateST000974AN0015951.910E-21.180E-1GENDER;F;M
2-hydroxyoctanoateST000974AN0015952.400E-27.490E-2REGION;AHRI;MRC;SUN
3-(4-hydroxyphenyl)propionateST000974AN0015954.120E-351.440E-33REGION;AHRI;MRC;SUN
3-ethylphenylsulfateST000974AN0015954.770E-22.100E-1GENDER;F;M
3-methoxytyramine sulfateST000974AN0015953.490E-289.040E-27REGION;AHRI;MRC;SUN
3-methyl catechol sulfate (1)ST000974AN0015952.590E-32.740E-2TIMEPOINT;BL;M06;M18
3-methyl catechol sulfate (2)ST000974AN0015952.990E-41.550E-3REGION;AHRI;MRC;SUN
3-S-cysteinyl-2-methylpropanoate*ST000974AN0015957.790E-43.600E-3REGION;AHRI;MRC;SUN
3-S-cysteinyl-2-methylpropanoate*ST000974AN0015951.770E-32.240E-2TIMEPOINT;BL;M06;M18
4-ethylphenylsulfateST000974AN0015954.380E-47.460E-3TIMEPOINT;BL;M06;M18
5-hydroxymethyl-2-furoylcarnitine*ST000974AN0015953.900E-207.380E-19REGION;AHRI;MRC;SUN
5-hydroxymethyl-2-furoylcarnitine*ST000974AN0015958.990E-36.750E-2GENDER;F;M
6-oxopiperidine-2-carboxylic acidST000974AN0015951.890E-32.280E-2TIMEPOINT;BL;M06;M18
ADSGEGDFXAEGGGVR*ST000974AN0015951.720E-37.270E-3REGION;AHRI;MRC;SUN
asparagylisoleucineST000974AN0015958.020E-41.170E-2TIMEPOINT;BL;M06;M18
asparagylisoleucineST000974AN0015959.860E-31.250E-1GROUP;case;control
C-glycosyltryptophan*ST000974AN0015956.170E-39.670E-2GROUP;case;control
cis-Cyclo[L-ala-L-Pro]ST000974AN0015953.890E-753.020E-73REGION;AHRI;MRC;SUN
cis-Cyclo[L-ala-L-Pro]ST000974AN0015956.830E-34.490E-2TIMEPOINT;BL;M06;M18
cyclo(leu-pro)ST000974AN0015953.560E-36.900E-2GROUP;case;control
cyclo(leu-pro)ST000974AN0015956.000E-34.240E-2TIMEPOINT;BL;M06;M18
cyclo(leu-pro)ST000974AN0015952.700E-21.470E-1GENDER;F;M
cyclo(L-phe-L-pro)ST000974AN0015956.490E-39.670E-2GROUP;case;control
cyclo(L-phe-L-pro)ST000974AN0015956.810E-35.410E-2GENDER;F;M
cyclo(L-phe-L-pro)ST000974AN0015958.970E-35.360E-2TIMEPOINT;BL;M06;M18
cyclo(L-phe-L-pro)ST000974AN0015952.640E-28.080E-2REGION;AHRI;MRC;SUN
DSGEGDFXAEGGGVR*ST000974AN0015951.620E-25.340E-2REGION;AHRI;MRC;SUN
Fibrinopeptide B (1-13)**ST000974AN0015953.670E-21.060E-1REGION;AHRI;MRC;SUN
Fibrinopeptide B (1-9)**ST000974AN0015956.390E-95.880E-8REGION;AHRI;MRC;SUN
gamma-CEHC glucuronide*ST000974AN0015952.690E-51.720E-4REGION;AHRI;MRC;SUN
glucuronide of piperine metabolite C17H21NO3 (3)*ST000974AN0015951.610E-91.630E-8REGION;AHRI;MRC;SUN
glucuronide of piperine metabolite C17H21NO3 (3)*ST000974AN0015951.010E-33.270E-2GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (4)*ST000974AN0015951.530E-91.570E-8REGION;AHRI;MRC;SUN
glucuronide of piperine metabolite C17H21NO3 (4)*ST000974AN0015956.040E-42.820E-2GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (5)*ST000974AN0015951.670E-81.430E-7REGION;AHRI;MRC;SUN
glucuronide of piperine metabolite C17H21NO3 (5)*ST000974AN0015954.970E-42.480E-2GROUP;case;control
hexanoylglutamineST000974AN0015953.820E-21.830E-1GENDER;F;M
HWESASXX*ST000974AN0015958.140E-43.160E-2GROUP;case;control
HWESASXX*ST000974AN0015951.140E-35.050E-3REGION;AHRI;MRC;SUN
inositol 1-phosphate (I1P)ST000974AN0015953.390E-36.770E-2GROUP;case;control
methylnaphthyl sulfate (2)*ST000974AN0015953.680E-21.060E-1REGION;AHRI;MRC;SUN
methylsuccinoylcarnitine (1)ST000974AN0015952.270E-531.130E-51REGION;AHRI;MRC;SUN
N-acetyl-2-aminoctanoateST000974AN0015951.990E-21.180E-1GENDER;F;M
N-acetyl-2-aminoctanoateST000974AN0015953.110E-29.200E-2REGION;AHRI;MRC;SUN
N-acetylisoleucineST000974AN0015951.340E-27.360E-2TIMEPOINT;BL;M06;M18
N-acetyl-isoputrenine*ST000974AN0015951.960E-44.560E-3TIMEPOINT;BL;M06;M18
N-acetyl-isoputrenine*ST000974AN0015951.420E-29.430E-2GENDER;F;M
N-acetyltheanineST000974AN0015955.370E-31.980E-2REGION;AHRI;MRC;SUN
o-cresol sulfateST000974AN0015952.200E-32.480E-2TIMEPOINT;BL;M06;M18
O-methylcatechol sulfateST000974AN0015952.970E-33.090E-2TIMEPOINT;BL;M06;M18
phenol redST000974AN0015952.570E-27.900E-2REGION;AHRI;MRC;SUN
pyroglutamylglycineST000974AN0015955.620E-42.640E-3REGION;AHRI;MRC;SUN
pyroglutamylisoleucineST000974AN0015951.570E-25.210E-2REGION;AHRI;MRC;SUN
pyroglutamylphenylalanine*ST000974AN0015952.040E-41.120E-3REGION;AHRI;MRC;SUN
sulfate*ST000974AN0015959.000E-61.910E-4GENDER;F;M
sulfate of piperine metabolite C16H19NO3 (2)*ST000974AN0015952.720E-82.260E-7REGION;AHRI;MRC;SUN
sulfate of piperine metabolite C16H19NO3 (2)*ST000974AN0015958.070E-43.160E-2GROUP;case;control
sulfate of piperine metabolite C16H19NO3 (3)*ST000974AN0015951.190E-101.280E-9REGION;AHRI;MRC;SUN
sulfate of piperine metabolite C16H19NO3 (3)*ST000974AN0015952.710E-41.890E-2GROUP;case;control
thioprolineST000974AN0015958.090E-31.110E-1GROUP;case;control
valine ionST000974AN0015955.140E-34.240E-2TIMEPOINT;BL;M06;M18
XHWESASXXR*ST000974AN0015952.950E-41.540E-3REGION;AHRI;MRC;SUN
XHWESASXXR*ST000974AN0015952.190E-34.850E-2GROUP;case;control
XHWESASXXR*ST000974AN0015955.480E-34.240E-2TIMEPOINT;BL;M06;M18
1-dihomo-linoleoylglycerophosphocholine (20:2n6)*ST000975AN0015969.970E-59.560E-4GENDER;F;M
1-docosapentaenoylglycerophosphocholine (22:5n3)*ST000975AN0015961.600E-62.650E-5GENDER;F;M
1-docosapentaenoylglycerophosphocholine (22:5n6)*ST000975AN0015961.060E-24.470E-2GENDER;F;M
2-ethylphenylsulfateST000975AN0015962.360E-48.250E-3REGION;MAK;SUN
2-ethylphenylsulfateST000975AN0015968.000E-45.090E-3GENDER;F;M
3-CMPFP**ST000975AN0015961.910E-21.340E-1GROUP;case;control
3-CMPFP**ST000975AN0015962.750E-22.930E-1REGION;MAK;SUN
3-ethylphenylsulfateST000975AN0015965.510E-55.860E-4GENDER;F;M
3-hydroxybutyroylglycine**ST000975AN0015968.260E-42.560E-2GROUP;case;control
3-methoxytyramine sulfateST000975AN0015969.000E-55.210E-3REGION;MAK;SUN
3-methoxytyramine sulfateST000975AN0015962.370E-21.540E-1GROUP;case;control
3-methyl catechol sulfate (1)ST000975AN0015961.500E-38.580E-3GENDER;F;M
3-methyl catechol sulfate (1)ST000975AN0015964.800E-23.890E-1REGION;MAK;SUN
3-methyl catechol sulfate (2)ST000975AN0015965.330E-41.580E-2REGION;MAK;SUN
3-S-cysteinyl-2-methylpropanoate*ST000975AN0015962.430E-31.020E-1TIMEPOINT;BL;M06;M18
3-S-cysteinyl-2-methylpropanoate*ST000975AN0015963.230E-21.870E-1GROUP;case;control
4-allylphenol sulfateST000975AN0015969.110E-45.690E-3GENDER;F;M
4-methylhexanoylglutamineST000975AN0015963.080E-23.160E-1REGION;MAK;SUN
6-bromotryptophanST000975AN0015961.590E-21.210E-1GROUP;case;control
6-oxopiperidine-2-carboxylic acidST000975AN0015963.330E-23.990E-1TIMEPOINT;BL;M06;M18
6-oxopiperidine-2-carboxylic acidST000975AN0015963.800E-23.590E-1REGION;MAK;SUN
acisogaST000975AN0015961.420E-48.210E-3GROUP;case;control
acisogaST000975AN0015961.600E-26.040E-2GENDER;F;M
C-glycosyltryptophan*ST000975AN0015961.290E-25.210E-2GENDER;F;M
cis-Cyclo[L-ala-L-Pro]ST000975AN0015963.230E-42.410E-3GENDER;F;M
cis-Cyclo[L-ala-L-Pro]ST000975AN0015961.800E-22.150E-1REGION;MAK;SUN
cyclo(pro-arg)*ST000975AN0015961.400E-21.770E-1REGION;MAK;SUN
Fibrinopeptide A (3-15)**ST000975AN0015962.810E-23.780E-1TIMEPOINT;BL;M06;M18
Fibrinopeptide A (4-15)**ST000975AN0015966.060E-37.640E-2GROUP;case;control
Fibrinopeptide B (1-11)**ST000975AN0015963.190E-31.610E-2GENDER;F;M
Fibrinopeptide B (1-12)**ST000975AN0015961.710E-22.840E-1TIMEPOINT;BL;M06;M18
Fibrinopeptide B (1-9)**ST000975AN0015961.410E-33.550E-2GROUP;case;control
Fibrinopeptide B (1-9)**ST000975AN0015968.510E-32.080E-1TIMEPOINT;BL;M06;M18
gamma-glutamyllysineST000975AN0015966.800E-33.090E-2GENDER;F;M
glucuronide of piperine metabolite C17H21NO3 (3)*ST000975AN0015963.190E-36.400E-2REGION;MAK;SUN
glucuronide of piperine metabolite C17H21NO3 (3)*ST000975AN0015966.450E-32.970E-2GENDER;F;M
glucuronide of piperine metabolite C17H21NO3 (3)*ST000975AN0015962.530E-21.600E-1GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (4)*ST000975AN0015961.490E-46.320E-3REGION;MAK;SUN
glucuronide of piperine metabolite C17H21NO3 (4)*ST000975AN0015961.990E-21.350E-1GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (4)*ST000975AN0015962.350E-28.290E-2GENDER;F;M
glucuronide of piperine metabolite C17H21NO3 (5)*ST000975AN0015962.330E-48.250E-3REGION;MAK;SUN
glucuronide of piperine metabolite C17H21NO3 (5)*ST000975AN0015969.700E-38.800E-2GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (5)*ST000975AN0015962.170E-27.920E-2GENDER;F;M
hexanoylglutamineST000975AN0015962.570E-34.570E-2GROUP;case;control
hydroxy-CMPFST000975AN0015967.060E-37.640E-2GROUP;case;control
hydroxy-CMPFST000975AN0015967.240E-31.270E-1REGION;MAK;SUN
hydroxy-CMPF*ST000975AN0015965.210E-39.850E-2REGION;MAK;SUN
hydroxy-CMPF*ST000975AN0015961.210E-29.890E-2GROUP;case;control
methylnaphthyl sulfate (2)*ST000975AN0015961.020E-51.730E-3REGION;MAK;SUN
methylnaphthyl sulfate (2)*ST000975AN0015961.670E-41.390E-3GENDER;F;M
methylsuccinoylcarnitine (1)ST000975AN0015961.820E-33.750E-2GROUP;case;control
N-acetyl-2-aminoctanoateST000975AN0015961.030E-49.590E-4GENDER;F;M
N-acetylalliinST000975AN0015963.290E-23.250E-1REGION;MAK;SUN
N-acetyl-isoputrenine*ST000975AN0015961.040E-51.770E-3GROUP;case;control
N-acetyltheanineST000975AN0015961.740E-26.460E-2GENDER;F;M
o-cresol sulfateST000975AN0015962.700E-42.040E-3GENDER;F;M
O-methylcatechol sulfateST000975AN0015962.800E-23.780E-1TIMEPOINT;BL;M06;M18
pyroglutamylglycineST000975AN0015964.210E-43.140E-2TIMEPOINT;BL;M06;M18
pyroglutamylglycineST000975AN0015963.150E-34.850E-2GROUP;case;control
pyroglutamylisoleucineST000975AN0015967.810E-56.650E-3GROUP;case;control
pyroglutamylphenylalanine*ST000975AN0015962.330E-21.540E-1GROUP;case;control
S-(3-hydroxypropyl)mercapturic acid (HPMA)ST000975AN0015962.290E-53.120E-3GROUP;case;control
S-(3-hydroxypropyl)mercapturic acid (HPMA)ST000975AN0015961.500E-41.300E-3GENDER;F;M
sulfate*ST000975AN0015961.260E-37.480E-3GENDER;F;M
sulfate of piperine metabolite C16H19NO3 (2)*ST000975AN0015967.780E-55.210E-3REGION;MAK;SUN
sulfate of piperine metabolite C16H19NO3 (3)*ST000975AN0015963.820E-41.240E-2REGION;MAK;SUN
thioprolineST000975AN0015966.910E-37.640E-2GROUP;case;control
valine ionST000975AN0015961.670E-33.640E-2GROUP;case;control
16a-hydroxy DHEA 3-sulfateST000976AN0015974.340E-25.670E-1GROUP;case;control
1-docosapentaenoylglycerophosphocholine (22:5n6)*ST000976AN0015975.960E-32.130E-1GENDER;F;M
2-hydroxydecanoateST000976AN0015971.470E-23.710E-1GROUP;case;control
3-CMPFP**ST000976AN0015971.350E-23.710E-1GROUP;case;control
3-hydroxybutyroylglycine**ST000976AN0015973.130E-32.090E-1GROUP;case;control
3-methyl catechol sulfate (1)ST000976AN0015978.690E-42.400E-1TIMEPOINT;BL;M06
6-bromotryptophanST000976AN0015974.050E-23.080E-1GENDER;F;M
gamma-glutamyllysineST000976AN0015972.510E-22.830E-1GENDER;F;M
hydroxy-CMPFST000976AN0015972.800E-22.830E-1GENDER;F;M
hydroxy-CMPF*ST000976AN0015971.760E-22.450E-1GENDER;F;M
N-acetylisoleucineST000976AN0015971.110E-22.940E-1TIMEPOINT;BL;M06
1-AG and 2-AGST000977AN0015992.400E-24.200E-2Group;Healthy Control;NAFLD
1-LG and 2-LGST000977AN0015997.190E-31.440E-2Group;Healthy Control;NAFLD
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMSST000978AN0016028.130E-191.400E-16Cox_RRT;.;N;Y
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMSST000978AN0016022.900E-182.120E-16Competitive_RRTvsDeath;.;N;RRT;DEATH
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMSST000978AN0016022.240E-65.470E-5Cox_Composite_DeathRRT;.;N;Y
2-Isopropyl-5-methyl-1-heptanolST000978AN0016022.580E-21.140E-1Cox_RRT;.;N;Y
Methyl CaprateST000978AN0016028.120E-35.410E-2Competitive_RRTvsDeath;.;N;RRT;DEATH
Methyl CaprateST000978AN0016028.750E-35.170E-2Cox_RRT;.;N;Y
Methyl CaprateST000978AN0016022.930E-21.820E-1Cox_Composite_DeathRRT;.;N;Y
Methyl DocosanoateST000978AN0016022.600E-21.140E-1Cox_RRT;.;N;Y
Methyl DocosanoateST000978AN0016024.640E-21.700E-1Competitive_RRTvsDeath;.;N;RRT;DEATH
Methyl LinocerateST000978AN0016023.630E-21.330E-1Cox_RRT;.;N;Y
N-(6-Quinolinyl)phthalimideST000978AN0016024.770E-21.540E-1Cox_RRT;.;N;Y
Pseudo uridine penta-tmsST000978AN0016021.140E-181.110E-16Competitive_RRTvsDeath;.;N;RRT;DEATH
Pseudo uridine penta-tmsST000978AN0016021.340E-179.810E-16Cox_RRT;.;N;Y
Pseudo uridine penta-tmsST000978AN0016029.440E-109.220E-8Cox_Composite_DeathRRT;.;N;Y
tert-Butyl(2-(tert-butyl)-4-methoxyphenoxy)dimethylsilaneST000978AN0016027.170E-34.470E-2Cox_RRT;.;N;Y
tert-Butyl(2-(tert-butyl)-4-methoxyphenoxy)dimethylsilaneST000978AN0016021.970E-21.010E-1Competitive_RRTvsDeath;.;N;RRT;DEATH
Trimethylsilyl 3-((trimethylsilyl)thio)propanoateST000978AN0016023.630E-21.330E-1Cox_RRT;.;N;Y
D-AlloseST000980AN0016062.470E-25.820E-2Classification;Mild;Moderate;Non-allergic;Severe
D-Mannose /D-AlloseST000980AN0016061.600E-33.060E-2Classification;Mild;Moderate;Non-allergic;Severe
L-Sorbose/FructoseST000980AN0016061.860E-33.060E-2Classification;Mild;Moderate;Non-allergic;Severe
Trihydroxybutyric acidST000980AN0016065.570E-34.270E-2Classification;Mild;Moderate;Non-allergic;Severe
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000992AN0016182.150E-26.470E-1Smoker;No;Yes
CerP(t39:1)[M+H]+ST000992AN0016214.140E-23.460E-1Metabolic syndrome;No;Yes
1-(2-(3-CYCLOHEXENYL)ETHYL)SILATRANEST001037AN0016981.400E-37.830E-3Description ;Blank;Reagent Blank;Serum Sample;Solvent
3-Ethyl-3-methylheptaneST001037AN0016983.560E-31.500E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
4-Aminomethylcyclohexane carboxylic acidST001037AN0016982.420E-41.780E-3Description ;Blank;Reagent Blank;Serum Sample;Solvent
4-METHYL-1-PENTENEST001037AN0016988.270E-32.930E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
4-tert-OctylphenolST001037AN0016986.700E-57.880E-4Description ;Blank;Reagent Blank;Serum Sample;Solvent
5-NonanolST001037AN0016981.720E-25.230E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
BergamottinST001037AN0016983.460E-29.520E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
CIS-4-NONENEST001037AN0016982.340E-26.810E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
D-Arabino-Hexonic acidST001037AN0016982.800E-71.640E-5Description ;Blank;Reagent Blank;Serum Sample;Solvent
Kinetin-9-ribosideST001037AN0016988.900E-33.010E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
Man6GlcNAc-VIST001037AN0016987.210E-61.770E-4Description ;Blank;Reagent Blank;Serum Sample;Solvent
Ne-AcetyllysineST001037AN0016983.850E-21.040E-1Description ;Blank;Reagent Blank;Serum Sample;Solvent
Phosphonic acidST001037AN0016985.960E-57.300E-4Description ;Blank;Reagent Blank;Serum Sample;Solvent
TrifloxystrobinST001037AN0016983.430E-61.010E-4Description ;Blank;Reagent Blank;Serum Sample;Solvent
TrinexapacST001037AN0016987.790E-32.800E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
SucccinateST001038AN0016991.250E-53.640E-5Timepoint;15 min;1 hr;24 hr;30 min;<5 min
SucccinateST001038AN0016995.900E-38.160E-3Placenta_Surface;Fetal;Maternal
Very low density lipoproteinST001038AN0016996.960E-72.200E-6Placenta_Surface;Fetal;Maternal
Very low density lipoproteinST001038AN0016991.480E-32.970E-3Timepoint;15 min;1 hr;24 hr;30 min;<5 min
3-(4-Hydroxyphenyl)Pyruvate / CaffeateST001040AN0017025.800E-42.630E-3Sample Type/Matrix;Pooled quality control sample;urine;Water...
4-Aminobenzoate / AnthranilateST001040AN0017028.390E-69.900E-5Sample Type/Matrix;Pooled quality control sample;urine;Water...
Adrenaline(Epinephrine)ST001040AN0017022.240E-75.670E-6Sample Type/Matrix;Pooled quality control sample;urine;Water...
Asymmetrical dimethylarginineST001040AN0017025.170E-81.830E-6Sample Type/Matrix;Pooled quality control sample;urine;Water...
Betaine / L-Valine/ NorvalineST001040AN0017022.750E-25.600E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
D/L Glucosamine / D/L GalactosamineST001040AN0017024.560E-28.310E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
D/L N-Acetylgalactosamine / D/L N-Acetylglucosamine / D/L N-AcetylmannosamineST001040AN0017027.970E-69.900E-5Sample Type/Matrix;Pooled quality control sample;urine;Water...
Galacturonate / GlucuronateST001040AN0017028.370E-43.610E-3Sample Type/Matrix;Pooled quality control sample;urine;Water...
Sucrose / Trehalose / LactoseST001040AN0017025.180E-31.480E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
3-MethyglutarateST001040AN0017034.200E-28.820E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
Anthranilate / 4-AminobenzoateST001040AN0017032.920E-41.400E-3Sample Type/Matrix;Pooled quality control sample;urine;Water...
Elaidate / Oleate /PetroselinateST001040AN0017036.700E-75.360E-6Sample Type/Matrix;Pooled quality control sample;urine;Water...
MBzPST001040AN0017034.790E-29.580E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
N-Acetylphenylalanine / Indole-3-EthanolST001040AN0017032.080E-38.340E-3Sample Type/Matrix;Pooled quality control sample;urine;Water...
GAB-13C0ST001045AN0017092.550E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
GAB-ALLST001045AN0017097.970E-37.720E-2protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
OHPro-13C0ST001045AN0017091.610E-21.050E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
OHPro-13C5ST001045AN0017091.080E-28.410E-2protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
OHPro-ALLST001045AN0017092.640E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
pyroGlu-13C3ST001045AN0017097.170E-37.720E-2protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
pyroGlu-ALLST001045AN0017092.330E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-13C0ST001045AN0017091.710E-33.910E-2protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-13C1ST001045AN0017092.270E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-13C2ST001045AN0017094.310E-21.510E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-13C4ST001045AN0017092.400E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
bOHbutyrate-13C1ST001046AN0017102.510E-24.100E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
GAB-13C3ST001046AN0017105.330E-31.530E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
OHPro-13C2ST001046AN0017101.700E-23.540E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
AcetyphenylalanineST001039AN0017129.670E-44.130E-3Sample.Matrix;Plasma;Urine
Alpha-acetyllysineST001039AN0017126.560E-43.900E-3Sample.Matrix;Plasma;Urine
DihydroxyacetophenoneST001039AN0017121.280E-22.220E-2Sample.Matrix;Plasma;Urine
MethoxytyramineST001039AN0017124.730E-31.150E-2Sample.Matrix;Plasma;Urine
34-Dihydroxymandelic acidST001039AN0017131.800E-22.680E-2Sample.Matrix;Plasma;Urine
Acetylneuraminic acidST001039AN0017131.180E-34.070E-3Sample.Matrix;Plasma;Urine
GulonolactoneST001039AN0017133.570E-37.750E-3Sample.Matrix;Plasma;Urine
4-Aminobenzoate / AnthranilateST001048AN0017162.360E-93.460E-9Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
4-Pyrodixic acid / XanthurenateST001048AN0017165.470E-171.170E-16Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Alanine / D-AlanineST001048AN0017161.750E-308.180E-30Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Aniline-2-SulfonateST001048AN0017161.130E-326.240E-32Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
D/L Glucosamine / D/L GalactosamineST001048AN0017169.910E-111.540E-10Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
D/L Glucosamine / D/L Galactosamine / D-MannosamineST001048AN0017161.190E-111.950E-11Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
D/L N-Acetylglucosamine / D/L N-Acetylgalactosamine / D/L N-AcetylmannosamineST001048AN0017165.780E-517.720E-50Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
L-Glutamic Acid / N-Methyl-D-aspartic acidST001048AN0017163.810E-1541.870E-152Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
L-Isoleucine / NorleucineST001048AN0017169.370E-202.400E-19Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
MevalolactoneST001048AN0017164.310E-566.330E-55Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Nicotine-1-N-oxideST001048AN0017163.070E-1672.260E-165Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Paraxanthine / Theobromine /TheophyllineST001048AN0017163.790E-178.430E-17Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
PhenylglycineST001048AN0017169.020E-1092.040E-107Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Sucrose / TrehaloseST001048AN0017162.700E-53.290E-5Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate) / 3OH-MBP (Mono-(3-hydroxy-n-butyl) phthalate)ST001048AN0017177.600E-51.110E-4Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
3-MethyglutarateST001048AN0017173.270E-54.880E-5Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
AzelateST001048AN0017178.970E-41.100E-3Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Elaidate / Oleate /PetroselinateST001048AN0017171.250E-236.660E-23Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
MCPP (Mono (3-carboxpropyl) phthalate)ST001048AN0017178.880E-163.770E-15Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
MECPP (Mono-2-ethyl-5-carboxypentyl phthalate)ST001048AN0017173.350E-44.180E-4Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
OH-MiNP (7-OH-(Mono-methyl-octyl) phthalate / Mono-(4-methyl-7-hydroxyloctyl) phthalate)ST001048AN0017173.460E-1182.940E-116Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Adenosine 35-diphosphateST001091AN0017773.740E-67.180E-6Sample.Matrix;Colon Mucosal Tissue;Plasma
16:1 (n-7)ST001098AN0017861.380E-23.360E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
18:3 (n-3)ST001098AN0017866.240E-32.650E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
20:2 (n-6)ST001098AN0017862.720E-24.210E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
20:3 (n-6)ST001098AN0017863.310E-32.650E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
22:1 (n-9)ST001098AN0017866.750E-41.150E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
Galactose-N-acetylgalactosamineST001104AN0017964.990E-337.630E-33Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
Galactose-N-acetylgalactosamine-SLST001104AN0017969.310E-342.330E-33Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
SLC1GST001104AN0017967.640E-317.640E-31Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
DG 37:2 (18:2/19:0/0:0) [M+NH4]+ST001111AN0018051.560E-21.990E-2Sample;Benign;Cancer;Metastasis
plasmenyl-PC 37:0 (20:0/17:0) [M+Na]+ST001111AN0018051.140E-83.470E-8Sample;Benign;Cancer;Metastasis
plasmenyl-PC 40:2 (18:0/22:2(13Z.16Z)) [M+Na]+ST001111AN0018058.150E-135.670E-12Sample;Benign;Cancer;Metastasis
plasmenyl-PC 42:1 (18:0/24:1(15Z)) [M+Na]+ST001111AN0018053.640E-34.990E-3Sample;Benign;Cancer;Metastasis
plasmenyl-PE 34:1 (16:0/18:1(11E)) [M+H]+ST001111AN0018052.650E-101.050E-9Sample;Benign;Cancer;Metastasis
plasmenyl-PE 36:2 (18:0/18:2(2E.4E)) [M+H]+ST001111AN0018054.340E-35.870E-3Sample;Benign;Cancer;Metastasis
plasmenyl-PE 38:4 (16:0/22:4(7Z.10Z.13Z.16Z)) [M+H]+ST001111AN0018051.570E-32.250E-3Sample;Benign;Cancer;Metastasis
CL 72:10 (18:2/18:3/18:2/18:3) [M-2H](2-)ST001111AN0018061.460E-43.520E-4Sample;Benign;Cancer;Metastasis
CL 72:10 (18:3/14:0/20:3/20:4) [M-2H](2-)ST001111AN0018061.580E-107.820E-10Sample;Benign;Cancer;Metastasis
CL 74:10 (16:0/22:5/16:1/20:4) [M-2H](2-)ST001111AN0018064.400E-165.840E-15Sample;Benign;Cancer;Metastasis
CL 74:10 (16:0/22:5/20:4/16:1) [M-2H](2-)ST001111AN0018061.320E-22.240E-2Sample;Benign;Cancer;Metastasis
CL 74:10 (16:1/22:5/20:4/16:0) [M-2H](2-)ST001111AN0018067.520E-191.360E-17Sample;Benign;Cancer;Metastasis
CL 74:9 (18:0/20:4/18:2/18:3) [M-2H](2-)ST001111AN0018061.440E-213.410E-20Sample;Benign;Cancer;Metastasis
CL 74:9 (18:2/20:3/18:3/18:1) [M-2H](2-)ST001111AN0018065.670E-167.230E-15Sample;Benign;Cancer;Metastasis
CL 74:9 (20:3/18:2/20:4/16:0) [M-2H](2-)ST001111AN0018062.150E-23.450E-2Sample;Benign;Cancer;Metastasis
CL 76:11 (16:0/18:1/22:6/20:4) [M-2H](2-)ST001111AN0018065.450E-179.050E-16Sample;Benign;Cancer;Metastasis
CL 76:11 (18:2/18:2/20:4/20:3) [M-2H](2-)ST001111AN0018065.070E-41.110E-3Sample;Benign;Cancer;Metastasis
CL 76:12 (18:3/20:3/20:4/18:2) [M-2H](2-)ST001111AN0018063.250E-47.440E-4Sample;Benign;Cancer;Metastasis
CL 76:9 (18:0/16:0/22:5/20:4) [M-2H](2-)ST001111AN0018062.150E-261.780E-24Sample;Benign;Cancer;Metastasis
CL 76:9 (18:0/20:4/18:1/20:4) [M-2H](2-)ST001111AN0018062.700E-278.950E-25Sample;Benign;Cancer;Metastasis
CL 78:12 (18:1/20:4/18:1/22:6) [M-2H](2-)ST001111AN0018064.880E-41.090E-3Sample;Benign;Cancer;Metastasis
CL 78:13 (18:1/20:4/18:2/22:6) [M-2H](2-)ST001111AN0018063.740E-132.820E-12Sample;Benign;Cancer;Metastasis
CL 80:14 (18:0/20:4/20:4/22:6) [M-2H](2-)ST001111AN0018062.740E-35.110E-3Sample;Benign;Cancer;Metastasis
CL 80:14 (18:0/22:6/18:2/22:6) [M-2H](2-)ST001111AN0018061.550E-22.600E-2Sample;Benign;Cancer;Metastasis
CL 82:11 (18:0/20:0/22:5/22:6) [M-2H](2-)ST001111AN0018065.690E-123.570E-11Sample;Benign;Cancer;Metastasis
CL 82:11 (18:0/20:0/22:6/22:5) [M-2H](2-)ST001111AN0018062.060E-131.670E-12Sample;Benign;Cancer;Metastasis
CL 82:11 (18:0/22:5/20:0/22:6) [M-2H](2-)ST001111AN0018062.120E-111.280E-10Sample;Benign;Cancer;Metastasis
CL 82:12 (20:1/18:0/22:5/22:6) [M-2H](2-)ST001111AN0018061.480E-85.660E-8Sample;Benign;Cancer;Metastasis
PC 24:2 (2:0/22:2(13Z.16Z)) [M+HCOO]-ST001111AN0018063.190E-111.860E-10Sample;Benign;Cancer;Metastasis
PC 28:2 (2:0/26:2(5E.9Z)) [M+HCOO]-ST001111AN0018063.500E-59.510E-5Sample;Benign;Cancer;Metastasis
PC 33:3 (15:1(9Z)/18:2(2E.4E)) [M-Ac-H]-ST001111AN0018068.940E-31.590E-2Sample;Benign;Cancer;Metastasis
PC 34:2 (17:2(9Z.12Z)/17:0) [M-Ac-H]-ST001111AN0018066.350E-156.200E-14Sample;Benign;Cancer;Metastasis
PC 36:2 (18:0/18:2(2E.4E)) [M+HCOO]-ST001111AN0018062.560E-34.860E-3Sample;Benign;Cancer;Metastasis
PC 36:4 (16:0/20:4(5E.8E.11E.14E)) [M+HCOO]-ST001111AN0018064.820E-41.080E-3Sample;Benign;Cancer;Metastasis
PC 40:3 (20:0/20:3(5Z.8Z.11Z)) [M-Ac-H]-ST001111AN0018068.690E-52.200E-4Sample;Benign;Cancer;Metastasis
PC 40:3 (20:1(11E)/20:2(11Z.14Z)) [M-Ac-H]-ST001111AN0018069.500E-52.390E-4Sample;Benign;Cancer;Metastasis
PC 40:4 (18:0/22:4(7Z.10Z.13Z.16Z)) [M-Ac-H]-ST001111AN0018061.430E-32.860E-3Sample;Benign;Cancer;Metastasis
PC 40:5 (20:2(5Z.8Z)/20:3(5Z.8Z.11Z)) [M+HCOO]-ST001111AN0018063.060E-47.060E-4Sample;Benign;Cancer;Metastasis
PC 40:8 (20:4(5E.8E.11E.14E)/20:4(5E.8E.11E.14E)) [M-Ac-H]-ST001111AN0018062.230E-34.250E-3Sample;Benign;Cancer;Metastasis
SB N-(15Z-tetracosenoyl)-sphing-4-enine (d18:1(4E)/24:1(15Z)) [M-H]-ST001111AN0018063.190E-81.150E-7Sample;Benign;Cancer;Metastasis
SB N-(9Z-octadecenoyl)-sphinganine (d18:0/18:1(9Z)) [M-H]-ST001111AN0018061.430E-32.860E-3Sample;Benign;Cancer;Metastasis
SB N-(docosanoyl)-sphing-4-enine (d18:1(4E)/22:0) [M-H]-ST001111AN0018061.120E-21.960E-2Sample;Benign;Cancer;Metastasis
SB N-(eicosanoyl)-sphing-4-enine (d18:1(4E)/20:0) [M-H]-ST001111AN0018062.230E-45.180E-4Sample;Benign;Cancer;Metastasis
SB N-(hexadecanoyl)-sphing-4-enine (d18:1(4E)/16:0) [M-H]-ST001111AN0018069.140E-104.100E-9Sample;Benign;Cancer;Metastasis
SB N-(octadecanoyl)-sphing-4-enine (d18:1(4E)/18:0) [M-H]-ST001111AN0018061.790E-33.500E-3Sample;Benign;Cancer;Metastasis
2-deoxytetronic acid NISTST001118AN0018171.340E-22.620E-2Treatment Group;Control;Wilson Disease
N-acetylglycine NISTST001131AN0018564.320E-21.810E-1Treatment;Healthy;Trauma
beta-hydroxymyristic acidST001133AN0018584.210E-32.540E-2CENPF;Control;KO
aOHglutarate-13C0ST001049AN0018642.580E-21.160E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
aOHglutarate-13C1ST001049AN0018643.790E-21.430E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
aOHglutarate-13C4ST001049AN0018643.170E-21.310E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
bOHbutyrate-13C0ST001049AN0018643.500E-21.340E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
c-aconitate-13C0ST001049AN0018642.370E-33.440E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
c-aconitate-13C1ST001049AN0018645.670E-35.620E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
c-aconitate-13C5ST001049AN0018641.700E-32.980E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C0ST001049AN0018642.190E-21.070E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C1ST001049AN0018643.090E-34.110E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C2ST001049AN0018641.050E-45.840E-3protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C3ST001049AN0018641.710E-32.980E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C4ST001049AN0018645.390E-35.570E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C5ST001049AN0018641.010E-28.270E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
PO4-ALLST001049AN0018643.270E-21.310E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
pyroGlu-13C0ST001049AN0018642.510E-21.160E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
pyroGlu-13C1ST001049AN0018644.350E-21.570E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
pyroGlu-13C4ST001049AN0018641.430E-29.730E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
pyroGlu-13C5ST001049AN0018641.670E-21.000E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
2-deoxycytidineST001142AN0018754.440E-66.840E-6Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
2-deoxycytidineST001142AN0018753.170E-54.010E-5Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
5-adenosylhomocysteineST001142AN0018753.890E-24.000E-2Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
cis/trans-hydroxyprolineST001142AN0018752.010E-741.030E-73Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
cis/trans-hydroxyprolineST001142AN0018751.690E-41.950E-4Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
hexoses (HILIC pos)ST001142AN0018753.470E-431.340E-42Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
hexoses (HILIC pos)ST001142AN0018759.570E-243.350E-23Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
NMMAST001142AN0018753.410E-157.960E-15Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
NMMAST001142AN0018752.820E-95.050E-9Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
SDMA/ADMAST001142AN0018755.730E-313.680E-30Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
SDMA/ADMAST001142AN0018753.570E-117.220E-11Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
3-methyladipate/pimelateST001142AN0018762.100E-281.630E-27Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
3-methyladipate/pimelateST001142AN0018764.270E-111.400E-10Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
F1P/F6P/G1P/G6PST001142AN0018766.960E-141.420E-13Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
F1P/F6P/G1P/G6PST001142AN0018764.930E-131.820E-12Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
fumarate/maleate/alpha-ketoisovalerateST001142AN0018761.800E-175.300E-17Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
fumarate/maleate/alpha-ketoisovalerateST001142AN0018762.320E-22.680E-2Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
glycodeoxycholate/glycochenodeoxycholateST001142AN0018767.320E-812.160E-79Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
glycodeoxycholate/glycochenodeoxycholateST001142AN0018766.990E-243.170E-23Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
hexoses (HILIC neg)ST001142AN0018763.470E-474.100E-46Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
hexoses (HILIC neg)ST001142AN0018767.600E-464.480E-44Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
ribose-5-P/ribulose5-PST001142AN0018769.640E-101.350E-9Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
ribose-5-P/ribulose5-PST001142AN0018761.850E-63.640E-6Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
succinate/methylmalonateST001142AN0018762.420E-292.380E-28Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
succinate/methylmalonateST001142AN0018761.080E-82.890E-8Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
taurodeoxycholate/taurochenodeoxycholateST001142AN0018767.860E-317.730E-30Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
taurodeoxycholate/taurochenodeoxycholateST001142AN0018762.810E-218.730E-21Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
C38:5 PCST001142AN0018777.780E-162.890E-15Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
C38:5 PCST001142AN0018773.600E-141.070E-12Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
4-hydroxy-3-methylacetophenoneST001000AN0018785.060E-74.130E-6Diagnosis;CD;Control;UC
ADMA/SDMAST001000AN0018781.100E-34.170E-3Diagnosis;CD;Control;UC
diacetylspermineST001000AN0018782.250E-37.240E-3Diagnosis;CD;Control;UC
tetrahydro-beta-carboline-carboxylic acidST001000AN0018783.160E-151.120E-13Diagnosis;CD;Control;UC
threosphingosineST001000AN0018784.590E-52.590E-4Diagnosis;CD;Control;UC
trimethylbenzeneST001000AN0018788.220E-32.180E-2Diagnosis;CD;Control;UC
tthyl hexadecenoateST001000AN0018784.950E-28.890E-2Diagnosis;CD;Control;UC
1-3-7-trimethylurateST001000AN0018793.930E-62.670E-5Diagnosis;CD;Control;UC
2-hydroxy-3-methylpentanoic acid / leucinic acidST001000AN0018791.050E-22.420E-2Diagnosis;CD;Control;UC
3-methyladipate-pimelateST001000AN0018791.660E-82.420E-7Diagnosis;CD;Control;UC
butyrate / isobutytareST001000AN0018791.750E-46.880E-4Diagnosis;CD;Control;UC
hydroxyisovaleric acidST001000AN0018792.200E-36.320E-3Diagnosis;CD;Control;UC
Methylbutyric aid / Valeric / IsovalericST001000AN0018793.820E-62.670E-5Diagnosis;CD;Control;UC
pantotheteST001000AN0018797.050E-42.320E-3Diagnosis;CD;Control;UC
succiteST001000AN0018794.890E-29.130E-2Diagnosis;CD;Control;UC
taurodeoxycholate/taurochenodeoxycholateST001000AN0018791.200E-22.670E-2Diagnosis;CD;Control;UC
acetytyrosineST001000AN0018802.910E-24.820E-2Diagnosis;CD;Control;UC
azelateST001000AN0018804.340E-61.620E-5Diagnosis;CD;Control;UC
ketodeoxycholateST001000AN0018802.460E-69.860E-6Diagnosis;CD;Control;UC
PGE2-d4ST001000AN0018803.480E-38.480E-3Diagnosis;CD;Control;UC
undecanedicarboxylic acidST001000AN0018806.110E-41.710E-3Diagnosis;CD;Control;UC
undecanedionateST001000AN0018802.230E-126.230E-11Diagnosis;CD;Control;UC
7-Hexadecenoic acid methyl esterST001000AN0018812.870E-28.680E-2Diagnosis;CD;Control;UC
C18:0e MAGST001000AN0018813.710E-71.140E-5Diagnosis;CD;Control;UC
C24:0 PCST001000AN0018811.470E-25.030E-2Diagnosis;CD;Control;UC
C36:5 PC plasmalogen-AST001000AN0018818.270E-71.860E-5Diagnosis;CD;Control;UC
3-APST001167AN0019291.060E-22.280E-2Time points;0.25h;0h;12h;24h;4h;6days
3-APST001167AN0019293.220E-26.260E-2Cell lines;RWPE1;VCaP
p-Toluic acid-M+0ST001167AN0019307.990E-114.020E-10Time points;0.25h;0h;12h;24h;4h;6days
p-Toluic acid-M+1ST001167AN0019306.730E-41.310E-3Time points;0.25h;0h;12h;24h;4h;6days
p-Toluic acid-M+3ST001167AN0019301.280E-38.600E-3Cell lines;RWPE1;VCaP
p-Toluic acid-M+3ST001167AN0019308.090E-31.320E-2Time points;0.25h;0h;12h;24h;4h;6days
2E-Eicosenoic acidST001191AN0019831.280E-61.310E-5Treatment;Control;QC;Sample
Ginsenoside ReST001191AN0019832.220E-61.780E-5Treatment;Control;QC;Sample
Ginsenoside Rg3ST001191AN0019836.790E-63.920E-5Treatment;Control;QC;Sample
DMGVST001192AN0019841.280E-21.780E-1Diet;-;Omnivore;Vegetarian
N-acetyphenylalanineST001192AN0019843.390E-22.800E-1Diet;-;Omnivore;Vegetarian
phenylalanine-d8ST001192AN0019842.550E-22.800E-1Diet;-;Omnivore;Vegetarian
3-hydroxykynurenateST001192AN0019852.210E-22.870E-1Diet;-;Omnivore;Vegetarian
thymine-d4ST001192AN0019854.910E-23.720E-1Diet;-;Omnivore;Vegetarian
10-nonadecenoateST001192AN0019869.500E-31.060E-1Diet;-;Omnivore;Vegetarian
acetytyrosineST001192AN0019861.920E-34.260E-2Diet;-;Omnivore;Vegetarian
crustecdysoneST001192AN0019864.370E-22.160E-1Diet;-;Omnivore;Vegetarian
ketodeoxycholateST001192AN0019861.590E-21.090E-1Diet;-;Omnivore;Vegetarian
24-DihydroxyacetophenoneST001193AN0019883.280E-24.810E-2Plasma;Cord blood;Plasma
24-DihydroxyacetophenoneST001193AN0019896.530E-41.080E-3Plasma;Cord blood;Plasma
Adenosine 35-diphosphateST001193AN0019891.550E-42.860E-4Plasma;Cord blood;Plasma
GulonolactoneST001193AN0019891.130E-21.500E-2Plasma;Cord blood;Plasma
2-acetamidoglucalST001201AN0019984.220E-51.310E-3treatment;DHA;DMSO;OZ277;OZ439
2-chloro-3-methyl-maleylacetateST001201AN0019984.340E-563.390E-54cell_type;iRBC;unRBC
2-oxo-5-methylthiopentanoic-acidST001201AN0019982.050E-506.680E-49cell_type;iRBC;unRBC
2-S-Glutathionyl acetateST001201AN0019983.450E-221.800E-21cell_type;iRBC;unRBC
3-(ADP)-2-phosphoglycerateST001201AN0019981.340E-134.580E-13cell_type;iRBC;unRBC
3-ButynoateST001201AN0019988.210E-122.570E-11cell_type;iRBC;unRBC
3-deoxy-D-galactoseST001201AN0019984.830E-388.580E-37cell_type;iRBC;unRBC
3-EthylmalateST001201AN0019988.810E-41.620E-3cell_type;iRBC;unRBC
4-amino-4-deoxy-L-arabinoseST001201AN0019989.770E-245.700E-23cell_type;iRBC;unRBC
4-(Trimethylammonio)but-2-enoateST001201AN0019981.120E-91.460E-7treatment;DHA;DMSO;OZ277;OZ439
4-(Trimethylammonio)but-2-enoateST001201AN0019986.350E-61.400E-5cell_type;iRBC;unRBC
5-6-DihydrouridineST001201AN0019981.220E-123.940E-12cell_type;iRBC;unRBC
5-6-DihydrouridineST001201AN0019988.640E-34.140E-2treatment;DHA;DMSO;OZ277;OZ439
6-Acetamido-2-oxohexanoateST001201AN0019981.130E-42.770E-3treatment;DHA;DMSO;OZ277;OZ439
6-deoxy-5-ketofructose-1-phosphateST001201AN0019981.860E-156.620E-15cell_type;iRBC;unRBC
6-deoxy-5-ketofructose-1-phosphateST001201AN0019981.700E-25.890E-2treatment;DHA;DMSO;OZ277;OZ439
8-Amino-7-oxononanoateST001201AN0019981.160E-24.700E-2treatment;DHA;DMSO;OZ277;OZ439
8-Amino-7-oxononanoateST001201AN0019984.280E-26.080E-2cell_type;iRBC;unRBC
Ala-Asn-Asn-SerST001201AN0019981.020E-24.530E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Asp-Asp-AspST001201AN0019984.170E-32.430E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Asp-Asp-AspST001201AN0019982.790E-24.070E-2cell_type;iRBC;unRBC
Ala-Asp-Asp-CysST001201AN0019981.110E-21.750E-2cell_type;iRBC;unRBC
Ala-Asp-Asp-HisST001201AN0019981.450E-31.460E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Asp-Asp-HisST001201AN0019982.190E-33.850E-3cell_type;iRBC;unRBC
Ala-Asp-Cys-SerST001201AN0019986.320E-243.740E-23cell_type;iRBC;unRBC
Ala-Asp-Cys-SerST001201AN0019984.550E-21.360E-1treatment;DHA;DMSO;OZ277;OZ439
Ala-Asp-Gly-ArgST001201AN0019982.320E-199.340E-19cell_type;iRBC;unRBC
Ala-Asp-Gly-ArgST001201AN0019981.490E-25.670E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Glu-Glu-HisST001201AN0019981.660E-332.410E-32cell_type;iRBC;unRBC
Ala-Glu-Glu-HisST001201AN0019982.310E-27.580E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Asn-ProST001201AN0019988.510E-297.080E-28cell_type;iRBC;unRBC
Ala-Leu-Asn-ProST001201AN0019983.900E-32.430E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Lys-AspST001201AN0019981.070E-21.700E-2cell_type;iRBC;unRBC
Ala-Leu-Thr-AlaST001201AN0019985.640E-33.110E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Trp-SerST001201AN0019983.340E-201.430E-19cell_type;iRBC;unRBC
Ala-Leu-Trp-SerST001201AN0019984.090E-32.430E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Trp-SerST001201AN0019983.270E-25.330E-1treatment_duration_(h);-;0.5;1.5;3
Ala-Lys-Asp-GlyST001201AN0019984.530E-408.430E-39cell_type;iRBC;unRBC
Ala-Thr-Ala-SerST001201AN0019981.470E-25.630E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Val-Asp-SerST001201AN0019981.720E-25.890E-2treatment;DHA;DMSO;OZ277;OZ439
Arg-Asp-Asp-GlyST001201AN0019986.120E-31.020E-2cell_type;iRBC;unRBC
Asn-Gly-Pro-ProST001201AN0019986.000E-316.380E-30cell_type;iRBC;unRBC
Asn-Gly-Pro-ProST001201AN0019981.140E-24.700E-2treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Lys-AspST001201AN0019984.920E-81.250E-7cell_type;iRBC;unRBC
Asn-Leu-Lys-AspST001201AN0019984.940E-21.460E-1treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Pro-ProST001201AN0019982.170E-251.410E-24cell_type;iRBC;unRBC
Asn-Leu-Pro-ProST001201AN0019982.950E-32.260E-2treatment;DHA;DMSO;OZ277;OZ439
Asn-Lys-Gly-ProST001201AN0019987.230E-339.430E-32cell_type;iRBC;unRBC
Asn-Lys-Gly-ProST001201AN0019982.910E-29.250E-2treatment;DHA;DMSO;OZ277;OZ439
Asp-Thr-Cys-CysST001201AN0019985.370E-101.520E-9cell_type;iRBC;unRBC
Cys-Cys-Pro-SerST001201AN0019983.690E-252.330E-24cell_type;iRBC;unRBC
Cys-Cys-Pro-SerST001201AN0019983.070E-44.610E-3treatment;DHA;DMSO;OZ277;OZ439
Cys-Phe-Trp-GlyST001201AN0019982.090E-26.980E-2treatment;DHA;DMSO;OZ277;OZ439
FA oxo(19:0)ST001201AN0019987.550E-328.440E-31cell_type;iRBC;unRBC
FA oxo(21:0)ST001201AN0019982.710E-415.290E-40cell_type;iRBC;unRBC
gamma-thiomethyl glutamateST001201AN0019982.430E-435.580E-42cell_type;iRBC;unRBC
Glu-Glu-Gln-HisST001201AN0019986.800E-285.120E-27cell_type;iRBC;unRBC
Glu-Glu-Gln-HisST001201AN0019981.030E-24.530E-2treatment;DHA;DMSO;OZ277;OZ439
L-a-glutamyl-L-LysineST001201AN0019983.910E-222.010E-21cell_type;iRBC;unRBC
L-a-glutamyl-L-LysineST001201AN0019981.310E-25.130E-2treatment;DHA;DMSO;OZ277;OZ439
L-beta-aspartyl-L-alanineST001201AN0019986.600E-31.080E-2cell_type;iRBC;unRBC
L-beta-aspartyl-L-serineST001201AN0019981.070E-31.190E-2treatment;DHA;DMSO;OZ277;OZ439
L-Glutamyl 5-phosphateST001201AN0019981.290E-412.650E-40cell_type;iRBC;unRBC
N2-Acetyl-L-aminoadipyl-delta-phosphateST001201AN0019983.780E-89.720E-8cell_type;iRBC;unRBC
N2-(D-1-Carboxyethyl)-L-arginineST001201AN0019983.440E-32.370E-2treatment;DHA;DMSO;OZ277;OZ439
N2-(D-1-Carboxyethyl)-L-arginineST001201AN0019983.550E-25.120E-2cell_type;iRBC;unRBC
N5-acetyl-N5-hydroxy-L-ornithineST001201AN0019986.110E-51.280E-4cell_type;iRBC;unRBC
N5-acetyl-N5-hydroxy-L-ornithineST001201AN0019983.930E-26.150E-1treatment_duration_(h);-;0.5;1.5;3
N-acetyl -D- glucosaminitolST001201AN0019985.380E-41.030E-3cell_type;iRBC;unRBC
N-Glycolyl-D-mannosamineST001201AN0019981.680E-63.840E-6cell_type;iRBC;unRBC
Ovothiol A-cysteine disulfideST001201AN0019989.400E-653.680E-62cell_type;iRBC;unRBC
PhenylacetonitrileST001201AN0019983.100E-88.030E-8cell_type;iRBC;unRBC
Procollagen 5-(D-galactosyloxy)-L-lysineST001201AN0019982.300E-44.530E-4cell_type;iRBC;unRBC
protocatechualdehydeST001201AN0019981.470E-53.170E-5cell_type;iRBC;unRBC
psicoselysineST001201AN0019987.260E-579.460E-55cell_type;iRBC;unRBC
trans-Hexadec-2-enoylcarnitineST001201AN0019981.260E-184.890E-18cell_type;iRBC;unRBC
2(alpha-D-Mannosyl)-D-glycerateST001201AN0019991.040E-65.590E-5treatment;DHA;DMSO;OZ277;OZ439
2(alpha-D-Mannosyl)-D-glycerateST001201AN0019991.040E-21.800E-2cell_type;iRBC;unRBC
2-amino-2-deoxy-isochorismateST001201AN0019993.640E-25.590E-2cell_type;iRBC;unRBC
2-BenzothiazolesulfonamideST001201AN0019993.060E-251.470E-24cell_type;iRBC;unRBC
2-C-Methyl-D-erythritol 4-phosphateST001201AN0019992.780E-97.280E-9cell_type;iRBC;unRBC
2-C-Methyl-D-erythritol 4-phosphateST001201AN0019993.590E-32.660E-2treatment;DHA;DMSO;OZ277;OZ439
2-deoxyglucose-6-phosphateST001201AN0019991.690E-145.490E-14cell_type;iRBC;unRBC
2-(Hydroxymethyl)-3-(acetamidomethylene)succinateST001201AN0019997.480E-41.460E-3cell_type;iRBC;unRBC
2-(Hydroxymethyl)-3-(acetamidomethylene)succinateST001201AN0019993.730E-21.540E-1treatment;DHA;DMSO;OZ277;OZ439
2-Phospho-D-glycerateST001201AN0019993.020E-26.950E-1treatment_duration_(h);-;0.5;1.5;3
3-(ADP)-glycerateST001201AN0019992.990E-139.430E-13cell_type;iRBC;unRBC
3-Deoxy-D-manno-octulosonate 8-phosphateST001201AN0019993.960E-272.120E-26cell_type;iRBC;unRBC
3-phosphoglucarateST001201AN0019991.500E-24.840E-1treatment_duration_(h);-;0.5;1.5;3
3-PhosphonopyruvateST001201AN0019991.020E-419.100E-41cell_type;iRBC;unRBC
3-ureidoacrylateST001201AN0019996.250E-61.380E-5cell_type;iRBC;unRBC
4-Amino-4-deoxychorismateST001201AN0019991.970E-23.160E-2cell_type;iRBC;unRBC
[6]-ParadolST001201AN0019993.000E-24.640E-2cell_type;iRBC;unRBC
A-KetoglutaricacidoximeST001201AN0019994.400E-51.180E-3treatment;DHA;DMSO;OZ277;OZ439
A-KetoglutaricacidoximeST001201AN0019994.870E-38.810E-3cell_type;iRBC;unRBC
A-KetoglutaricacidoximeST001201AN0019991.790E-24.950E-1treatment_duration_(h);-;0.5;1.5;3
Ala-Ala-Asp-TyrST001201AN0019994.300E-475.320E-46cell_type;iRBC;unRBC
Ala-Cys-Pro-SerST001201AN0019991.360E-27.050E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Lys-Ala-AlaST001201AN0019996.090E-242.760E-23cell_type;iRBC;unRBC
Ala-Lys-Ala-AlaST001201AN0019993.880E-32.710E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Phe-Tyr-TyrST001201AN0019996.290E-121.840E-11cell_type;iRBC;unRBC
Ala-Thr-Ala-GlyST001201AN0019992.520E-32.130E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Thr-Ala-GlyST001201AN0019991.990E-23.180E-2cell_type;iRBC;unRBC
Arg-Phe-Phe-ArgST001201AN0019992.250E-291.290E-28cell_type;iRBC;unRBC
Arg-Phe-Phe-ArgST001201AN0019991.290E-26.940E-2treatment;DHA;DMSO;OZ277;OZ439
Asn-Asn-Gly-HisST001201AN0019994.500E-46.300E-3treatment;DHA;DMSO;OZ277;OZ439
Asn-Asn-Gly-HisST001201AN0019991.760E-22.870E-2cell_type;iRBC;unRBC
Asn-Met-Thr-AspST001201AN0019994.440E-231.930E-22cell_type;iRBC;unRBC
Asp-Gly-Pro-SerST001201AN0019991.360E-297.990E-29cell_type;iRBC;unRBC
Asp-Val-Pro-SerST001201AN0019991.260E-564.500E-55cell_type;iRBC;unRBC
Bile saltST001201AN0019991.020E-31.970E-3cell_type;iRBC;unRBC
Bile saltST001201AN0019991.230E-37.900E-2treatment_duration_(h);-;0.5;1.5;3
CMP-N-trimethyl-2-aminoethylphosphonateST001201AN0019997.340E-49.090E-3treatment;DHA;DMSO;OZ277;OZ439
Cys-Gly-Pro-SerST001201AN0019992.130E-32.040E-2treatment;DHA;DMSO;OZ277;OZ439
Cys-Gly-Pro-SerST001201AN0019994.240E-26.440E-2cell_type;iRBC;unRBC
Cys-Leu-Cys-TyrST001201AN0019992.830E-35.260E-3cell_type;iRBC;unRBC
Cys-Leu-Cys-TyrST001201AN0019993.810E-21.540E-1treatment;DHA;DMSO;OZ277;OZ439
deacetylcolchicineST001201AN0019999.260E-264.660E-25cell_type;iRBC;unRBC
D-GalacturonateST001201AN0019992.790E-24.350E-2cell_type;iRBC;unRBC
H2S2O3ST001201AN0019991.230E-24.390E-1treatment_duration_(h);-;0.5;1.5;3
HEPESST001201AN0019993.490E-302.080E-29cell_type;iRBC;unRBC
HeptopyranosidesST001201AN0019993.060E-44.930E-3treatment;DHA;DMSO;OZ277;OZ439
HeptopyranosidesST001201AN0019991.570E-22.600E-2cell_type;iRBC;unRBC
IDP-D-mannoseST001201AN0019992.860E-128.780E-12cell_type;iRBC;unRBC
IDP-D-mannoseST001201AN0019995.750E-47.720E-3treatment;DHA;DMSO;OZ277;OZ439
L-cysteine sulfinateST001201AN0019994.040E-444.200E-43cell_type;iRBC;unRBC
L-ErythruloseST001201AN0019993.350E-362.630E-35cell_type;iRBC;unRBC
melibionateST001201AN0019992.950E-87.550E-8cell_type;iRBC;unRBC
MESST001201AN0019991.270E-26.940E-2treatment;DHA;DMSO;OZ277;OZ439
N5-formyl-N5-hydroxy-L-ornithineST001201AN0019992.250E-188.240E-18cell_type;iRBC;unRBC
N5-formyl-N5-hydroxy-L-ornithineST001201AN0019991.570E-27.650E-2treatment;DHA;DMSO;OZ277;OZ439
N-AcetylanthranilateST001201AN0019997.360E-57.900E-3treatment_duration_(h);-;0.5;1.5;3
N-AcetylanthranilateST001201AN0019996.670E-41.310E-3cell_type;iRBC;unRBC
N-AcetylanthranilateST001201AN0019992.880E-32.320E-2treatment;DHA;DMSO;OZ277;OZ439
N-Acetyl-D-glucosaminateST001201AN0019998.310E-31.450E-2cell_type;iRBC;unRBC
N-Acetyl-D-glucosamine 6-phosphateST001201AN0019993.920E-61.580E-4treatment;DHA;DMSO;OZ277;OZ439
N-Acetyl-D-glucosamine 6-phosphateST001201AN0019991.570E-22.600E-2cell_type;iRBC;unRBC
nicotinamide guanine dinucleotideST001201AN0019991.490E-124.600E-12cell_type;iRBC;unRBC
nicotinamide guanine dinucleotideST001201AN0019994.910E-21.910E-1treatment;DHA;DMSO;OZ277;OZ439
octulose 8-phosphateST001201AN0019993.580E-241.700E-23cell_type;iRBC;unRBC
Ovothiol disulfideST001201AN0019994.270E-32.920E-2treatment;DHA;DMSO;OZ277;OZ439
Ovothiol disulfideST001201AN0019993.130E-24.820E-2cell_type;iRBC;unRBC
P-DPDST001201AN0019996.760E-48.700E-3treatment;DHA;DMSO;OZ277;OZ439
phe-FMDPST001201AN0019991.930E-54.060E-5cell_type;iRBC;unRBC
PhenolsulfonphthaleinST001201AN0019993.910E-27.400E-1treatment_duration_(h);-;0.5;1.5;3
PIPESST001201AN0019991.380E-27.050E-2treatment;DHA;DMSO;OZ277;OZ439
(R)-3-((R)-3-Hydroxybutanoyloxy)butanoateST001201AN0019991.780E-22.890E-2cell_type;iRBC;unRBC
S-Methyl-5-thio-D-ribose 1-phosphateST001201AN0019995.200E-486.980E-47cell_type;iRBC;unRBC
XylobioseST001201AN0019998.800E-112.830E-8treatment;DHA;DMSO;OZ277;OZ439
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerolST001202AN0020003.320E-363.530E-35cell_type;iRBC;unRBC
2-(4-sulfophenyl)butyrateST001202AN0020001.090E-121.660E-12cell_type;iRBC;unRBC
2-(4-sulfophenyl)butyrateST001202AN0020008.240E-31.130E-2treatment_duration_(h);-;1.5;3;6;9
3-(1-Pyrrolidinyl)-2-pentanoneST001202AN0020003.990E-146.480E-14cell_type;iRBC;unRBC
3-(1-Pyrrolidinyl)-2-pentanoneST001202AN0020003.820E-24.640E-2treatment_duration_(h);-;1.5;3;6;9
3-ButynoateST001202AN0020003.650E-138.640E-12treatment_duration_(h);-;1.5;3;6;9
3-nitro-2-pentanolST001202AN0020009.710E-141.550E-13cell_type;iRBC;unRBC
3-nitro-2-pentanolST001202AN0020001.700E-81.030E-7treatment_duration_(h);-;1.5;3;6;9
4-amino-4-deoxy-L-arabinoseST001202AN0020006.470E-118.420E-10treatment_duration_(h);-;1.5;3;6;9
4-Hydroxy-4-methylglutamateST001202AN0020001.500E-182.980E-18cell_type;iRBC;unRBC
4-Hydroxy-4-methylglutamateST001202AN0020001.410E-88.620E-8treatment_duration_(h);-;1.5;3;6;9
4-Imidazolone-5-propanoateST001202AN0020008.720E-131.330E-12cell_type;iRBC;unRBC
4-Imidazolone-5-propanoateST001202AN0020006.530E-72.350E-6treatment_duration_(h);-;1.5;3;6;9
4-(Trimethylammonio)but-2-enoateST001202AN0020001.200E-61.410E-6cell_type;iRBC;unRBC
4-(Trimethylammonio)but-2-enoateST001202AN0020004.820E-37.080E-3treatment_duration_(h);-;1.5;3;6;9
5-6-DihydrouridineST001202AN0020006.290E-131.410E-11treatment_duration_(h);-;1.5;3;6;9
5-6-DihydrouridineST001202AN0020001.510E-71.830E-7cell_type;iRBC;unRBC
6-Acetyl-D-glucoseST001202AN0020007.530E-191.540E-18cell_type;iRBC;unRBC
6-Acetyl-D-glucoseST001202AN0020002.570E-81.400E-7treatment_duration_(h);-;1.5;3;6;9
6-diazo-5-oxonorleucineST001202AN0020001.430E-193.200E-19cell_type;iRBC;unRBC
6-diazo-5-oxonorleucineST001202AN0020002.130E-33.250E-3treatment_duration_(h);-;1.5;3;6;9
8-Amino-7-oxononanoateST001202AN0020002.410E-195.260E-19cell_type;iRBC;unRBC
8-Amino-7-oxononanoateST001202AN0020002.130E-66.100E-6treatment_duration_(h);-;1.5;3;6;9
AcetylpseudotropineST001202AN0020006.310E-151.050E-14cell_type;iRBC;unRBC
AcetylpseudotropineST001202AN0020001.080E-31.710E-3treatment_duration_(h);-;1.5;3;6;9
a Cysteine adductST001202AN0020004.380E-59.350E-5treatment_duration_(h);-;1.5;3;6;9
Ala-Ala-Ala-SerST001202AN0020002.710E-322.060E-31cell_type;iRBC;unRBC
Ala-Ala-Ala-SerST001202AN0020007.700E-31.070E-2treatment_duration_(h);-;1.5;3;6;9
Ala-Asp-Asp-CysST001202AN0020006.480E-314.150E-30cell_type;iRBC;unRBC
Ala-Asp-Asp-CysST001202AN0020001.470E-21.930E-2treatment_duration_(h);-;1.5;3;6;9
Ala-Asp-Cys-SerST001202AN0020005.710E-387.430E-37cell_type;iRBC;unRBC
Ala-Asp-Cys-SerST001202AN0020004.930E-25.930E-2treatment_duration_(h);-;1.5;3;6;9
Ala-Asp-Gly-TyrST001202AN0020003.130E-251.150E-24cell_type;iRBC;unRBC
Ala-Asp-Gly-TyrST001202AN0020002.150E-54.990E-5treatment_duration_(h);-;1.5;3;6;9
Ala-Leu-Lys-AspST001202AN0020001.050E-254.040E-25cell_type;iRBC;unRBC
Ala-Leu-Lys-AspST001202AN0020002.040E-54.770E-5treatment_duration_(h);-;1.5;3;6;9
Ala-Leu-Thr-AlaST001202AN0020008.570E-263.350E-25cell_type;iRBC;unRBC
Ala-Leu-Thr-AlaST001202AN0020005.480E-51.150E-4treatment_duration_(h);-;1.5;3;6;9
Ala-Thr-Ala-AspST001202AN0020007.080E-221.800E-21cell_type;iRBC;unRBC
Ala-Thr-Ala-AspST001202AN0020002.260E-44.220E-4treatment_duration_(h);-;1.5;3;6;9
Ala-Thr-Ala-SerST001202AN0020005.630E-282.770E-27cell_type;iRBC;unRBC
Ala-Thr-Ala-SerST001202AN0020005.100E-51.080E-4treatment_duration_(h);-;1.5;3;6;9
Ala-Trp-Gly-GlyST001202AN0020006.160E-139.480E-13cell_type;iRBC;unRBC
Ala-Trp-Gly-GlyST001202AN0020003.980E-47.040E-4treatment_duration_(h);-;1.5;3;6;9
Ala-Val-Asp-SerST001202AN0020006.450E-242.030E-23cell_type;iRBC;unRBC
Ala-Val-Asp-SerST001202AN0020007.590E-51.540E-4treatment_duration_(h);-;1.5;3;6;9
Arg-Asp-Asp-GlyST001202AN0020001.140E-121.730E-12cell_type;iRBC;unRBC
Arg-Asp-Asp-GlyST001202AN0020008.010E-51.610E-4treatment_duration_(h);-;1.5;3;6;9
ArsenobetaineST001202AN0020001.750E-41.960E-4cell_type;iRBC;unRBC
ArsenobetaineST001202AN0020005.080E-48.780E-4treatment_duration_(h);-;1.5;3;6;9
Asn-Asn-Gly-HisST001202AN0020003.410E-186.670E-18cell_type;iRBC;unRBC
Asn-Asn-Gly-HisST001202AN0020003.400E-35.060E-3treatment_duration_(h);-;1.5;3;6;9
Asn-Leu-Pro-ProST001202AN0020002.860E-196.160E-19cell_type;iRBC;unRBC
Asn-Leu-Pro-ProST001202AN0020003.860E-37.780E-1treatment;DHA;DMSO;OZ277;OZ439
Asn-Thr-Asn-AsnST001202AN0020006.110E-211.490E-20cell_type;iRBC;unRBC
Asn-Thr-Asn-AsnST001202AN0020001.570E-22.040E-2treatment_duration_(h);-;1.5;3;6;9
Asparaginyl-HydroxyprolineST001202AN0020004.400E-157.380E-15cell_type;iRBC;unRBC
Asparaginyl-HydroxyprolineST001202AN0020001.260E-87.840E-8treatment_duration_(h);-;1.5;3;6;9
Asp-Leu-Gln-ProST001202AN0020007.290E-201.660E-19cell_type;iRBC;unRBC
Asp-Leu-Gln-ProST001202AN0020001.400E-53.400E-5treatment_duration_(h);-;1.5;3;6;9
Asp-Leu-Lys-AspST001202AN0020001.750E-224.740E-22cell_type;iRBC;unRBC
Asp-Leu-Lys-AspST001202AN0020002.410E-55.470E-5treatment_duration_(h);-;1.5;3;6;9
Asp-Leu-Lys-LysST001202AN0020009.150E-101.210E-9cell_type;iRBC;unRBC
Asp-Leu-Lys-LysST001202AN0020006.940E-61.820E-5treatment_duration_(h);-;1.5;3;6;9
Asp-Val-Gly-SerST001202AN0020007.810E-242.440E-23cell_type;iRBC;unRBC
Asp-Val-Gly-SerST001202AN0020001.340E-42.580E-4treatment_duration_(h);-;1.5;3;6;9
Bisacurone epoxideST001202AN0020007.010E-131.070E-12cell_type;iRBC;unRBC
CMP-N-trimethyl-2-aminoethylphosphonateST001202AN0020001.290E-213.210E-21cell_type;iRBC;unRBC
CMP-N-trimethyl-2-aminoethylphosphonateST001202AN0020004.700E-59.980E-5treatment_duration_(h);-;1.5;3;6;9
Cohibin CST001202AN0020005.620E-365.660E-35cell_type;iRBC;unRBC
CrotanecineST001202AN0020001.500E-392.420E-38cell_type;iRBC;unRBC
CTABST001202AN0020002.130E-153.640E-15cell_type;iRBC;unRBC
Cysteinyl-HydroxyprolineST001202AN0020004.210E-103.950E-9treatment_duration_(h);-;1.5;3;6;9
Cysteinyl-HydroxyprolineST001202AN0020001.300E-41.460E-4cell_type;iRBC;unRBC
deacetylcolchicineST001202AN0020002.500E-383.600E-37cell_type;iRBC;unRBC
deacetylcolchicineST001202AN0020008.500E-31.150E-2treatment_duration_(h);-;1.5;3;6;9
dibenzothiophene-5-oxideST001202AN0020005.880E-128.590E-12cell_type;iRBC;unRBC
dibenzothiophene-5-oxideST001202AN0020001.330E-101.460E-9treatment_duration_(h);-;1.5;3;6;9
DL-Methionine sulfoneST001202AN0020005.570E-117.480E-10treatment_duration_(h);-;1.5;3;6;9
D-O-PhosphoserineST001202AN0020001.800E-153.100E-15cell_type;iRBC;unRBC
D-O-PhosphoserineST001202AN0020004.550E-71.710E-6treatment_duration_(h);-;1.5;3;6;9
EPC(d33:1)ST001202AN0020002.220E-81.280E-7treatment_duration_(h);-;1.5;3;6;9
EPC(d33:1)ST001202AN0020002.410E-32.640E-3cell_type;iRBC;unRBC
gamma-thiomethyl glutamateST001202AN0020009.020E-591.820E-56cell_type;iRBC;unRBC
Ganglioside GA1 (d18:1/24:0)ST001202AN0020001.350E-122.030E-12cell_type;iRBC;unRBC
HexadeceylaminST001202AN0020002.270E-271.030E-26cell_type;iRBC;unRBC
Lactosylceramide(d18ST001202AN0020001.770E-112.540E-11cell_type;iRBC;unRBC
Lactosylceramide(d18ST001202AN0020003.820E-24.640E-2treatment_duration_(h);-;1.5;3;6;9
MESST001202AN0020002.390E-247.640E-24cell_type;iRBC;unRBC
MESST001202AN0020001.130E-42.210E-4treatment_duration_(h);-;1.5;3;6;9
methiinST001202AN0020003.350E-491.500E-47cell_type;iRBC;unRBC
MontecristinST001202AN0020004.030E-282.030E-27cell_type;iRBC;unRBC
MOPSST001202AN0020006.460E-221.660E-21cell_type;iRBC;unRBC
MOPSST001202AN0020001.020E-52.560E-5treatment_duration_(h);-;1.5;3;6;9
N2-Acetyl-L-aminoadipyl-delta-phosphateST001202AN0020001.160E-81.480E-8cell_type;iRBC;unRBC
N2-Acetyl-L-aminoadipyl-delta-phosphateST001202AN0020003.560E-81.860E-7treatment_duration_(h);-;1.5;3;6;9
N2-(D-1-Carboxyethyl)-L-arginineST001202AN0020001.500E-402.630E-39cell_type;iRBC;unRBC
N2-(D-1-Carboxyethyl)-L-arginineST001202AN0020008.170E-31.120E-2treatment_duration_(h);-;1.5;3;6;9
N5-acetyl-N5-hydroxy-L-ornithineST001202AN0020001.940E-278.890E-27cell_type;iRBC;unRBC
N-(5-Methyl-3-oxohexyl)alanineST001202AN0020006.190E-77.420E-7cell_type;iRBC;unRBC
N-(5-Methyl-3-oxohexyl)alanineST001202AN0020007.990E-62.040E-5treatment_duration_(h);-;1.5;3;6;9
N-dimethylethanolamineST001202AN0020001.470E-91.930E-9cell_type;iRBC;unRBC
N-hydroxyisoleucineST001202AN0020005.440E-56.180E-5cell_type;iRBC;unRBC
N-hydroxyisoleucineST001202AN0020007.670E-41.240E-3treatment_duration_(h);-;1.5;3;6;9
O-Acetylneuraminic acidST001202AN0020004.790E-189.290E-18cell_type;iRBC;unRBC
O-Acetylneuraminic acidST001202AN0020001.260E-42.430E-4treatment_duration_(h);-;1.5;3;6;9
Ovothiol disulfideST001202AN0020001.590E-92.060E-9cell_type;iRBC;unRBC
Procollagen 5-(D-galactosyloxy)-L-lysineST001202AN0020004.120E-231.200E-22cell_type;iRBC;unRBC
Procollagen 5-(D-galactosyloxy)-L-lysineST001202AN0020001.380E-42.650E-4treatment_duration_(h);-;1.5;3;6;9
(R)-2-EthylmalateST001202AN0020001.660E-152.870E-15cell_type;iRBC;unRBC
(R)-2-EthylmalateST001202AN0020006.630E-39.340E-3treatment_duration_(h);-;1.5;3;6;9
Sesaminol glucosyl-(1->2)-[glucosyl-(1->6)]-glucosideST001202AN0020006.560E-108.720E-10cell_type;iRBC;unRBC
Sesaminol glucosyl-(1->2)-[glucosyl-(1->6)]-glucosideST001202AN0020003.120E-45.650E-4treatment_duration_(h);-;1.5;3;6;9
TolylacetonitrileST001202AN0020002.530E-261.040E-25cell_type;iRBC;unRBC
TolylacetonitrileST001202AN0020003.260E-71.260E-6treatment_duration_(h);-;1.5;3;6;9
trans-Hexadec-2-enoylcarnitineST001202AN0020008.190E-95.410E-8treatment_duration_(h);-;1.5;3;6;9
Trp-Trp-Tyr-TyrST001202AN0020008.160E-561.100E-53cell_type;iRBC;unRBC
2(alpha-D-Mannosyl)-D-glycerateST001202AN0020013.890E-199.570E-19cell_type;iRBC;unRBC
2(alpha-D-Mannosyl)-D-glycerateST001202AN0020011.690E-66.080E-6treatment_duration_(h);-;1.5;3;6;9
2-C-Methyl-D-erythritol 4-phosphateST001202AN0020019.320E-85.300E-7treatment_duration_(h);-;1.5;3;6;9
2-C-Methyl-D-erythritol 4-phosphateST001202AN0020013.610E-74.300E-7cell_type;iRBC;unRBC
3-(ADP)-2-phosphoglycerateST001202AN0020018.470E-91.110E-8cell_type;iRBC;unRBC
3-(ADP)-2-phosphoglycerateST001202AN0020014.520E-82.890E-7treatment_duration_(h);-;1.5;3;6;9
3-(ADP)-glycerateST001202AN0020011.150E-111.640E-10treatment_duration_(h);-;1.5;3;6;9
3-(ADP)-glycerateST001202AN0020013.300E-23.540E-2cell_type;iRBC;unRBC
3-deoxy-D-galactoseST001202AN0020012.310E-174.840E-17cell_type;iRBC;unRBC
3-deoxy-D-galactoseST001202AN0020011.430E-43.420E-4treatment_duration_(h);-;1.5;3;6;9
3-Deoxy-D-manno-octulosonate 8-phosphateST001202AN0020011.000E-63.880E-6treatment_duration_(h);-;1.5;3;6;9
3-Deoxy-D-manno-octulosonate 8-phosphateST001202AN0020011.350E-21.460E-2cell_type;iRBC;unRBC
3-phosphoglucarateST001202AN0020015.990E-139.350E-13cell_type;iRBC;unRBC
3-phosphoglucarateST001202AN0020015.350E-61.690E-5treatment_duration_(h);-;1.5;3;6;9
3-PhosphonopyruvateST001202AN0020013.090E-124.540E-12cell_type;iRBC;unRBC
3-PhosphonopyruvateST001202AN0020015.500E-105.420E-9treatment_duration_(h);-;1.5;3;6;9
4-Amino-4-deoxychorismateST001202AN0020011.800E-225.830E-22cell_type;iRBC;unRBC
4-Amino-4-deoxychorismateST001202AN0020012.080E-67.200E-6treatment_duration_(h);-;1.5;3;6;9
4-HydroxyphenylacetylglycineST001202AN0020012.120E-311.940E-30cell_type;iRBC;unRBC
4-HydroxyphenylacetylglycineST001202AN0020012.500E-45.510E-4treatment_duration_(h);-;1.5;3;6;9
[6]-ParadolST001202AN0020013.620E-94.780E-9cell_type;iRBC;unRBC
[6]-ParadolST001202AN0020015.060E-38.520E-3treatment_duration_(h);-;1.5;3;6;9
Ala-Cys-Pro-SerST001202AN0020014.120E-199.950E-19cell_type;iRBC;unRBC
Ala-Met-Asp-TyrST001202AN0020011.860E-321.980E-31cell_type;iRBC;unRBC
Ala-Met-Asp-TyrST001202AN0020016.660E-41.360E-3treatment_duration_(h);-;1.5;3;6;9
Arg-Phe-Phe-ArgST001202AN0020016.640E-98.720E-9cell_type;iRBC;unRBC
Arg-Phe-Phe-ArgST001202AN0020011.030E-31.960E-3treatment_duration_(h);-;1.5;3;6;9
Avenic acid AST001202AN0020011.470E-235.530E-23cell_type;iRBC;unRBC
Avenic acid AST001202AN0020011.240E-21.890E-2treatment_duration_(h);-;1.5;3;6;9
Bile saltST001202AN0020015.240E-262.690E-25cell_type;iRBC;unRBC
Bile saltST001202AN0020017.480E-51.880E-4treatment_duration_(h);-;1.5;3;6;9
Cys-Gly-Pro-SerST001202AN0020012.450E-251.140E-24cell_type;iRBC;unRBC
Cys-Gly-Pro-SerST001202AN0020018.010E-41.580E-3treatment_duration_(h);-;1.5;3;6;9
Cys-Leu-Cys-TyrST001202AN0020012.310E-322.360E-31cell_type;iRBC;unRBC
Cys-Leu-Cys-TyrST001202AN0020011.660E-43.870E-4treatment_duration_(h);-;1.5;3;6;9
D-1-[(3-Carboxypropyl)amino]-1-deoxyfructoseST001202AN0020014.520E-141.930E-12treatment_duration_(h);-;1.5;3;6;9
D-erythro-L-galacto-NonuloseST001202AN0020012.540E-333.430E-32cell_type;iRBC;unRBC
D-erythro-L-galacto-NonuloseST001202AN0020011.740E-43.980E-4treatment_duration_(h);-;1.5;3;6;9
D-GalacturonateST001202AN0020015.920E-221.740E-21cell_type;iRBC;unRBC
D-GalacturonateST001202AN0020015.560E-41.170E-3treatment_duration_(h);-;1.5;3;6;9
D-glycero-L-galacto-OctuloseST001202AN0020016.430E-201.630E-19cell_type;iRBC;unRBC
D-glycero-L-galacto-OctuloseST001202AN0020013.810E-71.690E-6treatment_duration_(h);-;1.5;3;6;9
FA hydroxy(10:0)ST001202AN0020011.390E-172.980E-17cell_type;iRBC;unRBC
FA hydroxy(10:0)ST001202AN0020013.990E-51.060E-4treatment_duration_(h);-;1.5;3;6;9
FA hydroxy(16:0)] hexadecanoic acidST001202AN0020011.750E-82.210E-8cell_type;iRBC;unRBC
FA hydroxy(18:0)ST001202AN0020013.520E-74.210E-7cell_type;iRBC;unRBC
FA methyl(14:0)ST001202AN0020014.720E-137.470E-13cell_type;iRBC;unRBC
FA methyl(14:0)ST001202AN0020013.580E-25.060E-2treatment_duration_(h);-;1.5;3;6;9
FA methyl(16:1)ST001202AN0020013.220E-145.520E-14cell_type;iRBC;unRBC
FA methyl(16:1)ST001202AN0020012.460E-23.550E-2treatment_duration_(h);-;1.5;3;6;9
FA methyl(18:0)ST001202AN0020019.430E-161.830E-15cell_type;iRBC;unRBC
FA methyl(18:0)ST001202AN0020014.770E-38.080E-3treatment_duration_(h);-;1.5;3;6;9
FA methyl(6:0)ST001202AN0020013.720E-231.320E-22cell_type;iRBC;unRBC
FA methyl(6:0)ST001202AN0020011.460E-43.470E-4treatment_duration_(h);-;1.5;3;6;9
FA methyl(8:0)ST001202AN0020011.110E-131.820E-13cell_type;iRBC;unRBC
FA methyl(8:0)ST001202AN0020012.020E-22.960E-2treatment_duration_(h);-;1.5;3;6;9
FA methyl (8:1)ST001202AN0020011.540E-235.710E-23cell_type;iRBC;unRBC
FA methyl (8:1)ST001202AN0020011.490E-22.220E-2treatment_duration_(h);-;1.5;3;6;9
FA oxo(16:0)ST001202AN0020011.630E-61.910E-6cell_type;iRBC;unRBC
FA oxo(18:0)ST001202AN0020014.220E-74.980E-7cell_type;iRBC;unRBC
GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))ST001202AN0020011.180E-81.510E-8cell_type;iRBC;unRBC
GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))ST001202AN0020011.760E-33.230E-3treatment_duration_(h);-;1.5;3;6;9
Gln-Leu-Lys-TyrST001202AN0020011.070E-182.440E-18cell_type;iRBC;unRBC
Gln-Leu-Lys-TyrST001202AN0020013.230E-35.630E-3treatment_duration_(h);-;1.5;3;6;9
Glu-Lys-Lys-PheST001202AN0020015.360E-171.110E-16cell_type;iRBC;unRBC
Glu-Lys-Lys-PheST001202AN0020013.530E-25.020E-2treatment_duration_(h);-;1.5;3;6;9
HEPESST001202AN0020011.250E-497.990E-48cell_type;iRBC;unRBC
hydrogen iodideST001202AN0020011.050E-81.350E-8cell_type;iRBC;unRBC
L-Ala-L-GluST001202AN0020014.390E-335.110E-32cell_type;iRBC;unRBC
melibionateST001202AN0020014.960E-391.270E-37cell_type;iRBC;unRBC
melibionateST001202AN0020011.020E-31.960E-3treatment_duration_(h);-;1.5;3;6;9
MesaconateST001202AN0020011.280E-121.940E-12cell_type;iRBC;unRBC
MesaconateST001202AN0020012.310E-81.600E-7treatment_duration_(h);-;1.5;3;6;9
N-Acetyl-D-glucosamine 6-phosphateST001202AN0020013.590E-282.490E-27cell_type;iRBC;unRBC
N-Acetyl-D-glucosamine 6-phosphateST001202AN0020018.070E-62.400E-5treatment_duration_(h);-;1.5;3;6;9
N-acetyl -D- glucosaminitolST001202AN0020011.010E-133.710E-12treatment_duration_(h);-;1.5;3;6;9
N-acetyl -D- glucosaminitolST001202AN0020013.110E-33.390E-3cell_type;iRBC;unRBC
N-Butyl-beta-carboline-3-carboxylateST001202AN0020019.270E-182.010E-17cell_type;iRBC;unRBC
N-Butyl-beta-carboline-3-carboxylateST001202AN0020011.220E-21.870E-2treatment_duration_(h);-;1.5;3;6;9
nicotinamide guanine dinucleotideST001202AN0020017.590E-118.830E-10treatment_duration_(h);-;1.5;3;6;9
nonulose 9-phosphateST001202AN0020019.490E-382.020E-36cell_type;iRBC;unRBC
nonulose 9-phosphateST001202AN0020014.680E-37.990E-3treatment_duration_(h);-;1.5;3;6;9
octulose 8-phosphateST001202AN0020011.650E-204.440E-20cell_type;iRBC;unRBC
octulose 8-phosphateST001202AN0020015.470E-51.420E-4treatment_duration_(h);-;1.5;3;6;9
P-DPDST001202AN0020015.420E-149.060E-14cell_type;iRBC;unRBC
P-DPDST001202AN0020019.650E-62.810E-5treatment_duration_(h);-;1.5;3;6;9
PhenolsulfonphthaleinST001202AN0020014.920E-231.700E-22cell_type;iRBC;unRBC
PhenolsulfonphthaleinST001202AN0020017.220E-41.460E-3treatment_duration_(h);-;1.5;3;6;9
PIPESST001202AN0020013.860E-282.600E-27cell_type;iRBC;unRBC
PIPESST001202AN0020011.030E-42.540E-4treatment_duration_(h);-;1.5;3;6;9
SulfateST001202AN0020015.520E-242.210E-23cell_type;iRBC;unRBC
SulfateST001202AN0020011.070E-53.010E-5treatment_duration_(h);-;1.5;3;6;9
SulforaphaneST001202AN0020013.780E-167.440E-16cell_type;iRBC;unRBC
SulforaphaneST001202AN0020018.990E-62.650E-5treatment_duration_(h);-;1.5;3;6;9
tartrazineST001202AN0020011.910E-353.490E-34cell_type;iRBC;unRBC
tartrazineST001202AN0020014.130E-25.740E-2treatment_duration_(h);-;1.5;3;6;9
1-(11Z-octadecenyl)-sn-glycero-3-phosphocholineST001204AN0020042.430E-34.600E-3cell_type;iRBC;unRBC
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerolST001204AN0020048.410E-231.380E-21cell_type;iRBC;unRBC
2-(acetylamino)-1-5-anhydro-2-deoxy-3-O-b-D-galactopyranosyl-D-arabino-Hex-1-enitolST001204AN0020048.160E-51.910E-4cell_type;iRBC;unRBC
2-amino-2-deoxyglucitol-6-phosphateST001204AN0020041.360E-73.920E-7cell_type;iRBC;unRBC
2-chloro-3-methyl-maleylacetateST001204AN0020041.120E-303.980E-29cell_type;iRBC;unRBC
2-S-Glutathionyl acetateST001204AN0020041.190E-191.220E-18cell_type;iRBC;unRBC
3-Deoxy-D-manno-octulosonate 8-phosphateST001204AN0020041.280E-351.240E-33cell_type;iRBC;unRBC
4-Hydroxy-4-methylglutamateST001204AN0020043.460E-68.970E-6cell_type;iRBC;unRBC
6-Acetyl-D-glucoseST001204AN0020041.530E-33.040E-3cell_type;iRBC;unRBC
6-Acetyl-D-glucoseST001204AN0020042.470E-22.530E-1treatment_duration_(h);-;3;6;9
Ala-Ala-Ala-SerST001204AN0020045.740E-132.630E-12cell_type;iRBC;unRBC
Ala-Asp-Cys-SerST001204AN0020041.720E-95.830E-9cell_type;iRBC;unRBC
Ala-Glu-Glu-HisST001204AN0020041.690E-95.770E-9cell_type;iRBC;unRBC
Ala-Glu-Glu-HisST001204AN0020041.000E-21.720E-1treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Trp-SerST001204AN0020044.910E-81.490E-7cell_type;iRBC;unRBC
Ala-Leu-Trp-SerST001204AN0020041.080E-21.750E-1treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Trp-SerST001204AN0020041.300E-21.810E-1treatment_duration_(h);-;3;6;9
Ala-Lys-Asp-ProST001204AN0020041.420E-94.920E-9cell_type;iRBC;unRBC
Ala-Lys-Asp-ProST001204AN0020045.050E-43.360E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Lys-Lys-AspST001204AN0020049.370E-92.960E-8cell_type;iRBC;unRBC
Ala-Lys-Lys-AspST001204AN0020048.700E-44.230E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Phe-Arg-HisST001204AN0020047.830E-261.690E-24cell_type;iRBC;unRBC
Antheridiogen-AnST001204AN0020046.890E-71.860E-6cell_type;iRBC;unRBC
Arg-Asp-Asp-GlyST001204AN0020048.910E-197.530E-18cell_type;iRBC;unRBC
Asn-Leu-Pro-ProST001204AN0020043.270E-79.150E-7cell_type;iRBC;unRBC
Asn-Leu-Pro-ProST001204AN0020045.180E-43.360E-2treatment;DHA;DMSO;OZ277;OZ439
Asn-Lys-Gly-ProST001204AN0020046.050E-112.380E-10cell_type;iRBC;unRBC
Asn-Lys-Gly-ProST001204AN0020048.160E-31.540E-1treatment;DHA;DMSO;OZ277;OZ439
Asn-Thr-Asn-AsnST001204AN0020041.170E-201.300E-19cell_type;iRBC;unRBC
Asn-Val-Gly-SerST001204AN0020047.760E-31.390E-2cell_type;iRBC;unRBC
Asp-Leu-Lys-AspST001204AN0020044.380E-24.260E-1treatment;DHA;DMSO;OZ277;OZ439
Asp-Met-Gln-GlnST001204AN0020042.280E-131.110E-12cell_type;iRBC;unRBC
Asp-Val-Pro-SerST001204AN0020047.500E-207.890E-19cell_type;iRBC;unRBC
Cinchonain 1aST001204AN0020042.120E-296.870E-28cell_type;iRBC;unRBC
dibenzothiophene-5-oxideST001204AN0020041.580E-84.930E-8cell_type;iRBC;unRBC
FA hydroxy(18:1)]ST001204AN0020043.160E-25.060E-2cell_type;iRBC;unRBC
gamma-thiomethyl glutamateST001204AN0020041.840E-161.170E-15cell_type;iRBC;unRBC
L-beta-aspartyl-L-leucineST001204AN0020041.700E-74.840E-7cell_type;iRBC;unRBC
L-beta-aspartyl-L-leucineST001204AN0020041.920E-34.380E-2treatment_duration_(h);-;3;6;9
Myxalamid DST001204AN0020041.890E-22.630E-1treatment;DHA;DMSO;OZ277;OZ439
N2-(D-1-Carboxyethyl)-L-arginineST001204AN0020041.710E-127.390E-12cell_type;iRBC;unRBC
N2-(D-1-Carboxyethyl)-L-arginineST001204AN0020043.940E-23.080E-1treatment_duration_(h);-;3;6;9
N-Acetyl-D-glucosaminateST001204AN0020041.170E-22.010E-2cell_type;iRBC;unRBC
N-Acetyl-D-glucosaminateST001204AN0020041.570E-22.340E-1treatment;DHA;DMSO;OZ277;OZ439
N-acetyl -D- glucosaminitolST001204AN0020044.890E-41.030E-3cell_type;iRBC;unRBC
N-Acetyl-O-acetylneuraminateST001204AN0020048.490E-231.380E-21cell_type;iRBC;unRBC
N-Acetyl-O-acetylneuraminateST001204AN0020042.660E-22.650E-1treatment_duration_(h);-;3;6;9
octulose 8-phosphateST001204AN0020042.890E-111.150E-10cell_type;iRBC;unRBC
Ovothiol disulfideST001204AN0020047.590E-31.360E-2cell_type;iRBC;unRBC
penem CGP31608ST001204AN0020041.040E-42.340E-4cell_type;iRBC;unRBC
psicoselysineST001204AN0020041.390E-252.700E-24cell_type;iRBC;unRBC
trans-Hexadec-2-enoylcarnitineST001204AN0020043.480E-141.850E-13cell_type;iRBC;unRBC
1-O-Methyl-myo-inositolST001204AN0020059.040E-113.440E-10cell_type;iRBC;unRBC
1-thio-beta-D-glucoseST001204AN0020053.940E-121.690E-11cell_type;iRBC;unRBC
3-deoxy-D-galactoseST001204AN0020051.580E-181.150E-17cell_type;iRBC;unRBC
3-deoxy-D-galactoseST001204AN0020051.800E-48.080E-3treatment_duration_(h);-;3;6;9
4-Amino-4-deoxychorismateST001204AN0020052.350E-76.900E-7cell_type;iRBC;unRBC
4-HydroxyphenylacetylglycineST001204AN0020054.870E-41.140E-3cell_type;iRBC;unRBC
6-Acetamido-2-oxohexanoateST001204AN0020052.140E-24.160E-2cell_type;iRBC;unRBC
a Cysteine adductST001204AN0020051.310E-221.410E-21cell_type;iRBC;unRBC
Ala-Asn-Gln-GlnST001204AN0020054.090E-193.250E-18cell_type;iRBC;unRBC
Ala-Cys-Pro-SerST001204AN0020052.030E-51.100E-3treatment_duration_(h);-;3;6;9
Ala-Cys-Pro-SerST001204AN0020051.640E-33.790E-3cell_type;iRBC;unRBC
Ala-Phe-Tyr-TyrST001204AN0020054.420E-121.860E-11cell_type;iRBC;unRBC
Albendazole sulfoneST001204AN0020055.040E-193.890E-18cell_type;iRBC;unRBC
Albendazole sulfoneST001204AN0020058.950E-31.210E-1treatment_duration_(h);-;3;6;9
Arg-Lys-Asp-AspST001204AN0020052.760E-22.760E-1treatment_duration_(h);-;3;6;9
Arg-Trp-Asp-CysST001204AN0020057.570E-75.110E-5treatment_duration_(h);-;3;6;9
Asp-Trp-Gly-GlyST001204AN0020053.370E-307.580E-29cell_type;iRBC;unRBC
Cys-Gly-Pro-SerST001204AN0020051.040E-22.080E-2cell_type;iRBC;unRBC
DihydrogenphosphateST001204AN0020055.260E-193.950E-18cell_type;iRBC;unRBC
DihydrogenphosphateST001204AN0020056.660E-31.110E-1treatment_duration_(h);-;3;6;9
iodoacetateST001204AN0020053.360E-26.260E-2cell_type;iRBC;unRBC
iodoacetateST001204AN0020054.410E-28.320E-1treatment;DHA;DMSO;OZ277;OZ439
L-Ascorbate 6-phosphateST001204AN0020051.350E-74.110E-7cell_type;iRBC;unRBC
L-methioninamideST001204AN0020053.860E-485.120E-46cell_type;iRBC;unRBC
Lys-Lys-Trp-ProST001204AN0020059.230E-134.080E-12cell_type;iRBC;unRBC
Lys-Lys-Trp-ProST001204AN0020054.690E-24.030E-1treatment_duration_(h);-;3;6;9
melibionateST001204AN0020051.730E-44.330E-4cell_type;iRBC;unRBC
N-Acetyl-D-glucosamine 6-phosphateST001204AN0020055.480E-102.000E-9cell_type;iRBC;unRBC
nonulose 9-phosphateST001204AN0020053.450E-48.310E-4cell_type;iRBC;unRBC
nonulose 9-phosphateST001204AN0020056.030E-31.090E-1treatment_duration_(h);-;3;6;9
O-glucosyl-tomatidineST001204AN0020054.060E-27.460E-2cell_type;iRBC;unRBC
Ovothiol BST001204AN0020054.840E-31.050E-2cell_type;iRBC;unRBC
P-DPDST001204AN0020052.190E-151.180E-14cell_type;iRBC;unRBC
PhenolsulfonphthaleinST001204AN0020052.650E-25.050E-2cell_type;iRBC;unRBC
S-Methyl-5-thio-D-ribose 1-phosphateST001204AN0020052.750E-141.370E-13cell_type;iRBC;unRBC
S-Methyl-5-thio-D-ribose 1-phosphateST001204AN0020052.440E-25.980E-1treatment;DHA;DMSO;OZ277;OZ439
SulfateST001204AN0020055.160E-236.330E-22cell_type;iRBC;unRBC
tetcyclacisST001204AN0020052.730E-36.140E-3cell_type;iRBC;unRBC
tetrahydrogeranylgeranyl-bacteriopheophytinST001204AN0020053.400E-48.270E-4cell_type;iRBC;unRBC
tetrahydrogeranylgeranyl-bacteriopheophytinST001204AN0020052.040E-22.300E-1treatment_duration_(h);-;3;6;9
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerolST001205AN0020061.170E-35.670E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
1-(9Z-octadecenoyl)-2-hexadecanoyl-sn-glycero-3-phosphocholineST001205AN0020062.440E-24.400E-1treatment_duration_(h);1;5;3
1-deoxyxylonojirimycinST001205AN0020063.170E-27.170E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
1-octadecanoyl-2-tetradecanoyl-sn-glycero-3-phosphocholineST001205AN0020062.120E-24.380E-1treatment_duration_(h);1;5;3
1-tetradecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholineST001205AN0020064.020E-25.090E-1treatment_duration_(h);1;5;3
3-ButynoateST001205AN0020062.720E-24.400E-1treatment_duration_(h);1;5;3
3-deoxy-D-galactoseST001205AN0020065.070E-82.310E-5treatment_duration_(h);1;5;3
3-deoxy-D-galactoseST001205AN0020068.310E-41.410E-1treatment;DHA;DMSO;OZ277;OZ439
3-EthylmalateST001205AN0020061.830E-41.490E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
3-propylphosphoenolpyruvateST001205AN0020061.750E-24.490E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
4-(Trimethylammonio)but-2-enoateST001205AN0020067.230E-32.260E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
6-deoxy-5-ketofructose-1-phosphateST001205AN0020063.900E-28.240E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
8-Amino-7-oxononanoateST001205AN0020067.190E-79.120E-5parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Ala-Ala-SerST001205AN0020064.320E-29.990E-1treatment;DHA;DMSO;OZ277;OZ439
Ala-Glu-Glu-HisST001205AN0020061.030E-41.120E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Leu-Lys-ProST001205AN0020064.270E-31.510E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Thr-Ala-GlyST001205AN0020067.240E-59.780E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Thr-Ala-SerST001205AN0020063.240E-55.410E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
Arg-Asp-Asp-GlyST001205AN0020062.160E-25.290E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Asn-Leu-Pro-ProST001205AN0020061.660E-31.410E-1treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Pro-ProST001205AN0020061.080E-23.100E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Asn-Lys-Gly-GlyST001205AN0020063.010E-31.110E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Avenic acid AST001205AN0020061.000E-69.120E-5parasite_line;Cam3.IIR539T;Cam3.IIrev
CrotanecineST001205AN0020062.610E-54.950E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
CTABST001205AN0020061.750E-24.490E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
EPC(d37:1)ST001205AN0020065.990E-43.250E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
EPC(d37:2)ST001205AN0020061.200E-35.780E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
EPC(d39:1)ST001205AN0020061.580E-36.780E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
gamma-thiomethyl glutamateST001205AN0020061.480E-36.620E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
Ganglioside GA1 (d18:1/24:1(15Z))ST001205AN0020062.300E-24.380E-1treatment_duration_(h);1;5;3
Glu-Cys-Gly-SerST001205AN0020064.260E-56.260E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
Hydroxyprolyl-AsparagineST001205AN0020064.760E-29.690E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
IDP-D-mannoseST001205AN0020065.790E-43.220E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
L-a-glutamyl-L-LysineST001205AN0020061.920E-24.380E-1treatment_duration_(h);1;5;3
MethylitaconateST001205AN0020064.840E-31.700E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
N2-(D-1-Carboxyethyl)-L-arginineST001205AN0020062.020E-25.050E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
N2-FructopyranosylarginineST001205AN0020062.080E-41.580E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
PutreanineST001205AN0020061.240E-35.890E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
(R)-piperidine-3-carboxylateST001205AN0020063.010E-26.900E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
2(alpha-D-Mannosyl)-D-glycerateST001205AN0020071.350E-24.100E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
2-Dehydro-D-xylonateST001205AN0020071.610E-41.540E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
2-Phospho-D-glycerateST001205AN0020076.090E-32.410E-1treatment_duration_(h);1;5;3
3-Deoxy-D-manno-octulosonate 8-phosphateST001205AN0020078.180E-32.780E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
4-Amino-4-deoxychorismateST001205AN0020072.570E-25.810E-1treatment_duration_(h);1;5;3
4-Amino-4-deoxychorismateST001205AN0020073.380E-28.690E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
4-Hydroxy-4-methylglutamateST001205AN0020076.090E-44.090E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
4-oxo-4-(3-pyridyl)-butanoateST001205AN0020075.280E-31.960E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
[6]-ParadolST001205AN0020071.640E-53.980E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Cys-Pro-SerST001205AN0020071.290E-24.050E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Asn-Thr-Trp-HisST001205AN0020071.840E-25.160E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
cis-AcetylacrylateST001205AN0020076.270E-44.950E-2treatment_duration_(h);1;5;3
cis-AcetylacrylateST001205AN0020073.440E-21.000E+0treatment;DHA;DMSO;OZ277;OZ439
D-GalacturonateST001205AN0020072.240E-25.990E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
D-glycero-L-galacto-OctuloseST001205AN0020076.310E-76.650E-5parasite_line;Cam3.IIR539T;Cam3.IIrev
Dide-O-methylsimmondsinST001205AN0020077.030E-44.530E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
dihydrogeranylgeranyl-bacteriopheophytinST001205AN0020074.590E-31.770E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
FA hydroxy(18:1)]ST001205AN0020079.210E-33.060E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
FA methyl(16:1)ST001205AN0020072.440E-26.440E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Gln-Phe-Gln-HisST001205AN0020073.580E-29.130E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
L-1-Pyrroline-3-hydroxy-5-carboxylateST001205AN0020073.820E-61.510E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
L-NoradrenalineST001205AN0020072.790E-27.230E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
MesaconateST001205AN0020071.740E-38.850E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
methanofuran biosynththesis intermediate MF1ST001205AN0020076.960E-58.460E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
N-AcetylanthranilateST001205AN0020074.490E-37.090E-1treatment;DHA;DMSO;OZ277;OZ439
nicotinamide guanine dinucleotideST001205AN0020071.220E-36.750E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
nonulose 9-phosphateST001205AN0020072.670E-55.630E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
octulose 8-phosphateST001205AN0020072.100E-41.900E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
[PA(18:0)] 1-octadecanoyl-2-sn-glycero-3-phosphateST001205AN0020071.350E-24.100E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
PhenolsulfonphthaleinST001205AN0020075.280E-31.960E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
phosphinomethylisomalateST001205AN0020071.600E-38.280E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
[PS(18:1)] 1-(9Z-octadecenoyl)-sn-glycero-3-phosphoserineST001205AN0020072.030E-25.570E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Sucrose monopalmitateST001205AN0020071.750E-69.200E-5parasite_line;Cam3.IIR539T;Cam3.IIrev
2-deoxypentitol NISTST001211AN0020165.250E-31.110E-2Group;Control;Methotrexate
5-methyluridine NISTST001211AN0020168.830E-31.790E-2Group;Control;Methotrexate
hexadecylglycerol NISTST001211AN0020163.630E-38.280E-3Group;Control;Methotrexate
isohexonic acidST001211AN0020162.390E-35.680E-3Group;Control;Methotrexate
1-Methyladenosine BST001211AN0020174.790E-31.810E-2Group;Control;Methotrexate
4-Methyl-5-thiazoleethanol?ST001211AN0020173.480E-29.980E-2Group;Control;Methotrexate
beta-HomophenylalanineST001211AN0020173.680E-31.410E-2Group;Control;Methotrexate
beta-Nicotinamide adenine dinucleotideST001211AN0020175.470E-103.760E-8Group;Control;Methotrexate
D5-L-Glutamine iSTDST001211AN0020172.960E-41.770E-3Group;Control;Methotrexate
D9-Choline iSTDST001211AN0020173.110E-29.160E-2Group;Control;Methotrexate
Dehydrocholic acidST001211AN0020171.520E-41.090E-3Group;Control;Methotrexate
Galacto-N-bioseST001211AN0020175.240E-66.260E-5Group;Control;Methotrexate
N-.alpha.-(tert-Butoxycarbonyl)-L-histidineST001211AN0020172.130E-41.430E-3Group;Control;Methotrexate
Val-Tyr-Val iSTDST001211AN0020171.190E-24.060E-2Group;Control;Methotrexate
FA (14:1) (physeteric acid)ST001211AN0020192.260E-47.630E-4Group;Control;Methotrexate
SM (d18:1/17:0) iSTDST001211AN0020194.140E-51.870E-4Group;Control;Methotrexate
19/20-OH PGE2ST001214AN0020251.550E-42.520E-4BMI group;lean;obese;overweight
19/20-OH PGF2aST001214AN0020257.720E-41.140E-3BMI group;lean;obese;overweight
5-HETrEST001214AN0020251.140E-75.890E-7BMI group;lean;obese;overweight
5-iPF2a-VIST001214AN0020259.870E-108.960E-9BMI group;lean;obese;overweight
8-HETrEST001214AN0020251.820E-65.830E-6BMI group;lean;obese;overweight
HETEST001223AN0020362.760E-81.200E-7Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
Lyso-PAF C18ST001223AN0020361.530E-91.990E-8Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
PUFAST001223AN0020362.500E-65.420E-6Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
Progtaglandin F2aST001229AN0020423.460E-196.910E-19Sample Source;Feces;Serum;Tissues
4-hydroxy-3-methylacetophenoneST001236AN0020543.760E-21.350E-1OS_Censor (1 means the time is a censoring time and 0 means ...
acetyl-galactosamineST001236AN0020543.910E-22.310E-1Nivolumab Dose (mg/kg);0.3;10;2
diacetylspermineST001236AN0020541.580E-58.080E-4OS_Censor (1 means the time is a censoring time and 0 means ...
DMGVST001236AN0020541.350E-26.930E-2OS_Censor (1 means the time is a censoring time and 0 means ...
DMGVST001236AN0020541.870E-21.940E-1Nivolumab Dose (mg/kg);0.3;10;2
glycodeoxycholate/glycochenodeoxycholateST001236AN0020542.220E-44.570E-3Time point;baseline;week 4;week 9
NMMAST001236AN0020541.180E-32.900E-2OS_Censor (1 means the time is a censoring time and 0 means ...
threo-sphingosineST001236AN0020545.220E-41.780E-2OS_Censor (1 means the time is a censoring time and 0 means ...
4-hydroxy-3-methylacetophenoneST001237AN0020552.350E-88.010E-7Time point;baseline;week 4;week 8
acetyl-galactosamineST001237AN0020552.020E-181.480E-17CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
acetyl-galactosamineST001237AN0020554.080E-82.980E-7OS_Censor (1 means the time is a censoring time and 0 means ...
diacetylspermineST001237AN0020559.340E-185.980E-17CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
diacetylspermineST001237AN0020551.060E-166.790E-15OS_Censor (1 means the time is a censoring time and 0 means ...
diacetylspermineST001237AN0020552.190E-27.140E-2Time point;baseline;week 4;week 8
diacetylspermineST001237AN0020553.880E-21.240E-1Treatment;EVEROLIMUS;NIVOLUMAB
DMGVST001237AN0020555.980E-205.110E-19CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
DMGVST001237AN0020552.960E-113.370E-10OS_Censor (1 means the time is a censoring time and 0 means ...
DMGVST001237AN0020551.350E-28.630E-2Prior antiangiogenic regimens (≥2);FALSE;TRUE
glycodeoxycholate/glycochenodeoxycholateST001237AN0020553.790E-49.130E-4CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
glycodeoxycholate/glycochenodeoxycholateST001237AN0020552.950E-21.080E-1Treatment;EVEROLIMUS;NIVOLUMAB
Kyn/TrpST001237AN0020551.650E-169.640E-16CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
Kyn/TrpST001237AN0020553.260E-122.230E-10Time point;baseline;week 4;week 8
Kyn/TrpST001237AN0020556.290E-73.790E-6OS_Censor (1 means the time is a censoring time and 0 means ...
Kyn/TrpST001237AN0020553.690E-43.600E-3Treatment;EVEROLIMUS;NIVOLUMAB
NMMAST001237AN0020553.030E-353.100E-33CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
NMMAST001237AN0020551.320E-166.790E-15OS_Censor (1 means the time is a censoring time and 0 means ...
NMMAST001237AN0020554.480E-21.610E-1Prior antiangiogenic regimens (≥2);FALSE;TRUE
threo-sphingosineST001237AN0020551.150E-22.130E-2CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
urobilinogenST001237AN0020556.100E-32.360E-2Time point;baseline;week 4;week 8
4-Aminobenzoate/AnthranilateST001317AN0021922.367E-22.549E-2SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Aminobenzoate/AnthranilateST001317AN0021922.367E-22.549E-2SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Hydroxy-4-(3-pyridyl)butanoic acidST001317AN0021922.629E-247.362E-24SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Hydroxy-4-(3-pyridyl)butanoic acidST001317AN0021922.629E-247.362E-24SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Allothreonine/L-ThreonineST001317AN0021921.776E-411.658E-40SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Allothreonine/L-ThreonineST001317AN0021921.776E-411.658E-40SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Aminocaproate/AdenineST001317AN0021921.375E-162.800E-16SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Aminocaproate/AdenineST001317AN0021921.375E-162.800E-16SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Beta-alanine methyl esterST001317AN0021926.364E-181.485E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Beta-alanine methyl esterST001317AN0021926.364E-181.485E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
L-Valine/Methyl 4-AminobutyrateST001317AN0021928.944E-501.252E-48SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
L-Valine/Methyl 4-AminobutyrateST001317AN0021928.944E-501.252E-48SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
MethylpicolinateST001317AN0021921.629E-72.225E-7SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
MethylpicolinateST001317AN0021921.629E-72.225E-7SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Pyroglutamate/OxoprolineST001317AN0021925.592E-353.914E-34SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Pyroglutamate/OxoprolineST001317AN0021925.592E-353.914E-34SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Theobromine /Theophylline/ ParaxanthineST001317AN0021922.012E-143.521E-14SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Theobromine /Theophylline/ ParaxanthineST001317AN0021922.012E-143.521E-14SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2-Methylmaleate/ItaconateST001317AN0021935.539E-375.601E-36SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2-Methylmaleate/ItaconateST001317AN0021935.539E-375.601E-36SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate)ST001317AN0021933.375E-181.228E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate)ST001317AN0021933.375E-181.228E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
3-Methylglutarate/AdipateST001317AN0021936.165E-111.368E-10SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
3-Methylglutarate/AdipateST001317AN0021936.165E-111.368E-10SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Anthranilate/4-AminobenzoateST001317AN0021936.526E-233.959E-22SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Anthranilate/4-AminobenzoateST001317AN0021936.526E-233.959E-22SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
cx-MiDP (MCNP) (Mono(2,7-dimethyl-7-carboxyheptyl) phthalate)ST001317AN0021939.596E-41.343E-3SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
cx-MiDP (MCNP) (Mono(2,7-dimethyl-7-carboxyheptyl) phthalate)ST001317AN0021939.596E-41.343E-3SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
ErucateST001317AN0021935.968E-81.073E-7SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
ErucateST001317AN0021935.968E-81.073E-7SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
P-Hydroxyphenylacetate/2-HydroxyphenylacetateST001317AN0021934.515E-181.522E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
P-Hydroxyphenylacetate/2-HydroxyphenylacetateST001317AN0021934.515E-181.522E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
S-BudesonideST001317AN0021937.378E-61.164E-5SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
S-BudesonideST001317AN0021937.378E-61.164E-5SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
9-myristoleateST001322AN0021988.071E-43.127E-3treatment;expecting 2 month - human breast milk;expecting 2 ...
9-myristoleateST001322AN0021981.094E-28.480E-2group;OB;NW
lysopalmitoyl monogalactosylglycerolST001322AN0021986.850E-42.740E-3treatment;expecting 2 month - human breast milk;expecting 2 ...
n-acetyl-d-hexosamineST001322AN0021983.197E-111.321E-9treatment;expecting 2 month - human breast milk;expecting 2 ...
n-acetyl-d-hexosamineST001322AN0021984.466E-21.870E-1group;OB;NW
DG(36:2)>DG(18:1_18:1_0:0)ST001325AN0022067.228E-284.437E-27Sample type;batch pool;chear plasma;master pool;red cross pl...
DG(36:2)>DG(18:1_18:1_0:0)ST001325AN0022062.022E-55.999E-5Gender;-;female;male
epibrassinolide+HCOOHST001325AN0022077.898E-127.437E-11Gender;-;female;male
epibrassinolide+HCOOHST001325AN0022074.327E-101.577E-9Sample type;batch pool;chear plasma;master pool;red cross pl...
m-hydroxybenzoic acidST001325AN0022072.036E-352.300E-34Sample type;batch pool;chear plasma;master pool;red cross pl...
m-hydroxybenzoic acidST001325AN0022079.617E-117.245E-10Gender;-;female;male

( Species:Human)
List of studies, analyses, submitted metabolite names, experimental conditions and RSD values

Replicate numbers reflect the number of replicates for each experimental condition where the measured value was not null
Name Study_id Analysis_id Factors Range(RSD) Replicates
  logo